Discovery, Optimization, and Characterization of Novel Subtype-Selective Muscarinic Acetylcholine Receptor M4 and M5 Positive Allosteric Modulators by Bridges, Thomas Miller
DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL 
SUBTYPE-SELECTIVE MUSCARINIC ACETYLCHOLINE RECEPTOR  
M4 AND M5 POSITIVE ALLOSTERIC MODULATORS 
By 
Thomas Miller Bridges 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
Pharmacology 
 
December, 2010 
Nashville, Tennessee 
 
 
Approved: 
Professor Craig Lindsley 
Professor Vsevolod Gurevich 
Professor Jeffrey Conn 
Professor Aaron Bowman 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
To my parents Vicki and Allen Bridges 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
ACKNOWLEDGEMENTS 
 
 Many individuals and organizations have provided indispensible help and support 
to myself and to the work described herein, and I wish to specifically name and thank a 
number of them.  My undergraduate biology professor, Jennifer Busch, who first 
introduced me to Vanderbilt and to the biomedical research field, has been a great friend 
and source of advice throughout my graduate career.  Without her invitation to pursue an 
internship at Vanderbilt, I would not have moved to Nashville and ultimately entered this 
program.  Likewise, Jackie Corbin and Sharron Francis allowed me to work as a summer 
research intern in their laboratory alongside Dr. Busch, for which I’m very grateful.  I 
also want to thank Martin Egli and his lab for granting me a research assistant position 
during the time I was applying to this program.  The IGP staff and the Vanderbilt 
department of Pharmacology as a whole have been an invaluable and integral part of my 
education and graduate training as well.  I thank all of the professors and the 
administration of the department, in particular Joey Barnett, who have taught or helped 
me throughout the past four years.  Furthermore, none of this research would have been 
possible without generous funding from the VICB, NIH, NIMH, and the Alzheimer’s 
Association. 
 My advisor Craig Lindsley deserves the greatest degree of gratitude and 
recognition for his help, consideration, and leadership during my training.  I’m forever 
indebted to him for first allowing me to rotate and later join his lab at a time when he was 
new to Vanderbilt and the lab was just beginning.  Virtually all of my research, 
publications, and other accomplishments during this degree program can be attributed 
 
 
iv 
largely to Craig for providing me with endless opportunities and encouragement.  Craig is 
one of the most intelligent, hard-working, and successful scientists I’ve known and I 
cannot thank him enough for all of his help and support throughout my time in his lab.  
Likewise, I would like to thank and acknowledge all past and present members of the 
Lindsley lab, and Phil Kennedy in particular, as well as the larger VPDD group for all of 
their help and for creating a friendly and all-round outstanding research environment. 
 Jeff Conn has been a fantastic co-mentor who has provided crucial advice, 
support, and encouragement throughout my graduate career.  Jeff is also a wonderful role 
model and thoughtful leader whom I deeply respect.  I thank him and all of his lab 
members for their never-ending help and instruction during my research.  Similarly, I’m 
grateful for the help and insight I’ve received from all of my committee.  Seva Gurevich 
and Aaron Bowman have been extremely kind and supportive to me, and I’m grateful for 
their participation and guidance as part of my committee.  I also thank Larry Marnett for 
his help throughout my training and for allowing me to participate in the ITTD.  Dave 
Weaver and his lab members have contributed greatly to this research in numerous ways 
and have provided me with crucial training and help throughout this work as well. 
 I would like to thank my friends and family for their continual support throughout 
the course of my degree.  My parents, Vicki and Al, have always provided me with 
everything I’ve needed or asked and have been a vital source of assurance and financial 
help.  My sister, Sydney, has also been a great friend and resource during this time.  I 
thank all of my extended family including my grandparents as well for their assistance 
and encouragement.  Last, I would like to thank my classmate Kelsey Duggan for her 
friendship and support during my pursuit of this degree. 
 
 
v 
TABLE OF CONTENTS 
 
  Page 
DEDICATION....................................................................................................................ii 
 
ACKNOWLEDGEMENTS.............................................................................................. iii 
 
LIST OF TABLES...........................................................................................................viii 
 
LIST OF FIGURES ............................................................................................................x 
 
LIST OF ABBREVIATIONS........................................................................................ xvii 
 
 
Chapter  
 
I.   INTRODUCTION............................................................................................................1 
 
          Muscarinic acetylcholine receptors..............................................................................1 
                  Acetylcholine biosynthesis and receptors............................................................1 
                  Structure and signaling of mAChR subtypes.......................................................4      
                  Localization of mAChR subtypes........................................................................6                                                                           
                  Genetic deletion of mAChR subtypes..................................................................8 
                  Therapeutic potential of mAChRs as drug targets...............................................15 
 Allosteric modulation of mAChRs..............................................................................24 
         Introduction to allosteric modulation of GPCRs.................................................24 
                  Characterization of allosteric modulators of GPCRs...........................................29 
                  Discovery of early allosteric modulators of mAChRs.........................................31 
           Notes on figure, table, and compound numbering/nomenclature ...............................33 
  
 
II:  MATERIALS AND METHODS.....................................................................................34 
 
    Medicinal chemistry ....................................................................................................34            
            General synthetic methods, instrumentation, and work-flow ..............................34           
            M4 PAM syntheses...............................................................................................37 
   M5 PAM syntheses...............................................................................................46 
   M1 PAM syntheses...............................................................................................53 
   M1 allosteric agonist syntheses ............................................................................61 
                  M1 agonist TBPB analog syntheses .....................................................................63 
   M1 antagonist syntheses.......................................................................................66 
            Jet-milling/scale-up..............................................................................................68 
  In vitro pharmacology .................................................................................................68 
 
 
vi 
   Cell lines and cell culture.....................................................................................68 
   Calcium mobilization assays................................................................................69 
   Radioligand binding assays..................................................................................71 
   Ancillary/off-target screening assays...................................................................76 
  In vivo pharmacology ..................................................................................................76 
   Amphetamine-induced hyperlocomotion behavioral rat studies .........................77 
   Roto-rod behavioral rat studies............................................................................78 
   Pharmacokinetic/PBL rat studies.........................................................................79 
 
 
III:  DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL                    
 SUBTYPE-SELECTIVE M4 POSITIVE ALLOSTERIC MODULATORS ................83 
 
     Discovery of M4 PAM VU010010 ..............................................................................83 
     Optimization of M4 PAM VU010010 to obtain VU0152099 and VU0152100 ..........85 
     In vitro characterization of M4 PAMs VU0152099 and VU0152100 .........................91 
     In vivo pharmacokinetics of M4 PAMs VU0152099 and VU0152100........................98 
     In vivo behavioral studies with M4 PAMs VU0152099 and VU0152100 ...................100 
     Optimization of M4 PAMs VU0152099 and VU0152100...........................................102 
     In vivo behavioral studies with 3rd-generation optimized M4 PAMs...........................114 
     Species-specific differences in 3rd-generation M4 PAM potencies..............................115 
          Potential for dual M4 PAM / H3 antagonist anti-psychotic activity.............................116 
          Summary ......................................................................................................................118 
 
 
IV:  DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL                 
 SUBTYPE-SELECTIVE M5 POSITIVE ALLOSTERIC MODULATORS ................119 
 
          Discovery of M1/M3/M5 PAM VU0119498 ................................................................119 
          Optimization of VU0119498 to obtain M5 PAM VU0238429 ...................................123 
          In vitro characterization of M5 PAM VU0238429 ......................................................141 
          In vivo rat pharmacokinetics of M5 PAM VU0238429 ...............................................146 
          Optimization of M5 PAM VU0238429........................................................................147 
          Ancillary pharmacology and physiochemical optimization of M5 PAMs...................177 
          In vitro characterization of M5 PAMs at rat M5 receptor.............................................193 
          Summary ......................................................................................................................195 
 
 
V:   DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL    
SUBTYPE-SELECTIVE M1 LIGANDS ......................................................................197 
 
          M1 PAMs derived from VU0119498...........................................................................197 
          M1 PAMs VU0028767 and VU0090157 .....................................................................206 
          M1 PAM BQCA and analogs.......................................................................................208 
          M1 PAMs derived from MLPCN probe project...........................................................214 
          M1 agonist VU0357017 and analogs ...........................................................................225 
 
 
vii 
          M1 agonist TBPB and analogs .....................................................................................235 
          M1 antagonist VU0255035 analogs .............................................................................242 
          Summary ......................................................................................................................249 
  
 
VI:  SUMMARY AND FUTURE DIRECTIONS ................................................................251 
 
 M4 PAMs based on VU010010 ...................................................................................252 
 M5 PAMs based on VU0238429 .................................................................................257 
 
 
REFERENCES ......................................................................................................................265 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
LIST OF TABLES 
 
Chapter III 
Table        Page 
 
1       M4 PAM potency and ACh CRC fold-shift SAR for VU010010 analogs based on 
scaffold 7.......................................................................................................................89 
 
2       Ancillary pharmacology activity of M4 PAMs VU0152099 and VU0152100 in 
singlepoint (10 µM) competition binding assays across a large panel of off-targets ...96 
 
3       Pharmacokinetic parameters calculated for M4 PAMs VU0152099 and VU0152100 
from a rat PK/PBL study...............................................................................................100 
 
4       M4 PAM SAR for select analogs from alkylamine library 9a-s and ether library 13a-
s chosen based on an initial singlepoint triage screen...................................................106 
 
5       M4 PAM SAR for select compounds from second library iteration analogs 17-21......112 
 
 
Chapter IV 
Table        Page 
 
1       Structures for compounds 21-112 and associated PAM activity data from initial 
single concentration (30 µM) potentiator screen against M1 and M5 ...........................125 
 
2       Potency SAR at M1 and M5 for 18 compounds selected from an initial singlepoint 
screen ............................................................................................................................139 
 
3       Structures and VU numbers for 13 VU01109498 analogs chosen for a M3 PAM 
singlepoint screen based on their inactivity at M1 and M5............................................141 
 
4       M1 and M5 potency SAR for biaryl/heterobiaryl and phenethyl analogs of 
VU0238429...................................................................................................................151 
 
5       Structures of western ether analog library based on M5 PAM VU0365114.................173 
 
6       Ancillary/off-target binding screening results for five M5 PAM leads.........................178 
 
7  Ancillary/off-target binding screening results for physiochemically-optimized M5 
PAMs VU0414747 and VU0415478............................................................................191 
 
 
 
ix 
 
Chapter V 
Table        Page 
 
1       SAR of fluorine-bearing analogs of lead compound VU0365137................................203 
 
2       SAR for 3-position biaryl/heterobiaryl analogs based on VU0402606 ........................220 
 
3       SAR for fluorinated analogs based on VU04010 lead..................................................221 
 
4       M1 and D2 potency/efficacy SAR for TBPB analogs synthesized according to 
Figure 30 .......................................................................................................................237 
 
5       SAR for fluorine-substituted TBPB analogs.................................................................241 
 
6       M1-M5 SAR for active M1 antagonist analogs 5...........................................................245 
 
7       Summary of functional and binding mAChR subtype-selectivity for M1 antagonist 
(compound 5b) ..............................................................................................................247 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
LIST OF FIGURES 
 
Chapter I 
Figure               Page 
 
1          Generalized diagram of cholinergic biosynthesis, packaging, degradation, and 
reuptake......................................................................................................................2 
 
2 Diagram of six main central cholinergic neuron projection pathways in the rat 
brain ...........................................................................................................................3 
 
3 Abbreviated diagram of the putative roles of M4 and M5 in the central mesolimbic 
DA pathway brain ......................................................................................................12 
 
4 Proposed signaling relationships between M1, APP processing, tau NFTs, and 
cognition, within the context of Alzheimer’s disease................................................20 
 
5 Generalized cartoon model of mAChR allosteric modulation depicting putative 
allosteric sites in relation to the orthosteric binding site............................................26 
 
6 Allosteric ternary receptor complex model describing interaction between two 
ligands and a receptor ................................................................................................28 
 
7 Example of a ‘double-add’ assay format designed to identify PAMs by functional 
fluorometric Ca2+ mobilization readout .....................................................................29 
 
8  Example of generic PAM CRC in the presence of a fixed submaximal 
concentration of orthosteric agonist to determine PAM potency (A) and agonist 
CRC in the absence and presence of increasing fixed concentrations of PAM to 
determine fold-shift (B) .............................................................................................30 
 
9 Structures of examples of early allosteric mAChR modulators.................................32 
 
 
Chapter II 
 
Figure               Page 
 
1 Generalized work-flow utilizing iterative synthesis and testing of parallel analog 
libraries aimed at optimizing a given property or characteristic of the lead 
structure/scaffold........................................................................................................36 
 
 
 
 
xi 
Chapter III 
 
Figure               Page 
 
1 Structures of Eli Lilly hM4 PAM LY2033298 and Vanderbilt rM4 PAM 
VU010010..................................................................................................................84 
 
2 Chemical optimization of VU010010........................................................................86 
 
3 Singlepoint screen of M4 PAM VU010010 analogs based on scaffold 7 bearing 
eastern amide side chain substitutions .......................................................................88 
 
4 Structures, potency CRCs, and ACh CRC fold-shifts for M4 PAM leads.................90 
 
5 GIRK-mediated thallium flux M4 PAM assays with lad compounds VU0152099 
and VU0152100.........................................................................................................92 
 
6 [3H]-NMS competition binding experiments with M4 PAMs VU0152099 and 
VU0152100 at rM4 cell membranes ..........................................................................93 
 
7 mAChR subtype-selectivity profiles for M4 PAMs VU0152099 and VU0152100 
determined by ACh CRC fold-shift ...........................................................................95 
 
8 Functional GPCR off-target activity screening for M4 PAMs VU0152099 and 
VU0152100................................................................................................................97 
 
9 In vivo rat pharmacokinetic/PBL studies with M4 PAMs VU0152099 and 
VU0152100................................................................................................................99 
 
10 Reversal of amphetamine-induced hyperlocomotion and absence of sedation in 
vivo by M4 PAMs VU0152099 and VU0152100 ......................................................101 
 
11 Structures of first- and second-generation M4 PAMs based on optimization of the 
dimethylamino-thienopyridine amide scaffold ..........................................................103 
 
12 Synthesis of M4 PAM analog libraries 9a-s and 13a-s ..............................................104 
 
13 CRCs and ACh fold-shift for analog 13k in rat M4 cells by Ca2+ mobilization 
assay...........................................................................................................................108 
 
14 Synthesis of M4 PAM analog libraries.......................................................................110 
 
15 Singlepoint (10 µM) M4 PAM screen of analog sets 17-21 ......................................110 
 
16 M4 PAM characterization of analog 21n in rat M4/Gqi5-CHO cells by functional 
Ca2+ mobilization assay .............................................................................................113 
 
 
xii 
 
17 Effects of compounds 13k, 18h, 21n, and 21o in human M4/Gq15/16-expressing 
cells by functional Ca2+ mobilization assay...............................................................116 
 
18 Alignment of M4 PAM lead compounds 21n with refined histamine H3 receptor 
antagonist pharmacophore .........................................................................................117 
 
 
Chapter IV 
 
Figure               Page 
 
1 Compounds identified by M1 PAM HTS chosen for in vitro characterization..........119 
 
2 In vitro characterization of VU0119498 ....................................................................120 
 
3 Resynthesis and retesting of HTS hit VU0119498....................................................122 
 
4 Synthesis and singlepoint screening of initial matrix library of VU0119498 
analogs .......................................................................................................................124 
 
5 Singlepoint screen of at M3 of a subset of VU0119498 analogs chosen based on 
inactivity at M1 and M5 ..............................................................................................140 
 
6 mAChR subtype-selectivity of compound 42 (VU0238429) displaying high M5 
PAM selectivity .........................................................................................................142 
 
7 mAChR subtype-selectivity of compound 56 displaying pan-mAChR PAM 
activity........................................................................................................................142 
 
8 Compound 42 (VU0238429) requires ACh to activate M5 and causes a robust 
increase in ACh potency at M5 ..................................................................................144 
 
9 Competition binding experiments with VU0238429 and compound VU0119498 ...145 
 
10 Rat pharmacokinetic PBL study of VU0238429 and calculated PK parameters.......146 
 
11 Initial optimization strategy for M5 PAM VU0238429 .............................................148 
 
12 Synthesis and M1/M5 singlepoint screening of biaryl/heterobiaryl and phenethyl 
analogs VU0238429...................................................................................................149 
 
13 M1, M3, and M5 subtype-selectivity and ACh CRC fold-shift of compound 6a 
(VU0365114) and 6d (VU0365117)..........................................................................153 
 
14 Strategy for second round of M5 PAM analog library iterations ...............................154 
 
 
xiii 
 
15 Structures, mAChR subtype-selectivity profile, and ACh CRC fold-shift for 
VU0400265, the first M5-selective PAM ..................................................................155 
 
16 M1/M5 singlepoint screening of substituted indole and oxindole analogs.................156 
 
17 Synthesis of oxindole M5 PAM analogs VU0402733, VU0402734, and 
VU0402735 ...............................................................................................................158 
 
18 Structures and CRCs for M5 PAM analogs bearing 3-position ketone repalcements159 
 
19 M1, M3, and M5 subtype-selectivity profile for VU0402734, the gem di-fluoro 
analog of M5 PAM VU0238429 ................................................................................160 
 
20 Optimization strategy for third round of M5 PAM library iterations.........................162 
 
21 Structure and M5 PAM activity of piperonyl analog VU0366628 ............................162 
 
22 Structures and CRCs for ortho-fluorinated M5 PAMs based on VU0365114 lead 
structure......................................................................................................................163 
 
23 Subtype-selectivity profiles for VU0400266 and VU0400267 .................................165 
 
24 Structures and M5 CRCs for 2x2 matrix library of phenoxybenzyl gen-difluoro 
analogs .......................................................................................................................167 
 
25 M1, M3, and M5 CRCs for VU0403751 and VU0403753 .........................................168 
 
26 ACh CRC fold-shift effect of gem-difluoro lead analogs VU0403751 and 
VU0403753................................................................................................................169 
 
27 M5 CRCs for tricyclic analogs VU0403897 and VU0403898...................................170 
 
28 Synthetic scheme for generation of a diverse set of M5 PAM analogs based on 
VU0365114 bearing western ethers...........................................................................172 
 
29 M5 singlepoint screening of wester ether analogs......................................................174 
 
30 Basic-amine containing western ether analogs that partially inhibited an ACh 
~EC20 response in M5 PAM screen shown in Figure 29, suggesting potential M5 
NAM or antagonism ..................................................................................................175 
 
31 Synthesis and M5 CRC for 5-methoxy analog VU0366627 .....................................177 
 
32 Synthesis of four southern hetereobiaryl ether analogs based on VU0400265 .........182 
 
 
 
xiv 
33 Structures, lipophilicities, and M5 potency/efficacy for four hetereobiaryl ether M5 
PAMs .........................................................................................................................183 
 
34 M5 ACh CRC foldshift assay with analog VU0414747 ............................................184 
 
35 Synthesis and SAR for southern heterobiaryl amine-containing M5 PAM analogs ..185 
 
36 M5 ACh CRC fold-shift assay with analog VU0415478...........................................187 
 
37 Synthesis and M5 potency/efficacy of VU0415486, the 3-pyridyl congener of 
VU0238429................................................................................................................188 
 
38 Structures and M5 potency/efficacy of acidic and basic moieties in the distal 
southern region of the M5 PAM scaffold...................................................................189 
 
39 M5 ACh inhibition CRCs for VU0414750, a potential M5 NAM .............................190 
 
40 Rat M5 ACh CRC fold-shift assay with early lead compound VU0238429..............194 
 
 
Chapter V 
 
Figure               Page 
 
1 Initial optimization strategy for VU0119498 aimed at discovering modifications 
that engender increased M1 PAM activity and subtype-selectivity ...........................198 
 
2 Synthesis of initial biaryl/heterobiaryl library based on VU0119498 .......................199 
 
3 Singlepoint (10 µM) M1/M5 screen of initial 12-member biaryl/heterobiaryl and 
Phenethyl analog library based on VU0119498 ........................................................200 
 
4 Structure and PAM activity of VU0365137 ..............................................................201 
 
5 Subtype-selectivity of M1 PAMs VU0366368 and VU0366369...............................204 
 
6 Structure and M1 PAM CRC for VU03663657 .........................................................206 
 
7 SAR summary for M1 PAM HTS hits VU0029767 and VU0090157.......................207 
 
8 Singlepoint (10 µM) M1 PAM screen of VU0090157 analogs bearing diverse 
northern substitutions.................................................................................................207 
 
9 Structures of VU0090157 analogs generated to explore SAR at the northern 
headpiece....................................................................................................................208 
 
 
 
xv 
10 Synthesis and screening of BQCA and BQCA analogs at rat M1..............................210 
 
11 CRCs of BQCA and three analogs at rM1 by Ca2+ mobilization assay .....................211 
 
12 Structure and M5 CRCs for BQCA-based analogs VU0400268 and VU0400269....214 
 
13 Structure of two M1 PAM hits identified by 30 µM singlepoint screen of 
approximately 200 re-ordered putative PAMs identified from a functional M1 
antagonist HTS campaign ..........................................................................................216 
 
14 M1 CRCs of PAM hits VU0108370 and VU0165202...............................................216 
 
15 Initial optimization strategy for M1 PAM hit VU0108370........................................217 
 
16 Synthesis of M1 PAM hit VU0108370 used to generate southern benzyl-
derivatized library ......................................................................................................217 
 
17 Structures and M1 PAM CRCs of southern benzyl analogs based on the 
VU0108370 / VU0165202 scaffold identified from a larger singlepoint triage 
assay...........................................................................................................................218 
 
18 Structures and M1 PAM CRCs of meta-substituted southern benzyl analogs based 
on the VU108370 / VU0165202 scaffold ..................................................................219 
 
19 Structure and ACh CRC fold-shifts for M1 PAM leads VU0405652 and 
VU0405645................................................................................................................222 
 
20 M3 and M5 subtype-selectivity CRCs for original M1 PAM HTS hits and select 
intermediate lead analogs...........................................................................................223 
 
21 mAChR subtype-selectivity for probe compound VU0405652.................................224 
 
22 Singlepoint  (10 µM) screen of large panel of compounds from the VU HTS 
collection identified from a VU0108370-based structure similarity virtual screen...225 
 
23 Structure and subtype-selectivity profiles of novel M1 agonist HTS hits..................227 
 
24 M1 agonist SAR revealed by initial matrix library and singleton syntheses..............228 
 
25 mAChR subtype-selectivity profiles of M1 agonist leads VU0184670 and 
VU0357017................................................................................................................229 
 
26 M2-M5 functional antagonism profiles of M1 agonist leads VU0184670 and 
VU0357017 as well as parent hits VU0177548 and VU0207811 .............................230 
 
 
 
xvi 
27 [3H]-NMS competition binding CRcs with parent M1 agonist leads VU0184670 
and VU0357017 as well as parent hits VU0177548 and VU0207811 ......................231 
 
28 CRCs of M1 agonist leads VU0184670 and VU0357017 as well as parent hits 
VU0177548 and VU0207811 ....................................................................................232 
 
29 Structure and mAChR subtype-selectivity of M1 agonist TBPB...............................235 
 
30 First round of synthesis of TBPB analogs .................................................................236 
 
31 mAChR subtype-selectivity profile for TBPB analog 1b ..........................................237 
 
32 Synthesis of fluorine-substituted TBPB analogs .......................................................239 
 
33 Synthesis of additional fluorinated TBPB analogs ....................................................240 
 
34 M1-M5 CRCs for M1 antagonist compound 1 ............................................................243 
 
35 Synthesis of M1 antagonist compound 1 analogs ......................................................244 
 
36 M1-M5 CRCs for lead compound 5b..........................................................................246 
 
37 Additional SAR exploration around the M1 antagonist scaffold resulting in 
inactive analogs..........................................................................................................248 
 
 
Chapter VI 
 
Figure               Page 
 
1 Optimization progression summary for M4 PAMs based on a substituted 
thienopyridine scaffold ..............................................................................................253 
 
2 Abbreviated SAR summary for M5 PAM optimization based on early lead 
VU0238429................................................................................................................258 
 
3 Overview of key lead compounds identified during M5 PAM optimization project.260 
 
 
 
 
 
 
 
xvii 
LIST OF ABBREVIATIONS 
 
°C Degrees celsius 
[3H]-NMS [3H]-N-methylscopolamine 
α Cooperativity factor 
AC Adenylyl cyclase 
Acetyl-CoA acetyl-coenzyme A 
ACh Acetylcholine 
AChE Acetylcholinesterase 
 
AChEI Acetylcholinesterase inhibitor 
 
AD Alzheimer’s disease 
 
Aβ Amyloid-β 
 
APP Amyloid precursor protein 
 
ATCM Allosteric ternary complex model 
 
AUC Area under the curve 
 
β Efficacy modulation factor 
 
BBB Blood-brain barrier 
 
BQCA Benzyl quinolone carboxylic acid 
 
BuChE Butyrylcholinesterase 
 
CAA Cerebral amyloid angiopathy 
 
cAMP Cyclic adenosine monophosphate 
 
CAR Conditioned avoidance responding 
 
CCh Carbachol 
 
cGMP Cyclic guanosine monophosphate 
 
CBF Cerebral blood flow 
 
ChAT Choline acetyltransferase 
 
 
xviii 
 
CHO-K1 Chinese hamster ovary-K1 
 
CNS Central nervous system 
 
CPP Conditioned place preference 
 
CRC Concentration-response curve 
 
CSF Cerebrospinal fluid 
 
D1 Dopamine D1 receptor 
 
D2 Dopamine D2 receptor 
 
DA Dopamine 
 
DMPK Drug metabolism and pharmacokinetic 
 
DMSO Dimethyl sulfoxide 
 
DOS Diversity-oriented synthesis 
 
EDTA Ethylenediamine tetra-acetic acid 
 
ELSD Evaporative light scattering device 
 
EPSC Excitatory post-synaptic current 
 
ERK Extracellular signal regulated kinase 
 
GABA γ-amino-butyric acid  
 
GABAA γ-amino-butyric acid receptor A 
 
GlyT1 Glycine type-1 transporter 
 
GIRK G-protein coupled inward-rectifying K+ channel 
 
GPCR G-protein coupled receptor 
 
GRK G-protein coupled receptor kinase 
 
GTPγS Guanosine trisphosphate-γS 
 
HPLC High-performance liquid chromatography 
 
HTS High-throughput screening 
 
Hz coupling constant 
 
IHC Immunohistochemistry 
 
IP Immunoprecipitation 
 
 
xix 
 
I.P. Intraperitoneal  
 
IP3 Inositol trisphosphate 
 
KA/a/KB/b/KD/d Equilibrium dissociation constant 
 
KI/i Equilibrium dissociation constant from competition binding 
 
KO Knockout 
 
LCMS Liquid chromatography mass spectrometry 
 
logP Log partition coefficient 
 
LTP Long-term potentiation 
 
M1-M5 Muscarinic acetylcholine receptor subtypes 1-5 
 
mAChR Muscarinic acetylcholine receptor 
 
MAPK Mitrogen-activated protein kinase 
 
MCH Melanin-concentrating hormone 
 
mGluR Metabotropic glutamate receptor 
 
MHz Megahertz 
 
MLSCN Molecular libraries screening center network 
 
MLPCN Molecular libraries probe center network 
 
mPFC Medial pre-frontal cortical/cortex 
 
NAc Nucleus accumbens 
 
nAChR Nicotinic acetylcholine receptor 
 
NAM Negative allosteric modulator 
 
NDMC N-desmethyl clozapine 
 
NFT Neurofibrillary tangle 
 
NMDA N-methyl-D-aspartic acid 
 
NMDAR N-methyl-D-aspartic acid receptor 
 
NMR Nuclear magnetic resonance 
 
NO Nitric oxide 
 
PAM Positive allosteric modulator 
 
 
xx 
 
PBL Plasma-brain levels 
 
PCP Phencyclidine 
 
PEG Polyethylene glycol 
 
PET Positron emission tomography 
 
P-gp P-glycoprotein 
 
PI3K Phosphatidyl inositol-3 kinase 
 
PK Pharmcokinetic 
 
PKA Protein kinase A 
 
PKG Protein kinase G 
 
PLA Phospholipase A 
 
PLC Phospholipase C 
 
PLD Phospholipase D 
 
PNS Peripheral nervous system 
 
PPI Prepulse-inhibition 
 
ppm Parts per million 
 
RT-PCR Reverse transcriptase polymerase chain reaction 
 
SAR Structure-activity relationship(s) 
 
S.C. Subcutaneous 
 
SEM Standard error of the mean 
 
SNc Substantia nigra pars compacta 
 
TCM Ternary complex model 
 
TLC Thin-layer chromatography 
 
UV Ultra-violet 
 
VAChT Vesicular ACh transporter 
 
VHTSC Vanderbilt high-throughput screening center 
 
VTA Ventral tegmental area 
 
WT Wild-type 
 
 
1 
Chapter I 
 
INTRODUCTION 
 
Muscarinic acetylcholine receptors 
 
Acetylcholine biosynthesis and receptors 
 Acetylcholine (ACh) is the only known non- amino acid or non- amino acid-
derived small molecule neurotransmitter and is vitally important to a wide range of basic 
physiological processes and functions throughout the mammalian body1-5.  ACh is 
synthesized endogenously from dietary choline, which is acetylated within the cell by the 
enzyme choline acetyltransferase (ChAT) using acetyl-coenzyme A (acetyl-CoA) as 
substrate to furnish the acetyl group (Fig. 1)1.  Subsequent intraneuronal packaging of 
cytoplasmic ACh into synaptic vesicles occurs via the vesicular ACh transporter 
(VAChT) (Fig. 1)6,7.  Following ACh release into the synapse, the enzyme 
acetylcholinesterase (AChE) rapidly terminates ACh signaling by hydrolyzing the ester 
of ACh to produce acetate and choline, the latter of which is then subject to local 
neuronal reuptake by the high-affinity choline transporter (Fig. 1)8,9.  Such reuptake 
represents the rate-limiting step in the ACh synthetic cycle9.  In addition to AChE, which 
is encoded by a single gene but occurs in multiple forms via alterative mRNA-splicing, 
butyrylcholinesterase (BuChE) serves as a second enzyme responsible for degradation of 
ACh10-12.  However, BuChE is mainly present in plasma and in non-neuronal tissues 
where it contributes to termination of ACh signaling11,12. 
 
 
2 
 
Figure 1.  Generalized diagram of cholinergic biosynthesis, packaging, degradation, and reuptake. 
 
 As a neurotransmitter, ACh plays essential roles in both the central nervous 
system (CNS) and peripheral nervous system (PNS)3,13.  Within the autonomic arm of the 
PNS, cholinergic signaling occurs at the pre-ganglionic sympathetic and parasympathetic 
synapses, the post-ganglionic parasympathetic synapses, and at a subset of post-
ganglionic sympathetic synapses in skin and sweat glands3,13.  ACh is also released at the 
skeletal neuromuscular junction, where it is responsible for initiation of muscle 
contraction3,13.  In the CNS, ACh is released from cholinergic neurons arising from six 
main brain regions (denoted as Ch. I – Ch. VI) and is responsible for a multitude of 
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integral brain functions and processes such as regulation of motor control, reward, 
sleep/wake cycles, metabolism, learning and memory, attention, and more (Fig. 2)3,13,14. 
 
 
Figure 2.  Diagram of six main central cholinergic neuron projection pathways in the rat brain (adapted 
from Woolfe 1991). 
 
 There exist two classes of ACh receptors, the ionotropic receptors activated by 
exogenous nicotine and the metabotropic receptors activated by exogenous muscarine, 
termed nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine 
receptors (mAChRs), respectively15,16.  These two classes can also be delineated by their 
sensitivity to antagonism by either tubocurarine (selective for nAChRs) or atropine 
(selective for mAChRs).  Of the nAChRs, muscular (Nm) nAChRs mediate the actions of 
ACh at the skeletal neuromuscular junction while neuronal (Nn) nAChRs are present in 
the autonomic ganglia and CNS15.  All nAChRs are pentameric ion channels comprised 
of various combinations of subunits (α1-10, β1-4, as well as the less common γ, δ, and ε 
subunits), which confer distinct structures and functions15.  In general, nAChRs in the 
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CNS, such as those comprised of α4 and β2 subunits or all α7 subunits, are present at both 
pre- and post-synaptic membranes where they enhance neuronal excitation by increasing 
Na+ and Ca2+ permeability15.  In contrast, mAChRs are G-protein coupled receptors 
(GPCRs) of which there exist five distinct subtypes (mAChR1-5 or M1-M5), each encoded 
by a separate intron-less gene (CHRM1-5)2,5,16.  These mAChR subtypes are expressed 
differentially in both central and peripheral tissues, where they mediate the metabotropic 
signaling of ACh. 
 
Structure and signaling of mAChR subtypes 
 Following cloning of the rat and human mAChR genes, a large body of research 
has focused on elucidating the molecular structure and function of these receptors.  
mAChRs are Type I (or Class A) rhodopsin-like GPCRs ranging in size from 460 (M1) to 
590 (M3) amino acids and sharing a high degree of homology among their respective 
orthosteric ACh-binding sites2,5,16-18.  M1, M3, and M5 exhibit higher structural homology 
to each other than to M2 and M4, which themselves share highest homology to each 
other2,5.  Correspondingly, the pre- versus post- synaptic localization patterns and 
associated downstream signaling pathways are generally similar for M1, M3, and M5 
versus M2 and M417,18.  The former three are often considered stimulatory or excitatory 
given their predominantly post-synaptic localization and coupling to the 
Gαq/phospholipase-C (PLC)/inositol triphosphate (IP3)/Ca2+ pathway, while the latter 
two are typically regarded as inhibitory with predominantly pre-synaptic localizations as 
autoreceptors or heteroreceptors with coupling to the Gαi/adenylyl cyclase (AC)/cyclic 
adenosine monophosphate (cAMP)/protein kinase A (PKA) effector system17,18.   
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 It is important to note that many of the intracellular effects of mAChR activation 
are also mediated by Gβγ, such as the Gβγ-induced opening of inward rectifying K+ 
channels (GIRKs) in the case of M2 and M4 or Gβγ-mediated phosphatidyl inositol-3 
kinase (PI3K)/Src signaling in the case of M117,19-24.  Furthermore, mAChRs have been 
found to activate many other downstream effectors including the phospholipases PLA 
and PLD, and all mAChRs have been shown to activate mitogen-activated protein kinase 
(MAPK)-signaling as measured by extracellular signal regulated kinase (ERK) 
phosphorylation17,25.  Like other Type I GPCRs, additional mAChR signaling occurs via 
β-arrestin1/2 (Arrestin2/3) binding following phosphorylation of the receptor by G-
protein coupled receptor kinases (GRKs)17.  In addition to their role(s) in receptor 
desensitization and internalization, Arrestins can also serve as protein scaffolds and 
signal-transduction nodes themselves26.  Thus, mAChR signaling within the cell can 
involve a broad and complex network of pathways, which are highly dependent upon the 
specific cell type and its protein composition.   
 More recently, pharmacological studies have revealed that different small 
molecule mAChR ligands are capable of exerting drastically different downstream 
signaling effects (through the same receptor subtype), presumably due to stabilization of 
distinct receptor structure conformations27,28.  Such phenomena, often referred to as 
ligand-induced receptor trafficking/signaling-bias, represent an important area of study 
for neuropharmacology, as ligands with the same mode of pharmacology (e.g. agonists) 
but of different chemical classes/chemotypes may cause divergent intracellular signaling 
through the same mAChR.  This has obvious implications for use of novel (and 
particularly allosteric) ligands in basic neurobiological research and in therapeutic drug 
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discovery because different compounds targeting the same receptor may yet cause 
different electrophysiological, neurochemical, and behavioral effects28. 
 Activation of mAChRs occurs via structural rearrangement and subsequent G-
protein activation in response to ACh-binding to the orthosteric site deep within the 
transmembrane-spanning α-helical domain of the receptor29.  Within this site, a number 
of key residues form reversible non-bonding interactions with ACh29.  For example in the 
case of M1, tyrosine-381, which is located in the 6th-transmembrane α-helix, forms a π-
cation interaction with the positively charged ACh quaternary amine that is crucial to 
potent receptor activation by ACh30.  When this residue is mutated to an alanine, ACh 
potency at M1 is right-shifted by several orders of magnitude30.  This M1 mutant is thus 
particularly useful for characterization of novel M1 activators because it can provide 
evidence for or against an orthosteric mode of binding31. 
 
Localization of mAChR subtypes 
 A number of molecular biology techniques, including in-situ mRNA 
hybridization, reverse transcriptase PCR (RT-PCR), immunohistochemistry (IHC), 
immunoprecipidation (IP), and radioligand-binding have been used to investigate the 
neuroanatomical localization patterns of each mAChR32-40.  Due to differences inherent 
among these various techniques, the fact that different investigators have used different 
antibody preparations (in the case of IHC/IP studies), and the observation that presence of 
mRNA for a given receptor in a particular tissue does not directly demonstrate equivalent 
functional protein levels in that tissue, has prevented widespread quantitative agreement 
on mAChR subtype density and localization.  Nonetheless, relative distributions and 
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general localization of each subtype is known.  At the mRNA level, transcripts for all five 
mAChR subtypes are found throughout the body in most tissues with detection levels 
ranging from high to near-baseline.  At the protein level, the breadth of mAChR 
expression appears lower; however, there is generally good agreement between receptor 
mRNA levels and protein levels in most brain regions of primary interest to 
neurobiological research.   
 In the CNS, M1 represents the predominant subtype, with high levels of 
expression throughout the cortex, striatum, hippocampus, and to a lesser extent the 
olfactory bulb and amygdala33,35,40.  M1 is also present at low levels in peripheral smooth 
muscle33.  Similar to M1, the M3 subtype is found in the brain cortex, striatum, 
thalamus/hypothalamus, hippocampus, and olfactory bulb; though, levels of M3 in the 
CNS are generally lower than those of M1 across each shared brain region33,35,40,41.  
Peripheral M3 is predominately found throughout cardiovascular and gastrointestinal 
smooth muscles as well as in numerous glandular tissues, and to a lesser extent in the 
heart33.  The structurally related M5 receptor initially proved the most difficult subtype to 
localize due to its extremely low levels of expression.  Indeed, it has been estimated that 
this subtype represents less than 2% of all mAChR protein in the brain38.  Ultimately, M5 
has been shown to be the only mAChR present on midbrain dopaminergic cell bodies 
originating in the ventral tegmental area (VTA) and substantial nigra pars compacta 
(SNc)34,37.  These midbrain regions contain the highest levels of M5 in the CNS, with 
cortical and hippocampal tissues containing M5 at levels far below those of M1 or 
M333,35,40.  Importantly, non-neuronal M5 is found throughout the cerebrovascular system, 
including within the microvessels and epithelial cells comprising the blood-brain barrier 
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(BBB), and in the larger arterioles and arteries of the brain36,42.  The M2 subtype is 
expressed largely on brainstem and basal forebrain cholinergic neurons (Ch. V-VI and 
Ch. IV, respectively) as well as in the thalamus, hippocampus, and striatum33,35,40.  M2 is 
also highly expressed in cardiac tissues and to a lesser extent in peripheral smooth 
muscles33.  The M4 subtype is most heavily expressed in the midbrain, striatum, and other 
areas of the basal ganglia, with lower levels present in the hippocampus and 
cortex32,33,35,37,40,43.  Peripherally, M4 may be present in mainly in lung tissue33. 
 
Genetic deletion of mAChR subtypes 
 Given the high structurally homology of the orthosteric ACh-binding site across 
the five mAChR subtypes, discovery of small molecule ligands possessing high binding 
and/or functional selectivity for an individual subtype has proven challenging44.  As 
discussed in greater detail in a subsequent section of this Chapter, a number of potent 
orthosteric mAChR agonists and antagonists have been discovered, which have provided 
utility in certain pharmacological research contexts but most have suffered from poor 
subtype-selectivity.  Due to the longstanding paucity of selective pharmacological tools, 
insight into the specific functions of each mAChR at the cellular, neurocircuitry, 
neurochemical, and behavioral levels have relied largely on studies using mice 
genetically engineered to lack one or more mAChR subtype45.  These receptor knockout 
(KO) mice have provided insight to the role(s) of each mAChR in basic physiology, 
neurobiology, and within the context of various CNS disorders45.  Overall, the multitude 
of findings from mAChR-KO mice agree well with the predicted functions of each 
subtype based on their localization and known signaling. 
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 Given the high density of M1 in brain regions known to be important to cognitive 
function, such as the cortex and hippocampus, it is not surprising that M1-KO mice 
exhibited deficits in multiple biochemical and behavioral studies related to learning and 
memory.  Specifically, M1-KO mice have been shown to exhibit cognitive deficits in 
behavioral tests such as the eight-arm radial maze, fear-conditioning (under conditions 
requiring extra-hippocampal mechanisms), and social discrimination45-47.  Interestingly, 
no deficits were found in other tests of cognition such as the Morris water maze, a 
common paradigm for assessing impairments in hippocampal-dependant spatial reference 
memory45,47.  These and other related behavioral findings have contributed to the 
hypothesis that M1 is not required for initial formation of memory in the hippocampus but 
is likely important to long-term memory consolidation and to interactions between the 
hippocampus and cortex46.  Electrophysiological experiments using M1-KO mice have 
suggested that M1 activation enhances N-methyl-D-aspartic acid receptor (NMDAR) 
currents in hippocampal slices48.  Likewise, in related electrophysiology experiments 
investigating long-term potentiation (LTP) in M1-KO mice, selective hippocampal 
impairments were found compared to wild-type (WT) under certain conditions45,49,50.  
Biochemical evidence from M1-KO mice also supports a role for M1 in certain learning 
and memory processes.  For instance, activation of MAPK signaling, which is believed to 
be highly important to synaptic plasticity, was absent in cultured cortical cells from M1-
KO mice (versus WT) following muscarinic agonist stimulation51,52.  Similar results were 
also found in analogous experiments using hippocampal pyramidal neurons from M1-KO 
mice52.   
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 Taken together, these and other related findings support the notion that M1 plays a 
role in learning and memory; however, it is likely that other mAChRs are also important 
to specific cognitive functions.  Indeed, pan-mAChR antagonists such as scopolamine 
induce substantial cognitive deficits beyond those observed with genetic deletion of M1 
alone, and other mAChRs have been implicated in various electrophysiological and 
biochemical roles highly relevant to learning and memory functions45,53,54.  Moreover, 
M1-KO mice exhibit hyperlocomotor activity, which complicates other behavioral 
assessments and may be related to the expression of striatal M1 receptors in WT 
animals45,47,55.  Such hyperlocomotion is likely due to elevated striatal dopamine (DA) 
levels in M1-KO mice, which were found to be approximately 2-fold greater than in WT 
controls55.  Lastly, WT mice given high doses of the muscarinic agonist pilocarpine will 
fall into seizures that most often culminate in death.  This effect was completely 
abolished in M1-KO mice, suggesting that M1-mediates pilocarpine-induced seizure 
activity, possibly via the enhancement of NMDAR signaling49. 
 Genetic deletion of M3 in mice has suggested that this subtype plays an important 
role in central regulation of metabolism, which is consistent with M3 localization in the 
thalamus/hypothalamus.  Specifically, mice lacking M3 are hypophagic and exhibit 
significantly reduced total body weight (~25% decrease versus WT), reduced fat pad 
mass (~50% decrease versus WT), and reduced serum levels of leptin and insulin (~5-10x 
decrease versus WT)45,56.  These effects have been hypothesized to occur due to absence 
of M3 that is normally expressed on melanin-concentrating hormone (MCH)-positive 
neurons located in the hypothalamus56.  Given the overlapping CNS expression pattern 
and similar signaling properties between M3 and M1, it is likely that cortical and/or 
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hippocampal M3 contributes to certain aspects of learning and memory.  Indeed, recent 
behavioral studies with M3-KO mice revealed profound deficits in contextual fear-
conditioning but none in auditory cue fear-conditioning, suggesting that M3 plays a role 
in hippocampal-dependent learning and memory57.  In agreement with localization data, 
deletion of M3 has also been shown to substantially reduce ACh-induced smooth muscle 
contraction in the periphery58-60.  Likewise, muscarinic agonist-induced salivation was 
decreased but not abolished in M3-KO mice, suggesting that M3 as well as other mAChRs 
play a role in salivary secretion61. 
 In the case of M5, consistent with its highest expression in midbrain dopaminergic 
neurons where it is the only mAChR present, M5-KO mice have suggested that this 
subtype plays an important role in mediating reward-responses through the mesolimbic 
DA pathway and in regulation of striatal DA levels (Fig. 3)34,37,45.  Specifically, 
muscarinic-agonist induced elevations in striatal DA release were reduced (~5-10x versus 
WT), but not abolished in M5-KO mice brain slices, which has led to the hypothesis that 
lack of pre-synaptic M5 heteroreceptors located on dopaminergic terminals innervating 
the striatum are responsible for this effect62.  However, based on numerous localization 
studies, a virtual absence of M5 expression in the striatum is at odds with this hypothesis, 
and the slices used in this particular study would not have contained the distal DA cell 
bodies that originate from the midbrain, where M5 is most likely excitatory and post-
synaptic37,62.  Additional evidence that M5 plays a vital role in the mesolimbic DA 
pathway comes from microdialysis experiments with M5-KO mice.  In WT mice, 
electrical stimulation of hindbrain cholinergic nuclei (Ch. V and Ch. VI) leads to a 
prolonged and significant rise in DA levels of the nucleus accumbens (NAc), the primary 
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forebrain target of VTA dopaminergic projections, which was completely abolished in 
M5-KO mice63.  Behaviorally, M5-KO mice exhibit substantially reduced sensitivity to 
the rewarding effects of drugs such as cocaine and opiates (both of which act as strong 
activators of mesolimbic DA signaling)45,64,65.  These mice displayed large decreases in 
self-administration of cocaine and decreased conditioned place-preference (CPP) in 
response to training with cocaine or morphine place-pairing64,65.  Additionally, morphine-
induced elevations of DA levels in the NAc and in Fos-B expression were reduced in M5-
KO mice64.  Furthermore, withdrawal-induced anxiety behaviors were less pronounced in 
M5-KO64.  Interestingly, morphine retained its analgesic efficacy in M5-KO mice, 
suggesting that if M5 antagonists proved useful in the treatment of opiate addiction, the 
pain-alleviating effects of such drugs may be retained in clinical settings64.   
 
 
Figure 3.  Abbreviated diagram of the putative roles of M4 and M5 in the central mesolimbic DA pathway 
(Wess 2007). 
 
 Taken together, this large body of data supports the hypothesis that the primary 
role of neuronal M5 is in regulation of central DA signaling/pathways.  Although less 
research has focused on nigrostriatal DA signaling, it is likely that M5 plays a similarly 
important and parallel role.  However, other studies with M5-KO mice have found subtle 
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deficits in cognitive function and in neuroanatomical/biochemical correlates of cognition.  
Specifically, atrophy of cortical pyramidal neurons from M5-KO mice was observed 
along with modest behavioral deficits in spatial and non-spatial memory functions (as 
assessed by Y-maze and novel object recognition tests, respectively)66.  LTP at the mossy 
fiber-CA3 synapse of the hippocampus was also impaired in brain slices from M5-KO 
mice66.  Some or all of these deficits may be indirect results of decreased cerebral blood 
flow (CBF) and oxygen delivery resulting from absence of M5 in the cerebrovascular 
system.  It is well established that decreased blood flow to the brain can disrupt cognitive 
functions and alter brain histology67,68.  In WT animals, ACh-induces a pronounced 
vasodilatory effect across multiple cerebrovascular structures, which is completely 
abolished in M5-KO mice62.  Furthermore, mice lacking M5 exhibit a tonic/constitutive 
constriction of cerebral blood vessels that results in decreased cerebral blood flow, which 
may underlie the cognitive effects66.  Interestingly, ACh-induced vasodilation in 
peripheral vascular tissues was unaffected by genetic M5 deletion, consistent with the 
hypothesis that the M3 receptor mediates the peripheral vasodilatory effects of ACh62.  
Cholinergic neurons, particularly those originating in basal forebrain structures, provide 
direct innervation to cerebral blood vessels, where ACh release induces vasodilation 
likely via a nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/protein kinase G 
(PKG)-dependent mechanism69-72.  Thus, some of the cognitive symptoms of CNS 
disorders, including Alzheimer’s disease (AD) and cerebrovascular dementia, may be 
related to decreased CBF resulting from loss of cholinergic nuclei of the basal forebrain 
and consequently decreased activation of cerebrovascular M566,67.  The potential 
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therapeutic relevance of these findings is discussed in more detail in a subsequent section 
of this Chapter. 
 High doses of muscarinic agonists such as oxotremorine induce tremor and 
hypothermia in rodents, which was completely abolished and reduced, respectively, in 
M2-KO mice73.  Likewise, analgesic efficacy of muscarinic agonist administration was 
reduced in these mice, consistent with related studies that found electrophysiological 
deficits in spinal ganglion neurons of M2-KO mice73,74.  In isolated heart atria, absence of 
M2 resulted in a complete lack of carbachol-induced bradycardia, which agrees with 
previous localization and pharmacological studies suggesting that M2 is the predominant 
mAChR mediating the parasympathetic actions of ACh in cardiac tissue75.  In the case of 
central M2, mice lacking this receptor were devoid of oxotremorine-induced inhibition of 
ACh-release in both cortical and hippocampal brain slices, which supports the hypothesis 
that M2 is mainly present as a pre-synaptic autoreceptor governing ACh release76.  In 
vivo, behavioral studies with M2-KO mice found impairments in passive avoidance as 
well as elevated ACh efflux in the hippocampus77. 
 Consistent with high striatal M4 expression and principally pre-synaptic 
auto/heteroreceptor role(s) for M4 in the CNS, M4-KO mice were found to lack 
oxotremorine-mediated inhibition of ACh and DA release in striatal slices76,78.  These 
mice also exhibited increased basal locomotor activity, increased sensitivity to dopamine 
D1 receptor (D1) agonist-induced hyperlocomotion, and increased sensitivity to 
phencyclidine (PCP)-mediated disruptions in pre-pulse inhibition (PPI)79,80.  These results 
are not surprising given the purported interplay between central M4 activation and 
decreased DA signaling81.  Futhermore, they suggest that activation of M4 may have 
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therapeutic relevance to treatment of the positive symptoms of schizophrenia, given the 
established role of elevated DA as a large component underlying this symptom cluster44. 
 Despite these pronounced phenotypic effects of selective mAChR genetic 
deletion, all M1-M5-KO mice are devoid of overt abnormalities in general development, 
reproductive ability, or lifespan45.  Furthermore, compensatory up-regulation of other 
mAChR subtypes in these KO mice appears to be absent, as expression levels for all 
remaining mAChR subtypes in every individual KO mice strain are approximately equal 
to those of WT mice45.  Nonetheless, genetic approaches to studying mAChR function 
suffer from several disadvantages and caveats, such as differences in genetic background 
between multiple strains, unseen compensatory effects beyond the context of the 
cholinergic system, and the generally challenging technical aspects of mouse 
neurobiological research. 
 
Therapeutic potential of mAChRs as drug targets 
 In light of the large body of data obtained from receptor localization and mAChR-
KO mice studies, it is evident that selective activation or inhibition of signaling through 
one or more mAChR subtype may provide therapeutic utility for treatment of a wide 
range of diseases and disorders.  Numerous pharmaceutical companies and research 
organizations have thus sought to discover and develop novel small molecule mAChR-
targeted drugs44.  However, due to the difficulty in obtaining truly selective ligands for a 
particular subtype that arises from high orthosteric binding site structural homology 
across all mAChRs, few muscarinic drugs have reached the market44.  Internationally, 
current clinical use of approved muscarinic drugs is generally limited to antagonists for 
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the treatment of urinary incontinence, gastrointestinal and respiratory disorders, and in 
some cases Parkinson’s disease.  Nevertheless, great potential remains for drug discovery 
and development projects aimed at identifying novel subtype-selective mAChR ligands, 
particularly in the treatment of numerous CNS disorders based on the following 
hypotheses.  For purposes of relevance to this thesis and in order to maintain focus on 
M1, M4, and M5, which comprise the most important subtypes to treatment of CNS 
disorders, discussion of the therapeutic potential of selective M2- or M3- targeting is 
limited in the sections below. 
 One of the most well-known therapeutic potentials of selective M1 activation is in 
the treatment of Alzheimer’s disease, the most common cause of dementia, which is 
characterized by the two pathophysiological hallmarks of amyloid plaques comprised of 
amyloid-β (Aβ) and neurobrillary tangles (NFTs) comprised of hyperphosphorylated 
tau44,82.  In general, progressive neurodegeneration with increased oxidative stress, 
inflammation, and decreased cerebral blood flow accompany these two hallmarks82.  As 
is the situation for many CNS disorders, obtaining a clear and comprehensive 
understanding of the cause, progression, and complex molecular characteristics of AD 
has proven challenging, but will likely be vital to development of newer, more effective 
therapies.  With the exception of the NMDA receptor antagonist Memantine, the only 
drugs currently approved for treatment of AD are AChE inhibitors (AChEIs), such as 
Donepezil and Rivastigmine, which are only moderately efficacious in addressing 
cognitive symptoms and cause numerous side effects83,84.  The rationale for this AChE 
inhibition approach stems from a longstanding cholinergic hypothesis of AD83,84.   
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 Degeneration of basal forebrain cholinergic neurons was observed as an early 
event in AD, and it is now believed that this contributes to the impairments in cognitive 
function85-87.  Furthermore, numerous links between decreased ACh, Aβ deposition, and 
tau NFTs, have been found88-91.  This may provide a connection between the historic 
cholinergic hypothesis and more recent hypotheses that center on Aβ or tau as the 
primary factor in AD.  Although a wide group of potential therapeutic strategies continue 
to emerge, many focus solely on reducing Aβ via inhibition of β-secretase, inhibition of 
γ-secretase, immunization to promote Aβ clearance, or prevention of Aβ aggregation92.  
However, cholinergic treatments directly targeting muscarinic receptors such as M1 have 
also been explored preclinical and clinically as a means to overcome the limitations of 
AChE inhibitors.  Although no M1 agonists have reached the market, many have 
provided preclinical evidence supporting the M1 receptor as a putative molecular target 
for AD44. 
 In the cortex and hippocampus, M1 is believed to mediate the post-synaptic 
actions of ACh released from basal forebrain neurons such as the nucleus basalis of 
Meynert (Ch. IV) and the diagonal band of Broca (Ch. II)41,53,93.  Early and selective loss 
of these cholinergic neurons is a frequent feature of AD, and the degree of this 
degeneration correlates well with degree of dementia94,95.  In light of this, lesioning of 
these neurons by molecular neurotoxins such as 192 IgG-saporin has been used in rats as 
a model for AD, which has been found to recapitulate many aspects of the disease96.  
Depending on specifics of the behavior test parameters, such as toxin dose and 
corresponding degree of lesioning, impairments in the learning of an attention task were 
observed in this model; however, performance defects in the Morris water maze were 
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only moderate, consistent with the results from studies using M1-KO mice in this 
behavioral paradigm96.  In agreement with in vitro experiments demonstrating that 
activation of M1 or M3 (but not M2 or M4) in recombinant cells drives amyloid precursor 
protein (APP) processing towards the non-amyloidogenic pathway, basal forebrain 
cholinergic lesioning has been shown to increase cortical APP expression and 
amyloidogenic processing97-99.  Interestingly, these effects can be partially reversed by 
treatment of lesioned animals with a muscarinic agonist, further implicating the 
connection between the muscarinic system and APP regulation99.  However, whether the 
observed non-amyloidogenic APP processing (i.e. reduction in Aβ secretion) in vivo is 
mediated by M1 or M3 and what downstream signaling pathways underlie this regulation 
remains to be determined, as the absence of subtype-selective ligands has hampered such 
investigation.   
 Many M1 agonists have been evaluated in human AD trials, such as talsaclidine, 
sabcomeline, and xanomeline100.  Although some of these compounds displayed efficacy 
in reducing behavioral symptoms or in decreasing Aβ levels in the cerebrospinal fluid 
(CSF), all such candidates to date have failed in development largely due to side effects 
arising from lack of subtype-selectivity, such as those mediated by peripheral M2 and M3 
activation44.  Efficacy of mAChR agonists in tests of cognitive function in AD trials was 
absent or moderate; however, it is not known whether this was due to lack of selectivity 
for M1, poor CNS penetration or other drug metabolism and pharmacokinetic (DMPK) 
factors, dose-limitations from peripheral side effects, or if M1 is simply not a clinically 
valid target for AD (or perhaps some combination of these possibilities)44. 
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 In cortical and hippocampal samples obtained post-mortem from human AD 
patients, the protein levels of M1 generally remain unaltered; however, M2 levels are 
significantly reduced101,102.  This is likely due to the pre-synaptic localization of M2 on 
basal forebrain cholinergic neurons, which would be expected to reflect decreased M2 
levels as degeneration occurs.  This decrease in M2 is also found in basal forebrain 
cholinergic lesioned animals96.  Given the pre-synaptic role of M2 in regulating ACh 
release from these nuclei, selective targeting of this mAChR by small molecule 
antagonists has been considered in pharmaceutical development for AD44.  In vivo 
antagonism of M2 has been shown to increase ACh release; although, this approach 
suffers from potential drawbacks associated with the likely diminished M2 receptor 
protein levels in already-diagnosed AD patients as well as the serious cardiovascular 
liabilities inherent to M2 antagonism44,102.  The fact that post-synaptic M1 levels in the 
cortex remain approximately the same throughout AD suggests that selective activation 
of this subtype may be a more optimal approach if truly selective drugs were available. 
These findings and related considerations based on  links between M1, cognition, APP 
processing, and tau phosphorylation have been used to construct proposals that integrate 
putative signaling relationships in AD (Fig. 4)44. 
 
 
 
20 
 
Figure 4.  Proposed signaling relationships between M1, APP processing, tau NFTs, and cognition, within 
the context of Alzheimer’s disease.  (Adapted from Langmead et al. 2008)  
   
 However, decreased functional activity of M1 in brain tissue from AD patients 
may still limit the utility of this strategy, which may have contributed to the failure of 
muscarinic agonists in clinical trials for AD.  Interestingly, decreases in high affinity 
agonist binding, agonist-stimulated PLC activity, agonist-stimulated guanosine 
trisphosphate-γS (GTPγS)-binding, and GTPase activity provide evidence that G-protein 
coupling downstream of M1 is disrupted in AD101,103.  The reason for this uncoupling is 
not known, nor is it established that restoration of G-protein signaling downstream of M1 
could be achieved via receptor agonism or potentiation by allosteric modulators known to 
increase G-protein coupling efficiency in recombinant systems. 
 In addition to AD, M1 activation may prove useful in the treatment of 
schizophrenia44.  Although a thorough discussion of the current understanding of the 
underlying mechanisms responsible for producing each of the positive, negative, and 
cognitive symptom clusters observed in schizophrenic patients lies beyond this scope of 
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this Chapter, it is generally believed that hyperactivity of the forebrain DA signaling 
contributes heavily to the positive symptom cluster104.  This belief arose from numerous 
lines of evidence, including the observation that chronic administration of dopaminergic 
drugs of abuse such as cocaine and amphetamine can lead to emergence of positive 
symptom-like behaviors in non-schizophrenic individuals as well as the fact that most 
currently used antipsychotic drugs with positive symptom efficacy possess high-affinity 
DA receptor antagonist properties104.  In light of the high expression of M1 and M4 in the 
striatum, the pronounced elevation in forebrain DA levels as well as the pro-psychotic 
phenotype (i.e. increased locomotion and increased sensitivity to dopamine agonists in 
behavioral models of psychosis) observed in mice lacking these receptors, it is possible 
that drugs targeting central M1 and/or M4 may prove efficacious in the alleviation of the 
positive symptoms of schizophrenia. 
 Interestingly, administration of NMDAR antagonists such as PCP can recapitulate 
all symptom clusters of schizophrenia in normal individuals and can also exacerbate 
symptoms in previously stable psychotic patients105-107.  Correspondingly, enhancement 
of NMDAR signaling by increasing the synaptic concentration of its co-agonist glycine 
via inhibition of the central glycine type-1 transporter (GlyT1) has exhibited broad and 
robust efficacy in numerous preclinical models of psychosis108,109.  These and other 
related findings have led to a NMDA hypofunction hypothesis of schizophrenia106.  
Given the importance of M1 to certain aspects of learning and memory, including 
potentiation of NMDAR signaling, it is possible that M1 activation may also prove 
efficacious in treatment of the cognitive symptom cluster.  Although less established, M4 
activation may affect certain cognitive aspects of schizophrenia as well, given its 
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hippocampal expression and putative autoreceptor-mediated regulation of ACh release in 
multiple brain regions. 
 Perhaps the strongest evidence that M1 and/or M4 activation represents a viable 
treatment strategy for schizophrenia comes from clinical trials with the M1/M4-preferring 
orthosteric agonist xanomeline.  Although lacking adequate subtype-selectivity and 
ultimately failing to successfully emerge from clinical development due to M2/M3-
mediated dose-limiting peripheral side effects and DMPK-related issues, this compound 
proved effective in reducing a broad range of psychotic-like behavioral disturbances in a 
large phase III AD trial100.  A subsequent phase II trial performed to directly explore the 
utility of xanomeline in treatment of schizophrenia revealed improvements in measures 
of cognitive function and in some positive symptoms, and a multitude of preclinical 
animal studies found similarly promising results110.  However, it has remained a 
longstanding question as to what degree activation of M1 and M4 has contributed to these 
anti-psychotic effects of xanomeline. 
 Given the relationships between M1- and M4-mediated regulation of striatal DA 
signaling and motor function, antagonism of M1 and/or M4 has been proposed as an 
attractive therapeutic strategy for treatment of various motor-related disorders such as 
Parkinson’s disease and dystonia44,81.  Orthosteric anticholinergic drugs, such as 
procylidine and trihexyphenidyl, are presently used in the clinical management of such 
disorders; however, they suffer from poor-subtype selectivity and carry numerous side 
effects.  Because M1 activation is likely to be more important to cognitive function than 
M4 activation in general, and because midbrain autoreceptor M4 expression on 
cholinergic neurons projecting to the SNc and VTA (where it is believed to regulate ACh 
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release and thus subsequent excitation of dopaminergic projection neurons) renders M4 
antagonism particularly suited to reduction of forebrain DA levels, it has been suggested 
that selective M4 antagonists would prove superior to M1 antagonists in the treatment of 
motor dysfunction44,111.  However, to date no highly selective M4 antagonists have passed 
through clinical development. 
 In the case of M5, selective antagonism could be hypothesized to provide efficacy 
in treating the positive symptoms of schizophrenia due to its associated but opposite 
relationship to M4 in regulation of mesolimbic DA release (Fig. 3).  Whereas activation 
of M4 in the VTA would purportedly cause decreased DA release in the NAc, antagonism 
of M5 would be required to exert the same effect, and vice-versa for increasing NAc DA 
levels, due to the putative post-synaptic excitatory role of M5 compared to the pre-
synaptic inhibitory role of M4, in the VTA.  Similarly, given the importance of activation 
of the mesolimbic DA pathway to the rewarding and addictive properties of many illicit 
drugs such as cocaine and opiates, similar pharmacological approaches may be useful in 
the treatment of drug addiction44,111.  This represents perhaps the most well recognized 
therapeutic hypothesis for selective M5 antagonism and lies in close agreement with  
studies using M5-KO mice in models of drug addiction and reward.  However, given the 
role of M5 in mediating ACh-induced cerebrovasodilation and the various 
neuroanatomical and behavioral cognitive defects observed in M5-KO mice, antagonism 
of M5 for treatment of drug addiction may carry cerebrovascular and/or cognitive side 
effects. 
 Conversely, selective M5 activation using a non-CNS penetrant drug would 
presumably produce the sole result of cerebrovasodilation, without impacting cholinergic 
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or dopaminergic neuronal activity and thereby avoiding unwanted side effects and 
recreational abuse potential.  This possibility presents M5 as a virtually ideal target for 
treatment of cerebrovascular disorders such as cerebrovascular dementia and prevention 
and/or treatment of ischemic stroke.  If M5 activation is found to regulate APP processing 
toward the non-amyloidogenic pathway in a manner analogous to that of M1 or M3, 
which would be predicted based on the close relationship between M1, M3, and M5 
intracellular signaling profiles, selective M5 agonists may also prove useful for treating 
cerebral amyloid angiopathy (CAA).  Furthermore, given that impaired cerebral blood 
flow and associated decreased cholinergic tone at cerebrovascular structures due to loss 
of cholinergic basal forebrain neurons has been observed in AD, it is possible that M5 
agonism alone or in combination with agonism of M1 could address multiple aspects of 
AD pathology and thereby provide greater therapeutic benefit.  However, no subtype-
selective or even –preferring agonists or antagonists for the M5 receptor have been 
reported, and therefore discovery of such ligands will clearly be necessary in order to 
pharmacological test these various therapeutic hypotheses. 
 
Allosteric modulation of GPCRs 
 
Introduction to allosteric modulation of GPCRs 
 Small molecules that bind to cell-surface receptors at sites topographically distinct 
from the orthosteric binding site and thereby modulate receptor activity were discovered 
long ago for ligand-gated ion channels such as the γ-amino-butyric acid (GABA) receptor 
A (GABAA)112.  Numerous drugs of the benzodiazepine class bind to such allosteric 
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(“other”) sites on GABAA, where they potentiate receptor activation in response to 
binding by orthosteric agonist (e.g. GABA)113.  More recently, a number of small 
molecule chemotypes have been found to bind to allosteric sites on various GPCRs, such 
as the Class C metabotropic glutamate receptors (mGluRs) as well as numerous members 
of GPCR Class A including mAChRs (Fig. 5) and various chemokine receptors112,114.  
Relatively fewer allosteric ligands have been identified for Class B GPCRs, which could 
related to their lower abundance compared to Class A GPCRs115.  These allosteric ligands 
may exhibit positive or negative modulatory effects on the target receptor, wherein the 
affinity and/or efficacy of the orthosteric probe (often the endogenous agonist) may be 
increased or decreased, termed positive allosteric modulation (PAM) and negative 
allosteric modulation (NAM), respectively115.  Such modulation is fully dependant upon 
presence of an orthosteric ligand; however, some series of allosteric modulators may also 
exhibit intrinsic receptor activity on their own in the absence of orthosteric ligand, which 
is typically observed at higher concentrations116.  Alternatively, an allosteric modulator 
may bind to a receptor but exhibit a pharmacologically neutral/silent effect, wherein 
binding affinity and functional efficacy of the orthosteric ligand remains unchanged114,116.  
Increasingly, evidence for probe-dependent allosteric modulation has demonstrated that a 
given PAM or NAM may cause dramatically different modulatory effects on the same 
receptor, depending on what orthosteric ligand is present115. 
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Figure 5.  Generalized cartoon model of mAChR allosteric modulation depicting putative allosteric sites in 
relation to the orthosteric binding site. 
 
 Because receptor structure is often less conserved at allosteric binding sites across 
a given receptor subfamily (e.g. mAChRs), allosteric modulators often represent a means 
to achieve increased subtype-selectivity within a particular GPCR subfamily.  However, 
given the possibility for probe-dependence, evidence is mounting that some purportedly 
highly-selective allosteric modulators only exhibit functional selectivity in the presence 
of a particular orthosteric agonist while actually binding to multiple subtypes of the target 
receptor subfamily with neutral modulation.  In the presence of a different orthosteric 
probe, positive or negative modulatory effects at the other receptor subtypes may emerge, 
which underlines the importance of exploring functional selectivity with multiple 
orthosteric ligands.  Nonetheless, allosteric modulators provide a number of possible 
therapeutic advantages over traditional orthosteric ligands beyond their often-superior 
selectivity for a given receptor115.  Allosteric modulators provide a more subtle and 
physiologically-relevant approach to increasing or decreasing target activity because 
receptor activation will still only occur in the presence of the endogenous agonist that 
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remains under normal regulation115,116.  This may confer greater therapeutic tolerability 
and benefit for different CNS disorders.  Furthermore, allosteric modulation may in some 
cases avoid receptor desensitization and/or down-regulation that often occurs following 
chronic administration of a traditional agonist115,116.  Target/mechanism-mediated side 
effects that could arise from accidental overdose may also be avoided with allosteric 
modulator drugs because they confer a ‘ceiling-effect’ where maximal receptor 
occupancy does not directly translate to a maximal effect of receptor activation that 
would normally result from a high dose of an orthosteric drug115. 
 Beyond the positive or negative modulation of a GPCR via an allosteric site, 
direct activation of the receptor in the absence of orthosteric ligand may also occur via 
allosteric ligand binding115.  However, such allosteric agonists may also exhibit distinct 
subtype-selectivity via binding or functional propensities, positive or negative 
cooperativity with certain orthosteric ligands, and other pharmacological properties 
similar to those of PAMs or NAMs.  Furthermore, different allosteric chemotypes may 
appear to be pure PAMs, NAMs, or agonists when a single receptor activation readout is 
used (e.g. mobilization of intracellular Ca2+) but in reality possess various degrees of 
potency and efficacy for modulation of multiple downstream signaling cascades through 
the same receptor117.  Such phenomena represent an additional layer of complexity in the 
study and use of allosteric modulators, which underlines the importance of thorough 
pharmacological characterization of a given compound prior to initiation of in vivo 
studies so that results may be properly interpreted. 
 Within the context of receptor theory, a variety of mathematical models have been 
presented to describe the relationships between allosteric modulator, orthosteric ligand, 
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and receptor.  These range in complexity from the simpler four-point allosteric ternary 
complex model (ATCM, Fig. 6) to intricate multidimensional sixteen-point models114,115.  
The former is based on the original ternary complex model (TCM) used to describe 
interactions between a ligand, receptor, and G-protein but is used here to describe 
interactions between two ligands and a receptor.  In this model, each ligand is assigned an 
equilibrium dissociation constant (Ka and Kb) as well as a cooperativity factor (α) that 
denotes the mutual effect of the two ligands’ on each other’s affinity for the receptor.  
The value of α for two ligands can be determined empirically by measuring the affinity 
of one ligand (e.g. an orthosteric agonist) in the absence and presence of a saturating 
concentration of the second ligand (e.g. allosteric modulator) and then dividing the latter 
affinity by the former.  Thus, values for α that are > 1.0 reflect positive cooperativity and 
those < 1.0 reflect negative cooperativity.  An α = 1.0 describes a cooperatively neutral 
relationship.  Furthermore, efficacy modulation can be included in the ATCM by addition 
of the β variable, to reflect the positive or negative effect of one ligand (e.g. PAM) on 
another’s efficacy (e.g. orthosteric agonist) (Fig. 6).  
 
 
Figure 6.  Allosteric ternary receptor complex model describing interaction between two ligands (e.g. 
allosteric modulator and orthosteric agonist) and a receptor.  Ka and Kb reflect equilibrium dissociation 
constants (i.e. affinity values) for two ligands A and B that both bind simultaneously to receptor R.  
Binding cooperativity between A and B is denoted by α.  Modulation of efficacy is denoted by β. 
 
 
29 
Characterization of allosteric modulators of GPCRs 
 A variety of functional and binding assays are often used to identify and 
characterize allosteric modulators.  In the case of cell-based functional high-throughput 
screening (HTS) campaigns aimed at discovering novel allosteric modulators, which 
often utilize recombinant stably-transfected receptor expression systems with a straight-
forward readout for receptor activation such as fluorometric determination of intracellular 
Ca2+ mobilization, ‘double-add’ or ‘triple-add’ assay formats are most often employed116.  
For example, under a double-add format (Fig. 7), test compound is added to the cells at a 
fixed concentration after baseline has been established (i.e. first add).  After a 2-5 minute 
equilibration period, a submaximal (e.g. ~EC20) concentration of agonist is added (i.e. 
second add).  If the test compound is a PAM, it will enhance or potentiate the response to 
the submaximal agonist concentration (Fig. 7).  Similar formats can be used to identify 
NAMs or antagonists by searching for compounds that decrease receptor activation in 
response to a near maximal (e.g. ~EC80) concentration of agonist. 
 
 
Figure 7.  Example of a ‘double-add’ assay format designed to identify PAMs by functional fluorometric 
Ca2+ mobilization readout. 
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 Once hits from such HTS have been identified, similar functional counter-
screening and secondary screening is often performed using a test compound CRC assay 
format in the presence of a fixed submaximal concentration of orthosteric agonist (Fig. 
8a).  This allows determination of PAM (or NAM) potency values.  Related functional 
assays using CRCs of orthosteric agonist in the absence and presence of increasing fixed 
concentrations of test compound can be used to assess a modulator’s maximum efficacy 
in terms of ‘fold-shift’ of the agonist EC50 induced by the test compound (Fig 8b).  
Together, these two basic assays can be used to characterize allosteric modulators’ 
functional effects, which are typically used as the primary parameters in SAR 
descriptions and for driving potency/efficacy optimization efforts. 
 
 
Figure 8.  Example of generic PAM CRC in the presence of a fixed submaximal concentration of 
orthosteric agonist to determine PAM potency (A) and agonist CRC in the absence and presence of 
increasing fixed concentrations of PAM to determine fold-shift (B). 
 
 Radioligand binding experiments are useful for assessing the location and 
mechanism(s) of modulation for a given allosteric ligand.  For instance, competition-
binding under equilibrium conditions using a fixed low concentration of orthosteric 
antagonist radioligand in the presence of a CRC of an unlabelled allosteric modulator can 
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suggest or confirm that a novel compound binds to a site other than the orthosteric site if 
no inhibition is observed (i.e. allosteric).  However, when a test compound causes 
binding inhibition, further experiments in the form of kinetic binding assays are often 
required to determine if such inhibition is via direct orthosteric competition with the 
radioligand or via a negative cooperativity effect (e.g. 1.0 > α > 0) through an allosteric 
site.  Similar competition binding experiments utilizing CRCs of an orthosteric agonist in 
the absence and presence of fixed concentration(s) of allosteric modulator can be used to 
assess the latter’s effect on the former’s affinity and thereby calculate cooperativity 
(α)114.  Together, these various functional and binding assays comprise the most common 
methods for characterizing novel allosteric modulators and have been used throughout 
many of the mAChR ligand optimization projects described in subsequent Chapters of 
this thesis (Chapters III-V). 
 
Discovery of early allosteric modulators of mAChRs 
 A number of small molecules emerged early on providing proof of concept for 
allosteric mAChR modulation (Fig. 9).  These included gallamine, brucine, thiochromine, 
and other related compounds, which where found to exhibit positive or negative 
cooperativity with an orthosteric probe at one or more mAChR in functional and/or 
binding assays118,119.  However, most of these ligands possessed poor potency, 
physiochemical properties, and DMPK liabilities that precluded their widespread use as 
mAChR research tools.  Similarly, one of the first putative mAChR allosteric agonists, 
AC-42 (Fig. 9), exhibited highly M1-selective functional activity but was found to exhibit 
little to no binding subtype-selectivity and displayed competition with multiple 
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orthosteric ligands119,120.  Interestingly, this compound was equipotent and efficacious in 
assays with the Y381A mutant M1 receptor, which has been used along with evidence 
from other experiments to argue that AC-42 interacts with either an ectopic site near or 
overlapping with the orthosteric ACh site or to multiple sites at M1117,121.  A second 
example of an early M1 allosteric agonist is N-desmethylclozapine (NDMC, Fig 9), the 
primary circulating human metabolite of the commonly used antipsychotic drug 
clozapine31.  Although NDMC is not completely selective for M1, strong evidence that it 
binds to an allosteric site completely distinct from the orthosteric ACh site has been 
obtained from pharmacological experiments and receptor-mutagenesis studies31. 
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Figure 9.  Structures of examples of early allosteric mAChR modulators. 
 
 Despite these discoveries and until recently, no highly subtype-selective mAChR 
allosteric ligands possessing the necessary drug-like pharmacological properties for 
universal and in vivo use had been reported.  For instance, the AC-42 scaffold (now 
represented by its newer analog 77-LH-28-1) has been shown to possess a wide range of 
problematic off-target activities, NDMC exhibits similarly broad polypharmacology, and 
the  early PAMs/NAMs do not represent tractable chemical optimization leads120,122.  
However, contemporary high-throughput screening technology utilizing functional cell-
based assays has led to a re-emergence of novel allosteric mAChR modulator discovery 
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projects.  Subsequent Chapters of this thesis present and discuss our own efforts at 
identifying, optimizing, and characterizing novel subtype-selective ligands for M4, M5, 
and M1 with the aim of obtaining useful drug-like tools suitable for the in vitro and in 
vivo study of mAChR neurobiology. 
 
Notes on figure, table, and compound numbering/nomenclature 
 
 Throughout the remaining Chapters, all figure and table numbering is specific to 
each Chapter.  Put differently, each Chapter’s figure and table numbering begins with 
“1”.  Similarly, compound numbering formats and nomenclature are specific to each 
Chapter and in some cases each section of a given Chapter.  Arbitrary numbering and 
letter codes (e.g. Compound 5 or (5), analog 9a or (9a)) are used interchangeably 
throughout each Chapter.  These are often used in place of full VU registration codes 
(e.g. VU0119498) in order to increase the ease of readability and to reduce space.  
Furthermore, for Materials and Methods Chapter II, compound numbering/nomenclature 
essentially mirrors that found in the associated Chapters III-V. 
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Chapter II 
 
MATERIALS AND METHODS 
 
 
 
Medicinal Chemistry 
 
General synthetic methods, instrumentation, and workflow 
 In general, small scale (20-100 mg) reactions were carried out in parallel to 
generate compound libraries ranging from approximately 4-100 members in size.  A 
small percentage of the total compounds synthesized across all projects were generated as 
singletons (i.e. individual isolated syntheses and not part of a library).  Standard 
chemistry techniques were used for all reactions, and traditional thin-layer 
chromatography (TLC) and liquid chromatography mass spectrometry (LCMS) was used 
for analytical reaction monitoring.  The following general purification methods were 
utilized depending on the particular chemical/compound and the amount of material: 
classical normal-phase glass-column silica gel chromatography, mass-directed reverse-
phase high-performance liquid chromatography (HPLC), ultraviolet (UV)-directed 
reverse-phase HPLC, and standard recrystallization/filtration.  Only high-quality HPLC 
grade solvents were used for purifications, and purity was defined as a sample containing 
approximately >98% of desired product by at least two independent analytical methods 
(e.g. evaporative light scattering device [ELSD], UV). 
 Microwave-assisted reactions were conducted using a Biotage Initiator-60.  All 
nuclear magnetic resonance (NMR) spectra were recorded on a 400 megahertz (MHz) 
Bruker AMX NMR.  1H chemical shifts are reported in δ values in parts per million 
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(ppm) downfield from TMS as the internal standard in dimethyl sulfoxide (DMSO).  Data 
are reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, br = broad, m = multiplet), coupling constant (Hz), and integration.  13C 
chemical shifts are reported in δ values in ppm with the DMSO carbon peak set to 39.5 
ppm.  Low resolution mass spectra were obtained on an Agilent 1200 LCMS with 
electrospray ionization.   High resolution mass spectra were recorded on a Waters QToF-
API-US plus Acquity system with electrospray ionization.  Analytical thin layer 
chromatography was performed on 250 µm silica gel 60 F254 plates.  Analytical HPLC 
was performed on an Agilent 1200 analytical LCMS with UV detection at 214 nm and 
254 nm along with ELSD detection.  Preparative purification of library compounds was 
performed on a custom Agilent 1200 preparative LCMS with collection triggered by 
mass detection. 
 For purposes of compound tracking and organization, all final compounds were 
transferred to 4 mL barcoded vials and diluted to a final concentration of 10 (or in some 
cases 50) mM in DMSO.  Each new compound and each new batch of a previously 
synthesized compound was registered into a central computer database system, which 
assigned a unique VU identification number.  A new synthetic batch of a given 
compound is designated by a corresponding number following a “—“ at the end of the 
VU identification number (e.g. batch one of VU0238429 is registered as VU0238429-1, 
batch two as VU0238429-2, etc...).  At the present time of writing, the commercially 
available ChemChart program was used as the compound registration database software. 
 Following purification, dilution, and registration, compounds were characterized 
and assayed for pharmacological activity using the methods described in the associated 
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pharmacology section of this Chapter.  In general, optimization projects utilized an 
iterative parallel library work-flow, wherein a certain region of a chemical scaffold was 
derivatized while the remainder of the scaffold was held constant for each analog of a 
given library.  After pharmacological evaluation, SAR data from a given present library 
was used to design/plan the subsequent library such that the optimization proceeds in a 
cyclic and progressive manner toward improvement of a given property or characteristic 
of the scaffold (e.g. potency, efficacy, subtype-selectivity, off-target activity, cLogP, 
etc..).  One implementation of this paradigm that was routinely utilized is presented in 
Figure 1.  For most projects, an initial HTS using a functional cell-based assay was 
performed with either the Molecular Libraries Screening Center Network 
(MLSCN)/Molecular Libraries Probe Center Network (MLPCN) or the Vanderbilt HTS 
center (VHTSC) compound collections to identify hits.  In other projects, lead 
compounds were identified via cheminformatics or via public disclosures (e.g. 
conferences, scientific literature, patent literature, etc…). 
  
 
Figure 1. Generalized work-flow utilizing iterative synthesis and testing of parallel analog libraries aimed 
at optimizing a given property or characteristic of the lead structure/scaffold. 
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 The complete details of each compound’s full synthetic and purification 
procedure are too expansive for inclusion in this Chapter, and therefore such are 
presented only for select key and representative compounds/libraries from the various 
mAChR small molecule discovery/optimization projects described in this thesis.  In 
general, the procedure for a specific type of reaction (e.g. amide-couplings, N- or O-
alkylations, Suzuki-couplings, etc...) that is described for a given compound/library is 
applicable to other related compounds/libraries of a project that were made using the 
same reaction.  Therefore, redundant procedures and procedures for non-key 
compounds/libraries have been excluded for sake of brevity and simplicity.  For 
compounds/libraries whose procedures are not explicitly described, the conditions for 
their synthesis are presented in abbreviated form in the figures and text of Chapters III-V 
and in more detail in the associated referenced publications.  Furthermore, to aid in 
clarity and organization, the order in which the syntheses are presented in this Chapter 
generally reflects the order in which the associated text and figures of Chapters III-V 
discuss the compounds/libraries.  For some compounds whose synthesis is described 
under an general library procedure, only analytical characterization data is presented.  
Compound numbering in this Chapter is the same as that which is used in the associated 
text/figures of Chapters III-V. 
 
M4 PAM syntheses 
 Initial eastern amide analog library general procedure.  Each of thirty-one 
glass vials containing 3 mL of CH2Cl2 were loaded with N,N-diisopropylethylamine (0.3 
mL, 1.70 mmol), 3-amino-4,6-dimethylthioenol[2,3-b]-pyridine-2-carboxylic acid (50 
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mg, 0.225 mmol, SPECS AM-807/25050004), 1-hydroxybenzotriazole hydrate (30.4 mg, 
0.225 mmol, 1.0 equivalents), polystyrene-bound N-cyclohexylcarbodiimide (317 mg, 
0.450 mmol, 1.42 mmol/g, 2.0 equivalents), and one of thirty-one amines (0.225 mmol, 
1.0 equivalents).  The reactions were stirred for 48 hours at room temperature. Next, 
macroporous triethylammonium methylpolystyrene carbonate (145 mg, 0.225 mmol, 3.11 
mmol/g, 2.0 equivalents) was added, and the reactions were stirred for an additional 3 
hours at room temperature.  Then, the reactions were filtered and concentrated on a heat-
air block to afford 84-99% pure products.  Those <99% pure were purified by mass-
directed HPLC. 
 VU0152099.  To a stirred solution of 3-amino-4,6-dimethylthioenol[2,3-b]-
pyridine-2-carboxylic acid (3.0 g, 13.51 mmol [Chembridge cat.# 4003557]) in CH2Cl2 
(90 mL) was added N,N-diisopropylethylamine (10 mL, 56.66 mmol), 1-
hydroxybenzotriazole hydrate (1.83 g, 13.51 mmol, 1.0 equivalents), 4-
methoxybenzylamine (2.04 g, 14.86 mmol, 1.1 equivalents), and N-(3-
dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride (5.18 g, 27.02 mmol, 2.0 
equivalents) at 25 °C under room atmosphere.  After 48 hours, macroporous 
triethylammonium methylpolystyrene carbonate (4.4 g, 13.51 mmol, 3.077 mmol/g, 1.0 
equivalents) was added to the solution, which was then stirred for 3 hours at 25°C under 
room atmosphere.  Next, the solution was vacuum filtered and the filtrate was separated 
with citric acid (1.0 M in water) and CH2Cl2.  The organics were dried over MgSO4 and 
concentrated in vacuo to produce a dark yellow solid.  The solid was purified by column 
chromatography (silica gel, fixed 1:2 EtOAc:hexanes) to afford 2.5 g (7.33 mmol, 54%) 
of the title compound as a bright yellow solid.  Analytical LC/MS (J-Sphere80-S4, 3.0 x 
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50 mm, 4.0 min gradient, 5%[CH3CN]:95%[0.1%TFA/H2O] to 100%[CH3CN]): 2.773 
min, >99% (214 nm and ELSD), M+1 peak m/e 342.12; 1H NMR (400 MHz, DMSO-d6) 
δ 7.27 (d, J = 8.8 Hz, 2H), 6.89 (s, 1H), 6.86 (d, J = 8.8 Hz, 2H), 6.34 (br s, 2H), 5.80 (s, 
1H), 4.53 (d, J = 6.0 Hz, 2H), 3.79 (s, 3H), 2.73 (s, 3H), 2.57 (s, 3H);  13C NMR (100 
MHz, DMSO-d6) δ 165.9, 159.3, 159.2, 147.7, 143.9, 130.7, 129.3, 123.7, 122.4, 114.4, 
98.5, 55.5, 43.3, 24.5, 20.4;  HRMS (Q-ToF): m/z calc for C18H19N3O2S [M + H]:  
342.1198; found, 342.1276. 
 VU0152100.  To a stirred solution of 3-amino-4,6-dimethylthioenol[2,3-b]-
pyridine-2-carboxylic acid (2.50 g, 11.26 mmol [Chembridge cat.# 4003557]) in CH2Cl2 
(90 mL) was added N,N-diisopropylethylamine (10 mL, 56.66 mmol), 1-
hydroxybenzotriazole hydrate (1.52 g, 11.26 mmol, 1.0 equivalents), piperonylamine 
(1.87 g, 12.38 mmol, 1.1 equivalents), and N-(3-dimethylaminopropyl)-N’-ethyl-
carbodiimide hydrochloride (4.32 g, 22.52 mmol, 2 equivalents) at 25 °C under room 
atmosphere. After 48 hours, macroporous triethylammonium methylpolystyrene 
carbonate (3.66 g, 11.26 mmol, 3.077 mmol/g, 1.0 equivalents) was added to the solution, 
which was then stirred for 3 hours at 25 °C under room atmosphere.  Next, the solution 
was vacuum filtered and the filtrate was separated with citric acid (1.0 M in water) and 
CH2Cl2.  The organics were dried over MgSO4 and concentrated in vacuo to produce a 
dark yellow solid.  The solid was purified by column chromatography (silica gel, fixed 
1:2 EtOAc:hexanes) to afford 2.0 g (5.63 mmol, 50%) of the title compound as a yellow 
solid.  Analytical LC/MS (J-Sphere80-S4, 3.0 x 50 mm, 4.0 min gradient, 
5%[CH3CN]:95%[0.1%TFA/H2O] to 100%[CH3CN]): 2.740 min, >99% (214 nm and 
ELSD), M+1 peak m/e 356.10; 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 7.18 (s, 
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1H), 6.88 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.98 (br s, 2H), 5.97 
(s, 2H), 4.30 (d, J = 5.2 Hz, 2H), 2.77 (s, 3H), 2.57 (s, 3H);  13CNMR (100 MHz, DMSO-
d6) δ 179.9, 164.8, 161.7, 158.0, 153.4, 147.4, 133.8, 122.4, 121.9, 120.5, 108.0, 107.9, 
100.8, 92.8, 42.1, 22.4, 20.0;  HRMS (Q-ToF): m/z calc for C18H17N3O3S [M + H]:  
356.0991; found, 356.1069. 
 6-amino-2-mercapto-4-methylnicotinonitrile (6).  To five 20 mL microwave 
vials containing 2-cyanothioacetamide (0.01 mol) each was added 3-aminocrotonitrile 
(0.01 mol) and then EtOH (10 mL).  Once dissolved, pyridine (0.05 mol) was added and 
the vial was capped.  The reaction mixtures were heated to 160oC for 12 min. 
consecutively.  The crude reaction mixtures were combined and concentrated to a dark 
red oil.  To this was added MeOH (150ml) and heated to reflux, upon cooling an orange 
solid crashed out which was filtered and washed with ether to afford 3.47g of pure (6) 
(42%).   1H NMR (400MHz, DMSO-d6): d= 7.20 (br s, 2H), 5.90 (s, 1H), 2.2 (s, 3H).  13C 
(100MHz, DMSO-d6): d= 175.3, 155.1, 153.5, 118.0, 100.2, 98.9, 20.8. HRMS calcd for 
C7H7N3S [M + H] 166.0435; found 166.0439.                                                                                                                  
 3,6-diamino-N-(4-methoxybenzyl)-4-methylthieno[2,3-b]pyridine-2-
carboxamide  (8).  To a 20 mL microwave vial containing (6) (3.0 mmol) was added 
K2CO3 (6 mmol), and DMF (10 mL).  To this solution was added solid (7) then capped, 
and heated to 160oC for 10 min.  Once complete the reaction was partitioned between 
H2O (100 mL) and DCM (100 mL), separated, and the aqueous layer washed 2x with 
DCM (100 mL).  The organic layer was dried with solid MgSO4, filtered, and 
concentrated to a light brown solid.  This solid was crystallized in EtOAc and Hexanes 
and filtered to obtain 0.8g of pure (8) as a light yellow solid (75%).   1H NMR (400MHz, 
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DMSO-d6): d= 8.41 (s, 1H), 7.13 (d, J = 8.8Hz, 2H), 6.98 (br s, 2H), 6.83 (d, J = 8.4 Hz, 
2H), 6.12 (s, 1H), 3.89 (s, 2H), 3.72 (s, 3H), 2.22 (s, 3H).  13C (100MHz, DMSO-d6): d= 
167.4, 160.8, 160.1, 158.1, 151.0, 131.1, 128.3, 116.7, 113.7, 103.9, 55.0, 41.9, 32.8, 
19.6. HRMS calcd for C17H18N4O2S [M + H] 343.1222; found 343.1229.         
 Alkylamine library (9a-s) general procedure.  To a 5 mL microwave vial 
containing (8) (0.073 mmol), was added Cs2CO3 (0.21 mmol), KI (0.073 mmol), R1-Cl 
(0.080 mmol), and DMF (3 mL).  The reaction was stirred 5 min. to eliminate CO2, 
capped, and heated to 160oC for 30 min.  Once complete the reaction was partitioned 
between H2O (5 mL), and DCM (5 mL), separated via a 12 mL IST phase separator, 
concentrated and purified by mass directed HPLC to furnish 9a-s (15-80%). 
 Alkylether library (13a-s) general procedure.  To a 5 mL microwave vial 
containing (12) (0.146 mmol), was added Cs2CO3 (0.438 mmol), KI (0.291 mmol), R1-Cl 
(0.219 mmol), and DMF (3 mL).  The reaction was stirred 5 min. to eliminate CO2, 
capped, and heated to 160oC for 30 min.  Once complete the reaction was partitioned 
between H2O (5 mL), and DCM (5 mL), separated via a 12 mL IST phase separator, 
concentrated and purified by mass directed HPLC to furnish 13a-s (15-80%). 
 2-mercapto-4-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile (11). To 
twelve 20 mL microwave vials containing 2-cyanothioacetamide (0.01 mol) each was 
added morpholine (0.01 mol) and then EtOH (10 mL).  Once dissolved, ethylacetoacetate 
(0.01 mol) was added and the vial was capped.  The reaction mixtures were heated to 
160oC for 10 min. consecutively.  The crude reaction mixtures were combined and 
concentrated to a dark red oil.  To this was added DCM (200ml) and heated to reflux. 
Once cool, the solid product was filtered and washed 2x with DCM (200ml) to give 12.4g 
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of pale yellow (11) (62%).     1H NMR (400MHz, DMSO-d6): d= 10.40 (br s, 1H), 8.67 
(br s, 1H), 5.38 (s, 1H), 1.99 (s, 3H).  13C (100MHz, DMSO-d6): d= 176.3, 162.4, 151.0, 
120.7, 106.8, 92.7, 20.5.  HRMS calcd for C7H6N2OS [M + H] 167.0277; found 
167.0279. 
 3-amino-N-(4-methoxybenzyl)-4-methyl-6-oxo-6,7-dihydrothieno[2,3-
b]pyridine-2-carboxamide (12).  To a flask containing (11) (6.0 mmol) was added DMF 
(30 mL) then TEA (6.6 mmol),  and cooled to 0oC with an ice bath.  A solution of (7) (6.0 
mmol) in DMF (30 mL) was slowly added to the reaction via addition funnel over 30 
min. and allowed to return to r.t. overnight.  The reaction was concentrated then 
partitioned between DCM (100 mL) and H2O (100 mL), separated, and the aqueous layer 
washed 2x with DCM (100 mL).  The organic layer was dried with solid MgSO4, filtered, 
and concentrated to a pale yellow solid which was washed with EtOAc (3x 50 mL) to 
give 1.28g of pure (12) as a light yellow solid (62%). 1H NMR (400MHz, DMSO-d6): d= 
8.52 (br s, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.40 (s, 1H), 4.22 (d, J 
= 6.0 Hz, 2H), 3.97 (br s, 2H), 3.71 (s, 3H), 2.32 (s, 3H).  13C (100MHz, DMSO-d6): d= 
167.3, 158.2, 130.9, 128.7, 128.5, 115.5, 113.7, 113.6, 55.0, 42.0, 19.7. HRMS calcd for 
C17H17N3O3SNa [M + Na] 366.0888, found 366.0887. 
 Ethyl 3-amino-4-methyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-
carboxylate (15).  To a flask containing (11) (26.5 mmol) was added DMF (250 mL) 
then TEA (29.2 mmol), and cooled to 0oC with an ice bath.  A solution of (14) (26.5 
mmol) in DMF (60 mL) was slowly added to the reaction via addition funnel over 30 
min. and allowed to return to r.t. overnight.  The reaction was concentrated then 
partitioned between DCM (250 mL) and H2O (250 mL), separated, and the aqueous layer 
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washed 2x with DCM (150 mL).  The organic layer was dried with solid MgSO4, filtered, 
and concentrated to a pale yellow solid which purified via chromatography (1:1.5 
EtOAc:Hexanes) to give 4.15g of pure (15) as a light yellow solid (63%).1H NMR 
(400MHz, DMSO-d6): d= 6.42 (s, 1H), 4.12 (m, 4H), 2.34 (s, 3H), 1.18 (t, J = 7.2 Hz, 
3H). 13C (100MHz, DMSO-d6): d= 168.3, 164.8, 160.0, 154.5, 115.5, 106.8, 97.8, 59.9, 
19.7, 13.9.  HRMS calcd for C11H13N2O3S [M + H] 253.0647, found 253.0644. 
 Alkyl pyridone ethyl ester (16a-e) general procedure.  To a 20 mL microwave 
vial containing (15) (0.04 mol), was added Cs2CO3 (0.012 mol), KI (0.008 mol), R1-Cl 
(0.0044 mmol), and DMF (10 mL).  The reaction was stirred 5 min. to eliminate CO2, 
capped, and heated to 160oC for 30 min.  Once complete the reaction was partitioned 
between H2O (50 mL), and DCM (50 mL), separated, and the aqueous washed 1x with 
DCM (50 mL).  The organic layer was dried with MgSO4, filtered and concentrated.  The 
resulting material was added to a 10g 60CC SCX cartridge and washed with 3 column 
volumes of MeOH.  The product was then eluted with 2 column volumes of 2M NH3 in 
MeOH to provide pure (16a-e) (75-95%). 
 Ethyl 3-amino-6-(3-(dimethylamino)propoxy)-4-methylthieno[2,3-b]pyridine-
2-carboxylate (16a).  1H NMR (400MHz, DMSO-d6); d= 6.72 (s, 2H), 6.57 (s, 1H), 4.25 
(m, 4H), 2.66 (s, 3H), 2.37 (t, J = 7.2 Hz, 2H), 2.16 (s, 6H), 1.84 (m, 2H), 1.27 (t, J = 6.8 
Hz, 3H). 13C (100MHz, DMSO-d6): d= 164.7, 163.8, 159.3, 150.3, 147.6, 119.1, 109.5, 
64.5, 59.7, 55.5, 44.9, 26.3, 19.8, 14.4. HRMS calcd for C16H24N3O3S [M + H] 338.1538, 
found 338.1527. 
 Ethyl 3-amino-4-methyl-6-(2-morpholinoethoxy)thieno[2,3-b]pyridine-2-
carboxylate (16b).  1H NMR (400MHz, DMSO-d6): d= 6.76 (s, 2H), 6.65 (s, 1H), 4.57 
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(br s, 2H), 4.24 (q, J = 14.4, 7.2 Hz, 2H), 3.72 (br s, 4H), 3.20 (br s, 6H), 2.70 (s, 3H), 
1.27 (t, J = 6.8 Hz, 3H).  13C (100MHz, DMSO-d6): d= 164.7, 163.1, 159.0, 150.3, 148.1, 
119.6, 118.7, 115.7, 109.6, 64.3, 59.8, 55.5, 52.3, 19.9, 14.4.  HRMS calcd for C17H24N-
3O4S [M + H] 366.1488, found 366.1476. 
 Ethyl 3-amino-4-methyl-6-(pyridin-2-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate (16c).  1H NMR (400MHz, DMSO-d6): d= 8.55 (d, J = 4.4 Hz, 1H), 7.80, (t, 
J = 8.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 6 Hz, 1H), 6.74 (s, 2H), 6.73 (s, 
1H), 5.45 (s, 2H), 4.23 (q, J = 14.0, 7.2 Hz, 2H), 2.70 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).   
13C (100MHz, DMSO-d6): d= 164.7, 163.3, 159.0, 156.3, 150.2, 149.1, 148.1, 136.8, 
122.9, 121.7, 119.6, 109.6, 68.1, 59.8, 19.9, 14.4.   HRMS calcd for C17H18N3O3S [M + 
H] 344.1069, found 344.1057. 
 Ethyl 3-amino-4-methyl-6-(pyridin-3-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate (16d).  1H NMR (400MHz, DMSO-d6): d= 8.70 (s, 1H), 8.54 (d, J = 4.8 Hz, 
1H), 7.89 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 4.8 Hz, 1H), 6.75 (s, 2H), 6.97 (s, 1H), 5.42 (s, 
2H), 4.24 (q, J = 14.4, 7.2 Hz, 2H), 2.69 (s, 3H), 1.28 (t, J = 6.8 Hz, 3H).  13C (100MHz, 
DMSO-d6): d= 164.7, 163.3, 159.0, 150.3, 149.4, 149.1, 148.1, 136.1, 132.3, 123.5, 
119.6, 109.6, 65.3, 59.8, 19.9, 14.4.  HRMS calcd for C17H18N3O3S [M + H] 344.1069, 
found 344.1064. 
 Ethyl 3-amino-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate (16e).  1H NMR (400MHz, DMSO-d6): d= 8.56 (d, J = 6.0 Hz, 2H), 7.45 (d, 
J = 6.0 Hz, 2H), 6.77 (s, 1H), 6.75 (s, 2H), 5.45 (s, 2H), 4.24 (q, J = 14.0, 6.8 Hz, 2H), 
2.71 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H).  13C (100MHz, DMSO-d6): d= 164.6, 163.1, 159.0, 
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150.2, 149.6, 148.3, 145.9, 122.0, 109.6, 65.7, 59.8, 19.9, 14.4.  HRMS calcd for 
C17H18N3O3S [M + H] 344.1069, found 344.1057. 
 3-amino-N-(4-methoxybenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride (13k).  1H NMR (400MHz, DMSO-d6): d= 
8.90 (d, J = 6.4 Hz, 2H), 8.14 (t, J = 5.6 Hz, 1H), 8.05 (d, J = 6.4 Hz, 2H), 7.22 (d, J = 
8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.84 (s, 1H), 5.73 (s, 2H), 4.32 (d, J = 5.6 Hz, 2H), 
3.72 (s, 3H), 2.74 (s, 3H). ).  13C (100MHz, DMSO-d6): d= 165.0, 162.0, 158.1, 156.9, 
148.1, 147.9, 142.2, 132.0, 129.3, 128.5, 124.1, 121.0, 115.1, 113.6, 109.4, 65.3, 55.0, 
41.6, 19.9. HRMS calcd for C23H23N4O3S [M + H] 435.1491, found 435.1490. 
 3-amino-N-(2,3-difluorobenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride (21n).  1H NMR (400MHz, DMSO-d6): d= 
8.92 (d, J = 6.8 Hz, 2H), 8.30 (t, J = 5.6 Hz, 1H), 8.09 (d, J = 6.4 Hz, 2H), 7.32 (m, 1H), 
7.16 (m, 2H), 6.85 (s, 1H), 5.75 (s, 2H), 4.46 (d, J = 5.6 Hz, 2H), 2.74 (s, 3H).  13C 
(100MHz, DMSO-d6): d= 165.2, 162.1, 157.8, 157.0, 150.8, 148.8, 148.3, 148.1, 146.4, 
146.2, 141.4, 129.3 (d, J = 11.0 hz), 124.5, 124.3, 120.9, 115.6 (d, J = 17.0 Hz), 109.5, 
65.3, 35.7, 19.9.  HRMS calcd for C22H19N4O2F2S [M + H] 441.1197, found 441.1196. 
 3-amino-N-(2,5-difluorobenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride (21o).  1H NMR (400MHz, DMSO-d6): d= 
8.57 (d, J = 6.0 Hz, 2H), 8.19 (t, J = 5.6 Hz, 1H), 7.44 (d, J = 6.0 Hz, 2H), 7.24 (m, 1H), 
7.10 (m, 2H), 6.77 (br s, 2H), 6.77 (s, 1H), 5.46 (s, 2H), 4.43 (d, J = 5.6 Hz, 2H), 2.72 (s, 
3H). ).  13C (100MHz, DMSO-d6): d= 165.3, 162.7, 159.3, 157.2, 156.9, 154.7, 149.6, 
148.4, 147.9, 146.0, 128.8 (dd, J = 7.0, 17.0 Hz), 121.9, 120.6, 116.6 (dd, J = 8.0, 24.0 
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Hz), 115.2 (dd, J = 5.0, 25.0 Hz), 114.9 (dd, J = 8.0, 24.0 Hz), 109.6, 65.7, 35.9, 19.9.   
HRMS calcd for C22H19N4O2F2S [M + H] 441.1197, found 441.1194. 
 3-amino-N-tert-butyl-4-methyl-6-(2-morpholinoethoxy)thieno[2,3-b]pyridine-
2-carboxamide dihydrochloride (18h).  1H NMR (400MHz, DMSO-d6): d= 6.65 (s, 
1H), 6.62 (s, 1H), 6.31 (br s, 3H), 4.71 (t, J = 4.8 Hz, 2H), 3.87 (m, 4H), 3.50 (m, 4H), 
3.17 (m, 2H), 2.70 (s, 3H), 1.36 (s, 9H).  13C (100MHz, DMSO-d6): d= 165.3, 162.2, 
162.1, 156.6, 147.6, 147.1, 120.9, 109.5, 62.0, 60.5, 54.7, 51.6, 51.2, 28.8, 19.9.  HRMS 
calcd for C19H29N4O3S [M + H] 393.1960, found 393.1958. 
 
M5 PAM syntheses 
 Initial matrix library of VU0119498 analogs.  Compounds 21-112 were 
synthesized in parallel according to the following procedure.  Isatin starting materials 
(0.34 mmol) were added to vials containing ACN (3 mL), K2CO3 (0.68 mmol, 2.0 eq), KI 
(0.03 mmol, 0.1 eq), and respective benzyl halides (0.85 mmol, 2.5 eq).  The reactions 
were microwave irradiated at 160 °C for 10 min.  Next, the reactions were partitioned 
into CHCl2 and H2O and then passed through disposable phase-separator columns 
(Biotage Isolute).  The organics were concentrated on a heated air-drying block and then 
analyzed by LCMS.  Purification by mass-directed Preparative HPLC afforded desired 
products as colored solids (20-95%) with >98% purity by ELSD and 214 nM UV 
analysis. 
 VU0119498.  This HTS screening hit was resynthesized classically as a singleton 
prior to the library synthesis.  To a vial containing ACN (25 mL) was added isatin (1.00 
g, 6.80 mmol), K2CO3 (13.6 mmol, 2.0 eq), KI (0.68 mmol, 0.1 eq), and 4-
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bromobenzylbromide (7.48 mmol, 1.1 eq).  The reaction was stirred for ~24 hours at 
room temperature while monitored by TLC.  After judging complete, the reaction was 
partitioned into EtOAc and H2O, and the combined organics were dried over MgSO4, 
filtered, and then concentrated in vacuo.  The dried solid was then washed with diethyl 
ether (3 x 15 mL) to afford the pure 1-(4-bromobenzyl)indoline-2,3-dione title compound 
as a bright orange solid (1.96 g, 6.18 mmol, 91%).  1H-NMR (400MHz, d6 - DMSO) δ 
7.55 (m, 4H), 7.39 (d, J = 8.5, 2H), 7.11 (t, J = 7.8, 1H), 6.94 (d, J = 8.1, 1H), 4.88 (s, 
2H).  13C-NMR (100MHz, d6 - DMSO) δ 182.91, 158.35, 150.07, 137.87, 135.01, 131.47, 
129.64, 124.46, 123.33, 120.65, 117.80, 110.95, 42.27.  LCMS (214 nm) 3.25 min 
(>98%); m/z 316.0 [M+H].  HRMS cald for C15H10BrNO2 [M+H] 315.9973 found 
315.9974. 
 VU0238429.  To a vial containing ACN (15 mL) was added 5-
trifluoromethyoxyisatin (1.00 g, 4.33 mmol), K2CO3 (8.66 mmol, 2.0 eq), KI (0.43 mmol, 
0.1 eq), and 4-methoxybenzyl chloride (4.76 mmol, 1.1 eq).  The reaction was stirred for 
~24 hours at room temperature while monitoring by TLC.  After judging complete, the 
reaction was partitioned into EtOAc and H2O, and the combined organics were dried over 
MgSO4, filtered, and then concentrated in vacuo to afford the pure 1-(4-methoxybenzyl)-
5-(trifluoromethoxy)indoline-2,3-dione title compound as an orange solid (1.50 g, 4.26 
mmol, 98%).  1H-NMR (400MHz, d6 - DMSO) δ 7.60 (m, 2H), 7.36 (d, J = 8.7, 2H), 7.04 
(m, 1H), 6.89 (m, 2H), 4.84 (s, 2H), 3.71 (s, 3H).  13C-NMR (100MHz, d6 - DMSO) δ 
181.99, 158.73, 158.33, 149.00, 143.83, 130.35, 128.88, 126.94, 121.32, 118.79, 117.66, 
114.02, 112.36, 55.05, 42.45.  LCMS (214 nm) 3.37 min (>98%); m/z 352.1 [M+H].  
HRMS calcd for C17H12F3NO4 [M+H] 352.0797 found 352.0795. 
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 VU0238441.  To a vial containing ACN (3 mL) was added 7-chloroisatin (150 
mg, 0.826 mmol), K2CO3 (1.652 mmol, 2.0 eq), KI (0.083 mmol, 0.1 eq), and 4-
trifluoromethylbenzyl bromide (0.909 mmol, 1.1 eq).  The reaction was stirred for ~24 
hours at room temperature while monitoring by TLC.  After judging complete, the 
reaction was partitioned into EtOAc and H2O, and the combined organics were dried over 
MgSO4, filtered, and then concentrated in vacuo to afford the pure 7-chloro-1-(4-
(trifluoromethyl)benzyl)indoline-2,3-dione title compound as an orange solid (267 mg, 
0.786 mmol, 95%).  1H-NMR (400MHz, d6 - DMSO) δ 7.64 (m, 4H), 7.15 (m, 3H), 5.28 
(s, 2H).  13C-NMR (100MHz, d6 - DMSO) δ 181.56, 159.37, 145.27, 142.25, 139.26, 
127.01, 125.30, 124.80, 123.51, 121.40, 115.58, 44.28.  LCMS (214 nm) 3.46 min 
(>98%); m/z 340.0 [M+H].  HRMS calcd for C16H9ClF3NO2 [M+H] 340.0352 found 
340.0353. 
 General procedure for Suzuki-coupling libraries.  Glass vials containing 1-2 
mL anhydrous THF were charged with starting material bearing a –bromo or –chloro 
substituted aryl/heteroaryl ring, a substituted boronic acid (1.2 equivalents), aqueous 1M 
Cs2CO3 solution (2.0 equivalents), and tetrakis(PPh3)Pd(0) catalyst (0.1-0.2 equivalents).  
The vials were flushed with argon and then subjected to microwave irradiation for 5-20 
min at 120 °C.  Once complete, the reactions were passed through disposable celite 
(Isolute HM-N) columns (rinsing 2-3x column volume with DCM).  The filtered organics 
were then concentrated in-vacuo or on a heated-air drying block to provide the crude 
products, which were analyzed by LCMS and then purified by HPLC. 
 VU0400265.  To a flask containing acetonitrile (20 mL) was added 5-
trifluoromethoxyisatin (750 mg, 3.245 mmol), potassium carbonate (897 mg, 6.490 
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mmol), 4-phenoxybenzyl bromide (897 mg, 3.407 mmol), and potassium iodide (54 mg, 
0.325 mmol).  The reaction was stirred overnight at room temperature and then judged 
complete by LCMS analysis.  The solution was partitioned between CHCl2 and H2O, the 
organics were dried over MgSO4, and then the solution was filtered and concentrated in-
vacuo to afford the crude product.  Purification by silica gel plug (1:3 EtOAc:Hexanes 
fixed solvent gradient) afforded the title compound as a bright red-orange sticky solid 
(1.340 g, 3.242 mmol, 99%); LCMS (>98%) M+H = 414.09 (1.65 min retention),1H 
NMR (>95%) (400 MHz, CDCl3) d = 7.52 (s, 1H), 7.36 (m, 6H), 7.15 (t, J = 7.2 Hz, 1H), 
7.10 (t, J = 5.2 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.93 (s, 2H). 
 VU0402735.  A 100 mL round bottom flask containing 5-
(trifluoromethoxy)indoline-2-one (250 mg, 1.15 mmol) was vacuum purged 3x with 
argon, dissolved in DMF (30 mL), and cooled to 0 oC.  Solid sodium hydride (82.8 mg, 
3.45 mmol, 60% in mineral oil) was then added all at once and the reaction stirred until 
bubbling ceased.  Dibromoethane (259 mg, 1.38 mmol) was added all at once and the 
reaction allowed to warm to room temperature overnight.  Once complete the reaction 
was quenched with H2O (4 mL) and concentrated in situ.  The remaining material was 
partitioned between H2O (50 mL) and DCM (50 mL) and filtered through a phase 
separator, and concentrated.  The crude material was purified by HPLC (Gilson, 
ACN:H2O w/ 0.1% TFA) obtain the pure intermediate (35 mg, 12.5% yield).  LCMS 
[M+H]: 218.1. 
 This intermediate (30 mg, 0.138 mmol) was then brought up in ACN (1.5 mL) in 
a glass vial, to which K2CO3 (0.274 mmol), 4-methoxybenzyl chloride (0.166 mmol), and 
KI (0.014 mmol) was added.  The vial was sealed and subjected to microwave irradiation 
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at 160 °C for 10 mins.  After LCMS analysis, the reaction was judged complete and the 
solution was partitioned between DCM and H2O before passage through a disposable 
phase separator column (Isolute).  The organics were then concentrated on a heated-
drying block to afford the crude product.  Purification by HPLC (Gilson, ACN:H2O w/ 
0.1% TFA) provided the title compound with 98% purity (LCMS).  LCMS [M+H]: 
364.33 
 VU0402734. A 50 mL round bottom flask containing VU0238429 as starting 
material (50 mg, 0.142 mmol) was vacuum purged 3x with argon, dissolved in DCM (2 
mL), added EtOH (100 mL) and cooled to 0 oC.  Once cool added DAST (68.8 mg, 0.427 
mmol) and allowed to warm to room temperature overnight.  Once complete the reaction 
was quenched with saturated sodium bicarbonate (50 mL), H2O (50 mL) and partitioned 
between DCM and filtered through a phase separator and concentrated.  The crude 
material was purified by HPLC (Gilson, ACN:H2O w/ 0.1% TFA) obtain the pure final 
product (23 mg, 43.4 % yield).  LCMS [M+H]: 374.1. 
 VU0402733.  A 100 mL round bottom flask containing VU0238429 as starting 
material (117 mg, 0.333 mmol) was vacuum purged 3x with argon, dissolved in THF (30 
mL) and cooled to -78 oC.  Once cool added 3.0 M solution of methyl magnesium 
bromide (0.122 mL, 0.366 mmol) over 5 min. and the reaction allowed to warm to room 
temperature overnight.  Once complete the reaction was quenched with H2O (50 mL), 1N 
HCl (50 mL) and partitioned between DCM and filtered through a phase separator and 
concentrated.  The crude material was purified via column chromatography using 
EtOAc:Hexanes (1:2) to afford the pure final product (45 mg, 37 % yield).  LCMS 
[M+H]: 368.1. 
 
 
51 
 VU0414747.  To a glass vial containing 3 mL DMF was added methyl 4-
hydroxybenzoate (500 mg, 3.286 mmol), Cs2CO3 (4.929 mmol), and 2,6-
difluoropyridine.  The vial was then sealed and thermally heated to 130 °C for 
approximately 5 hr before judging complete by TLC/LCMS.  The reaction was then 
partitioned between EtOAc and H2O, and the organics were washed with brine, dried 
over MgSO4, filtered, and then concentrated in-vacuo.  The crude intermediate product 
was carried forward without purification as highly pure (>90%) clear oil (738 mg, 2.985 
mmol, 91%). 
 To a vial containing this intermediate product (431 mg, 1.88 mmol) was added 30 
mL toluene under air-free argon atmosphere and the solution was cooled to 0 °C by ice 
bath.  Next, DIBAL (1M solution in toluene, 2.1 equivalents) was added to the vial via 
argon syringe slowly over approximately 5 min.  The reaction was stirred and allowed to 
warm to room temperature by removal of the ice bath.  After approximately 2 hr, the 
reaction was judged complete by LCMS and then quenched with excess Rochelle’s salt 
solution while continuing to stir at room temperature for 1.5 hr.  The solution was then 
partitioned into EtOAc and H2O, and the organics were dried over MgSO4, filtered, and 
then concentrated in-vacuo to afford the crude product with high (>90%) purity, which 
was carried forward without further purification (627 mg, 2.86 mmol, 96%). 
 To a glass vial containing this second intermediate product (100 mg, 0.456 mmol) 
was added 3 mL anhydrous DCM and then PBr3 (0.547 mmol) under air-free argon 
atmosphere at 0 °C by ice bath.  The reaction was stirred and allowed to warm to room 
temperature by removal of the ice bath.  After 2 hr, the reaction was judged complete by 
LCMS and then quenched with aqueous saturated sodium bicarbonate solution.  The 
 
 
52 
solution was then partitioned with DCM, the organics were separated and concentrated 
in-vacuo to afford the crude product.  Purification by HPLC (Gilson, ACN:H2O w/ 0.1% 
TFA) provided the pure intermediate (>95% by LCMS) as a clear oily solid (75 mg, 
0.266 mmol, 58%). 
 To a glass vial containing 1.5 mL DMF was added 5-trifluoromethoxyisatin (30 
mg, 0.130 mmol), K2CO3 (0.260 mmol), the third intermediate product (0.156 mmol), 
and KI (0.013 mmol).  The vial was then sealed and subjected to microwave irradiation at 
120 °C for 30 min.  The reaction was judged complete by LCMS and then partitioned 
between EtOAc and H2O.  The organics were then washed with brine, dried over MgSO4, 
filtered, and concentrated in-vacuo to afford the crude final product.  Purification by 
HPLC (Gilson, ACN:H2O w/ 0.1% TFA) provided the title compound with high purity 
(>98% by LCMS) as an orange solid (8.8 mg, 0.020 mmol, 16%). 
 General procedure for O-alkylations.  To a glass vial containing 1-2 mL DMF 
was added a phenol-bearing starting material (25-50 mg), substituted alkyl halide (1.5 
equivalents), Cs2CO3 (3.0 equivalents), KI (0.2 equivalents), and HMPA (4.0 
equivalents).  The vial was then flushed with argon and subjected to microwave 
irradiation at 160 °C for 15 min.  The reaction was then partitioned between EtOAc and 
saturated aqueous sodium bicarbonate.  The organics were washed with brine, dried over 
MgSO4, filtered, and then concentrated in-vacuo or on a heated-air drying block to accord 
the crude products, which were purified by HPLC. 
 General procedure for Mitsunobu libraries.  To glass vials containing 2 mL 
THF was added PS-PPh3 (2.63 mmol/g, 0.334 mmol) and DIAD (0.243 mmol) under 
argon.  The solutions were stirred for 20 min at room temperature and then a phenol-
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bearing starting material (0.152 mmol) and a substituted alcohol (0.197 mmol) was added 
under argon.  The solutions were then stirred overnight at room temperature before being 
partitioned into DCM and H2O.  The solutions were passed through a disposable phase-
separator column (Isolute) and the resulting organics were concentrated on a heated-air 
drying block to afford the crude products.  Purification by mass-directed HPLC provided 
the final products with high purity (>98% by LCMS). 
 
M1 PAM syntheses  
 VU HTS hit VU0029767.  To a solution of 4-ethoxyaniline (10.0 g, 72.9 mmol) 
in EtOH (100 mL) was added ethyl 2-bromoacetate (14.61 g, 87.0 mmol) and sodium 
acetate (8.97 g, 109.0 mmol) and stirred for 48 h at room temperature.  Once complete, 
the reaction was then partitioned into H2O and EtOAc and the organics washed with brine 
and dried over MgSO4 before concentration in vacuo.  The crude product was purified by 
passage through a silica plug eluting with 5% EtOAc in hexanes to afford the 
intermediate product ethyl 2-(4-ethoxyphenylamino)acetate (11.7 g, 72%) as a dark 
brown oil.  To a solution of the acetate intermediate (4.0 g, 17.93 mmol) in MeOH (50 
mL) was added hydrazine (177.9 mL, 177.9 mmol) and stirred for 16 h at 65 degrees C. 
Once complete, the reaction was then partitioned into H2O and EtOAc, and the organics 
washed with brine and dried over MgSO4 before concentration in vacuo.  The crude 
product was purified by column chromatography (silica gel) eluting with 5% MeOH in 
CH2Cl2 to afford the intermediate product 2-(4-ethoxyphenylamino)acetohydrazide (2.5 
g, 67%) as a white solid.  To a solution of the hydrazide intermediate (2.0 g, 9.56 mmol) 
in DMF (100 mL) was added 2-hydroxy-1-napthaldehyde (1.64 g, 9.56 mmol) and stirred 
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for 16 h at room temperature.  Once complete, the reaction was concentrated in vacuo 
and the crude product was purified by filtration with diethyl ether wash (3x250 mL) to 
afford title compound (3.41 g, 98%) as a yellow solid; 1H NMR (400 MHz, DMSO-d6) δ 
9.38 (s, 1H), 8.09 (d, J = 4.2 Hz, 1H), 7.80 (dd, J = 8.8, 4.4 Hz, 2H), 7.50 (t, J = 7.2 Hz, 
1H), 7.31 (t, J = 7.2 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 6.67 (d, J = 8.8 Hz, 2H), 6.49 (d, J 
= 8.8 Hz, 2H), 5.69 (t, J = 6.0 Hz, 1H), 3.80 (q, J = 6.8 Hz, 2H), 3.73 (d, J = 5.6 Hz, 1H), 
3.32 (s, 2H), 1.18 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 167.2, 157.8, 
150.6, 146.3, 142.7, 132.6, 131.6, 128.9, 127.8, 123.5, 120.7, 118.8, 115.4, 113.5, 113.3, 
108.4, 63.3, 47.4, 14.8.; LC-MS (214 nm) 3.09 min (>98%); m/z 364.2 [M+H]. 
  VU HTS hit VU0090157.  To a solution of 6-nitrobenzo[d][1,3]dioxole-5-
carbaldehyde (195 mg, 1.0 mmol) in MeOH (100 mL) was added 2-cyanoethyl 3-
oxobutanoate (186 mg, 1.2 mmol), 1-methylurea (111 mg, 1.5 mmol), and p-TsOH (17 
mg, 0.1 mmol) and refluxed for 4 h.  Once complete, the reaction was filtered and the 
crude product was purified by recrystallization with MeOH and H2O to afford the 
intermediate product 2-cyanoethyl 1,6-dimethyl-4-(6-nitrobenzo[d][1,3]dioxol-5-yl)-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (283 mg, 78%) as a white crystalline 
solid.  To a solution of the carboxylate intermediate (1.0 g, 2.57 mmol) in acetone/H2O 
(6/2 mL) was added 2 M NaOH (4 mL) at 0 degrees C, and the solution was warmed to 
room temperature and stirred for 2 h.  Once complete, the reaction was acidified with 2 N 
HCl and partitioned into H2O and CH2Cl2 and the organics were concentrated in vacuo.  
The crude product was purified by recrystallization with MeOH and H2O to afford the 
intermediate product 1,6-dimethyl-4-(6-nitrobenzo[d][1,3]dioxol-5-yl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylic acid (790 mg, 92%) as a white crystalline solid.  To a 
 
 
55 
solution of the acid intermediate (500mg, 1.49 mmol) in DMF (12 mL) was added 
cyclopentanol (385 mg, 4.48 mmol), EDC (428 mg, 2.24 mmol), and polystyrene-bound 
DMAP (1.5 mmol/g, 5.96 mmol) and irradiated at 100 degrees C for 20 m.  Once 
complete, the reaction was partitioned into 1N HCl in H2O and CH2Cl2 and the organics 
were concentrated in vacuo.  The crude product was purified by recrystallization in 
EtOAc and hexanes to afford the title compound (200 mg, 33%) as a brown crystalline 
solid. 1H NMR (400 MHz, DMSO-d6) δ 7.60 (s 1H), 7.58 (d, J = 1.6 Hz, 1H), 6.95 (s, 
1H), 6.23 (s, 1H), 6.20 (s, 1H), 5.81 (d, J = 1.4 Hz, 1H), 4.93 (m, 1H), 3.16 (s, 3H), 2.57 
(s, 3H), 1.66 (m, 1H), 1.55 (m, 1H), 1.40 (m, 4H), 1.19 (m, 1H), 1.09 (m, 1H).  13C NMR 
(100 MHz, DMSO-d6) δ 164.5, 152.6, 152.3, 151.8, 147.0, 141.3, 135.3, 106.9, 104.8, 
103.4, 100.4, 75.9, 48.5, 32.0, 29.6, 23.0, 15.9.  ; LC-MS (214 nm) 3.14 min (>98%); m/z 
404.2 
 General procedure for Suzuki-coupling libraries.  Glass vials containing 1-2 
mL anhydrous THF were charged with starting material bearing a –bromo or –chloro 
substituted aryl/heteroaryl ring, a substituted boronic acid (1.2 equivalents), aqueous 1M 
Cs2CO3 solution (2.0 equivalents), and tetrakis(PPh3)Pd(0) catalyst (0.1-0.2 equivalents).  
The vials were flushed with argon and then subjected to microwave irradiation for 5-20 
min at 120 °C.  Once complete, the reactions were passed through disposable celite 
(Isolute HM-N) columns (rinsing 2-3x column volume with DCM).  The filtered organics 
were then concentrated in-vacuo or on a heated-air drying block to provide the crude 
products, which were analyzed by LCMS and then purified by HPLC. 
 General procedure for BQCA library I.  Each of seven glass vials containing 2 
mL of DMF were loaded with ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
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(25 mg, 0.106 mmol, Maybridge BTB02003EA), K2CO3 (30 mg, 0.212 mmol, 2.0 
equivalents), KI (2 mg, 0.011 mmol, 0.1 equivalents), and one of seven benzyl bromides 
(0.319 mmol, 3.0 equivalents).  The reactions were stirred for 24 hours at room 
temperature before receiving polystyrene-bound thiophenol (0.159 mmol, 1.5 
equivalents) each, and then stirred for an additional 3 hours.  The reactions were then 
judged complete by LCMS, filtered, and separated into CH2Cl2 and H2O.  The organics 
were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo yielding 
seven benzyl-substituted ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylates 
confirmed by analytical LCMS.  Next, crude products (0.1 mmol) and LiOH (8 mg, 0.3 
mmol, 3.0 equivalents) were dissolved in 3 mL of THF:H2O (9:1) in glass vials.  The 
reactions were microwave irradiated at 120 °C for 10 minutes and then separated into 
EtOAc and H2O, which was acidified to pH 4 drop-wise using 1N HCl.  Organics were 
dried over MgSO4, filtered, and concentrated in vacuo yielding seven benzyl-substituted 
8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids confirmed by LCMS.  
Purification using mass-directed HPLC afforded the seven compounds (25-85% total 
yield) as TFA salts with >98% purity. 
 General procedure for BQCA library II.  Each of seven glass vials containing 2 
mL of DMF were loaded with ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate (25 mg, 
0.115 mmol, Ryan Scientific 6J-050), K2CO3 (32 mg, 0.230 mmol, 2.0 equivalents), KI 
(2 mg, 0.012 mmol, 0.1 equivalents), and one of seven benzyl bromides (0.345 mmol, 3.0 
equivalents).  The reactions were stirred for 24 hours at room temperature before 
receiving polystyrene-bound thiophenol (0.173 mmol, 1.5 equivalents) each, and then 
stirred for an additional 3 hours.  The reactions were then judged complete by LCMS, 
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filtered, and separated into CH2Cl2 and H2O.  The organics were washed with brine, dried 
over MgSO4, filtered, and concentrated in vacuo yielding seven benzyl-substituted ethyl 
4-oxo-1,4-dihydroquinoline-3-carboxylates confirmed by analytical LCMS.  Next, crude 
products (0.1 mmol) and LiOH (8 mg, 0.3 mmol, 3.0 equivalents) were dissolved in 3 mL 
of THF:H2O (9:1) in glass vials.  The reactions were microwave irradiated at 120 °C for 
10 minutes and then separated into EtOAc and H2O, which was acidified to pH 4 drop-
wise using 1N HCl.  Organics were dried over MgSO4, filtered, and concentrated in 
vacuo yielding seven benzyl-substituted 4-oxo-1,4-dihydroquinoline-3-carboxylic acids 
confirmed by LCMS.  Purification using mass-directed HPLC afforded the seven 
compounds (25-85% total yield) as TFA salts with >98% purity.   
 General procedure for BQCA library III.  Each of seven glass vials containing 
2 mL of DMF were loaded with ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (25 mg, 0.099 mmol, Ryan Scientific 6J-020), K2CO3 (27 mg, 0.198 mmol, 
2.0 equivalents), KI (2 mg, 0.099 mmol, 0.1 equivalents), and one of seven benzyl 
bromides (0.297 mmol, 3.0 equivalents).  The reactions were stirred for 24 hours at room 
temperature and atmosphere before receiving polystyrene-bound thiophenol (0.149 
mmol, 1.5 equivalents) each, and then stirred for an additional 3 hours.  The reactions 
were then judged complete by LCMS, filtered, and separated into CH2Cl2 and H2O.  The 
organics were washed with brine, dried over MgSO4, and concentrated in vacuo yielding 
seven benzyl-substituted ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylates 
confirmed by analytical LCMS.  Next, crude products (0.1 mmol) and LiOH (8 mg, 0.3 
mmol, 3.0 equivalents) were dissolved in 3 mL of THF:H2O (9:1) in glass vials.  The 
reactions were microwave irradiated at 120 °C for 10 minutes and then separated into 
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EtOAc and H2O, which was acidified to pH 4 drop-wise using 1N HCl.  Organics were 
dried over MgSO4 and concentrated in vacuo yielding seven benzyl-substituted 5,8-
difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids confirmed by LCMS.  
Purification using mass-directed HPLC afforded the seven compounds (25-85% total 
yield) as TFA salts with >98% purity. 
 BQCA.  To stirred solution of 200 mL DMF in a glass flask was added ethyl 4-
oxo-1,4-dihydroquinoline-3-carboxylate (3.40 g, 15.66 mmol, Ryan Scientific 6J-050), 
K2CO3 (4.33 g, 31.32 mmol, 2.0 equivalents), KI (260 mg, 1.57 mmol, 0.1 equivalents), 
and 4-methoxybenzyl bromide (4.70 g, 23.49 mmol, 1.5 equivalents).  After 48 hours of 
stirring at room temperature and atmosphere, the reaction was monitored by LCMS and 
judged complete.  The reaction was then partitioned into CH2Cl2 and H2O, and the 
organics were washed with brine, dried over MgSO4, and concentrated in vacuo.  
Purification by diethyl ether washing (6 x 50 mL) afforded the intermediate product ethyl 
1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (4.99 g, 14.83 mmol, 
95%) as an off-white solid at >98% purity by LCMS.  To a glass vial containing ethyl 1-
(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (4.99 g, 14.83 mmol) in 90 
mL THF:H2O (5:1) was added LiOH (1.07 g, 44.49 mmol, 3.0 equivalents).  The reaction 
was microwave irradiated at 120 °C for 10 minutes and then partitioned into CH2Cl2 and 
H2O.  The solution was re-acidified to pH 5 drop-wise using 2N HCl.  The organics were 
dried over MgSO4, filtered, concentrated in vacuo, and analyzed by LCMS.  The crude 
product was purified by diethyl ether washing (6 x 50 mL) and additional H2O wash (1 x 
100 mL) to afford the intermediate product 1-(4-methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (3.20 g, 10.35 mmol, 70%) as an off-white crystalline 
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solid at >98% purity by LCMS.  To a stirred solution of 1-(4-methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (1.89 g, 6.11 mmol) in 25 mL DMF in a glass flask at 
0 °C was added NaH (143 mg, 5.99 mmol, 0.98 equivalents).  The reaction was allowed 
to warm to room temperature and stirred for 1 hour before concentration in vacuo.  The 
crude product was washed with diethyl ether (3 x 30 mL) to afford the title compound 
(1.80 g, 5.44 mmol, 89%) as a white solid at >98% purity by LCMS.  1H NMR (400 
MHz, D2O): d= 9.07 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.4 Hz, 1H), 7.45 (d, J 
= 8.4 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 
5.35 (s, 2H), 3.67 (s, 3H).  13C NMR (100 MHz, D2O, externally referenced to DMSO-
d6): d= 176.3, 172.2, 158.0, 147.4, 138.5, 132.3, 127.5, 127.2, 126.9, 125.5, 124.5, 117.5, 
116.9, 113.8, 55.8, 54.7.  HRMS calcd for C18H14NO4Na2 [M + 2Na] 354.0718, found 
354.0716. 
 MLPCN M1 PAM probe VU0405652. 
 
 To a solution of indole (3.00 g, 25.6mmol) and methyl thioglycolate (2.40 mL, 
25.6 mmol) in methanol:water (80 mL : 20 mL) was added iodine (6.50 g, 25.6 mmol) 
and potassium iodide (4.25 g, 25.6 mmol).  The reaction mixture was stirred at ambient 
temperature for 60 hours.  Methanol was removed in vacuo and the aqueous layer diluted 
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with a saturated solution of sodium bicarbonate and extracted with ethyl acetate.  The 
organic layer was dried over magnesium sulfate, evaporated in vacuo and the resulting 
residue was purified on a silica gel column (0-100% ethyl acetate:hexanes over 33 min) 
to afford compound 1 as an oil (LCMS >98%).  Compound 1 was dissolved in a mixture 
of tetrahydrofuran (20 mL) and 2.0M aqueous LiOH (15 mL), then stirred vigorously at 
ambient temperature for 30 minutes.  Tetrahydrofuran was removed in vacuo, the 
aqueous layer neutralized with 1.2 N HCl and extracted with CH2Cl2. The organic layer 
was dried over magnesium sulfate and removed in vacuo to produce an oily residue.  
Upon diluting the residue in dichloromethane a reddish-brown solid formed which was 
filtered and dried to yield compound 2 (2.00 grams, 9.65 mmol, 38% yield over 2 steps, 
LCMS >98%). 
 Compound 2 (650 mg, 3.14 mmol), 3-amino-5-methyl-isoxazole (616 mg, 6.28 
mmol), PyClu (2.00 g, 6.28 mmol), and DIEA (1.36 mL, 7.85 mmol) were added to 
dichloroethane (25 mL) and microwave irradiated at 110 °C for 20 minutes.  After 
cooling, the solvent was removed in vacuo and the remaining residue purified on a silica 
gel column (0-70% ethyl acetate:hexanes over 33 min) to yield compound 3 (642 mg, 
2.23 mmol, 71% yield, LCMS >98%).  Compound 3 (502 mg, 1.77 mmol) was dissolved 
in 25 mL (9:1, methanol:water) and oxone (10.0 g, 17.7 mmol) was added. Stirring at 
ambient temperature continued overnight.  Water (20 mL) was added and the mixture 
extracted with ethyl acetate (3x20 mL).  The organics were combined, dried over 
magnesium sulfate, and concentrated in vacuo to give an oily residue which was purified 
on silica gel (0-50% ethyl acetate:hexanes over 19 min) to yield compound 4 (500 mg, 
1.57 mmol, 88% yield, LCMS >98%).   
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 In a 5 mL microwave vial, compound 4 (55.0 mg, 0.174 mmol) was dissolved in 
DMF (3 mL) and cooled to 0 °C.  Sodium hydride (60% by weight, 14.0 mg, 0.348 
mmol) was then added in one portion and the reaction mixture vigorously stirred at 0 °C 
for 15 minutes.  4-bromo-2-bromomethyl-1-flouro-benzene (51.0 mg, 0.191 mmol) was 
added in one portion and the reaction mixture was stirred while being allowed to warm to 
ambient temperature over 3 hours.  The reaction mixture was quenched with water (2 
mL) and the solution was extracted with ethyl acetate (3x4 mL).  The combined organics 
were dried over magnesium sulfate, concentrated in vacuo to give an oily residue which 
was purified on silica gel (0-70% ethyl acetate:hexanes over 19 min) to yield the final 
product (compound 5, 45 mg, 0.088 mmol, 51%  yield).  LCMS >98% 214 nm, RT = 1.34 
min, m/z = 506 ([79Br]m+1), 508 ([81Br]m+1). 1H NMR (400 MHz, DMSOD6) 11.27 (s, 
1H), 8.23 (s, 1H), 7.82 (d,  J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.56-7.58 (m, 1H), 
7.47 (dd, J = 2.4 Hz, 6.4 Hz, 1H), 7.35-7.23 (m, 3H), 6.54 (s, 1H), 5.62 (s, 2H), 4.43 (s, 
2H), 2.37 (s, 3H),  HRMS found: 506.0184; calculated for C21H17BrFN3O4S: 506.0185. 
 
M1 allosteric agonist syntheses 
 VU0184670.  To a solution of benzoyl chloride (87.7 mg, 0.624 mmol) in 
dichloromethane (2 mL) was added N-boc-ethylenediamine (100.0 mg, 0.624 mmol) and 
PS-DIEA (2 eq, 356.6 mg). The reaction was agitated overnight at room temperature, 
after which the reaction mixture was filtered to remove polymer-supported resin. The 
filtrate was then concentrated and dissolved in 1mL of dichloromethane, to which was 
added 1mL of trifluoroacetic acid (1:1 DCM:TFA) and stirred at room temperature for 30 
min. Following deprotection, the reaction mixture was again concentrated to dryness, 
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after which the product was dissolved in dimethylformamide (2mL). To this solution was 
added 1-carbethoxy-4-piperidone (106.8 mg, 0.624 mmol) and MP-BH(OAc)3 (2.5 eq, 
645 mg). The reaction mixture was then agitated overnight at room temperature, after 
which the resin was filtered off.  Aqueous workup of the reaction mixture using brine and 
ethyl acetate, followed by filtration of the organic layer using an Isolute Phase Separator 
and sample concentration yielded ethyl 4-(2-(2-methylbenzamido)ethylamino)piperidine-
1-carboxylate as a pale yellow oil. The product was then dissolved in 1 mL of DMSO and 
purified by mass-directed preparative HPLC to afford ethyl 4-(2-(2-
methylbenzamido)ethylamino)piperidine-1-carboxylate -2,2,2-trifluoroacetate as a clear 
oil (64.5 mg, 23.9 %); 1H-NMR (400 MHz, d6 - DMSO) δ 7.9-7.8 (m, 1H), 7.52-7.42 
(m, 5H), 6.73 (br s, 1H), 4.16-4.11 (q, J = 7.07 Hz, 1H), 3.56-3.50 (m, 4H), 2.92-2.90 (m, 
6H), 2.29 (s, 1H), 1.38-1.32 (m, 7H); 13C-NMR (100 MHz, d6 – CDCl3): δ 166.95, 
154.84, 134.20, 131.82, 128.65, 127.78, 61.24, 54.36, 43.60, 42.03, 36.30, 14.95; HRMS 
(m/z): [M+H] calcd. for C17H26N3O3, 320.1974; found, 320.1966. 
 VU0357017.  To a solution of o-toluoyl chloride (96.5 mg, 0.624 mmol) in 
dichloromethane (2 mL) was added N-boc-ethylenediamine (100.0 mg, 0.624 mmol) and 
PS-DIEA (2 eq, 356.6 mg). The reaction was agitated overnight at room temperature, 
after which the reaction mixture was filtered to remove polymer-supported resin. The 
filtrate was then concentrated and dissolved in 1mL of dichloromethane, to which was 
added 1mL of trifluoroacetic acid (1:1 DCM:TFA) and stirred at room temperature for 30 
min. Following deprotection, the reaction mixture was again concentrated to dryness, 
after which the product was dissolved in dimethylformamide (2mL). To this solution was 
added 1-carbethoxy-4-piperidone (106.8 mg, 0.624 mmol) and MP-BH(OAc)3 (2.5 eq, 
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645 mg). The reaction mixture was then agitated overnight at room temperature, after 
which the resin was filtered off.  Aqueous workup of the reaction mixture using brine and 
ethyl acetate, followed by filtration of the organic layer using an Isolute Phase Separator 
and sample concentration yielded ethyl 4-(2-(2-methylbenzamido)ethylamino)piperidine-
1-carboxylate as a pale yellow oil. The product was then dissolved in 1 mL of DMSO and 
purified by mass-directed preparative HPLC to afford ethyl 4-(2-(2-
methylbenzamido)ethylamino)piperidine-1-carboxylate -2,2,2-trifluoroacetate as a clear 
oil (102.9 mg, 36.9 %); 1H-NMR (400 MHz, d6 – CDCl3) δ 7.37-7.18 (m, 7H), 6.30 (br s, 
1H), 4.15-4.10 (q, J = 7.07 Hz, 1H), 3.54-3.50 (q, J = 5.74 Hz, 4H), 2.91-2.86 (m, 6H), 
2.35 (s, 1H), 1.27-1.20 (m, 7H); 13C-NMR (100 MHz, d6 - DMSO) δ 130.96, 129.99, 
127.76, 125.83, 61.23, 54.32, 43.38, 42.01, 28.07, 20.01, 14.94; HRMS (m/z): [M+H] 
calcd. for C18H28N3O3, 334.2131; found, 334.2130. 
 
M1 agonist TBPB analog syntheses 
 Reductive Amination with commercial piperidinones.  Each of twenty-four 
glass reaction vials containing 3 mL of CH2Cl2 were loaded with MP-B(OAc)3H (142 
mg, 0.345 mmol, 2.42 mmol/g, 3.0 equivalents) and 4-(2-keto-1-
benzoimidazolinyl)piperidine (25 mg, 0.115 mmol, 1.0 equivalents).  Then, one of 24 N-
functionalized piperidinones (0.115 mmol, 1.0 equivalents) with either an alkyl or 
carbamate moiety was added to each reaction tube.  The reactions were stirred overnight 
at room temperature.  The next day, the solutions were filtered and washed with CH2Cl2 
(3 x 3 mL), then dried before purification by mass-directed preparative HPLC. 
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 General Procedures for Library Synthesis (Scheme 1): Synthesis of N-benzyl 
piperidinones.  Each of sixty-four glass reaction vials containing 3 mL of CH2Cl2 and 
0.1 mL of MeOH were loaded with piperidone hydrochloride (25 mg, 0.185 mmol, 1.0 
equivalents) and K2CO3 (51 mg, 0.370 mmol, 2.0 equivalents).  Then, one of sixty-four 
functionalized benzyl bromides (0.185 mmol, 1.0 equivalents) was added to each reaction 
tube.  The reactions were stirred overnight at room temperature, partitioned between 
CH2Cl2 and H2O, and the organics were concentrated on a heat-air block.  Purification by 
preparative LCMS was performed to afford N-benzyl piperidinones products for 
subsequent reductive amination. 
 Reductive Aminations.  Each of sixty-four glass reaction vials containing 3 mL 
of CH2Cl2 were loaded with MP-B(OAc)3H (142 mg, 0.345 mmol, 2.42 mmol/g, 3.0 
equivalents) and 4-(2-keto-1-benzoimidazolinyl)piperidine (25 mg, 0.115 mmol, 1.0 
equivalents) or 5-chloro-1-(4-piperidinyl)-2-benzimidazolone (29 mg, 0.115 mmol, 1.0 
equivalents).  Then, one of sixty-four tertiary amine hydrates (0.115 mmol, 1.0 
equivalents) from the previous alkylation reactions was added to each vial, and the 
reactions were stirred overnight at room temperature. The next day, the solutions were 
filtered and washed with CH2Cl2 (3 x 3 mL), then dried before purification by mass-
directed preparative HPLC. 
 TBPB.  To a stirred solution of 4-piperidone monohydrate HCl (2.00 grams, 
13.02 mmol) in dimethylformamide (100 mL) was added 2-methylbenzyl bromide (2.44 
grams, 13.02 mmol) and K2CO3 (3.60 grams, 26.04 mmol, 2.0 equivalents) at room 
temperature.  The reaction was then monitored by analytical LCMS, and once judged 
complete, the reaction was separated with water and EtOAc.  The organics were next 
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washed with a saturated solution of NaCl and dried over MgSO4 before being 
concentrated in vacuo to afford 2.59 grams (90%) of the hydrate form of 1-(2-
methylbenzyl)piperidin-4-one as a colorless oil.  Analytical LCMS (J-Sphere80-C18, 3.0 
x 50.0 mm, 4.1 min gradient, 5%[0.05% TFA/CH3CN]:95%[0.05% TFA/H2O]:1.64 min, 
>99% (214 nm, 254 nm and ELSD) M+1 peak m/e 204.1; 1H NMR (400 MHz, DMSO-d-
6) d 7.28 (m, 1H), 7.16 (m, 3H), 3.53 (s, 2H), 2.67 (t, J = 6.4 Hz, 4H), 2.36 (s, 3H), 2.32 
(t, J = 6.4 Hz, 4H).  13C NMR (100 MHz, DMSO-d6) d 137.0, 136.4, 130.1, 129.3, 127.0, 
125.4, 58.7, 52.4, 40.6, 18.8; HRMS calc’d for C13H20NO2[M+H]; 222.1494 found                      
222.1488.   
 This intermediate 1-(2-methylbenzyl)piperidin-4-one (2.00 grams, 9.04 mmol) 
product was then brought up in a stirred solution of CH2Cl2 (100 mL) to which 4-(2-keto-
1-benzimidazolinyl)piperidine (2.16 grams, 9.95 mmol, 1.1 equivalents) was added at 
room temperature.  Then, MP-triacetoxyborohydride (13.57 grams, 27.132 mmol [2.0 
mmol/gram loading], 3.0 equivalents) was added and the reaction was monitored by 
analytical LCMS.  Once judged complete, the reaction was filtered and the filtrate was 
purified by mass-directed preparative HPLC to afford 2.92 grams (80%) of title 
compound as a pure white solid.  Analytical LCMS (J-Sphere80-C18, 3.0 x 50.0 mm, 4.1 
min gradient, 5%[0.05% TFA/CH3CN]:95%[0.05% TFA/H2O]:2.34 min, >99% (214 nm, 
254 nm and ELSD) M+1 peak m/e 405.2;  1H NMR (400 MHz, DMSO-d6) d 7.26 (d, J = 
4.0 Hz, 1H), 7.18 (m, 3H), 6.96 (m, 4H), 4.22 (m, 1H), 4.09 (m, 1H), 3.37 (m, 2H), 3.18 
(s, 1H), 3.05 (m, 1H), 2.96 (br d, J = 7.6 Hz, 2H), 2.81 (br d, J = 11.2 Hz, 2H), 2.67 (t, J 
= 6.0 Hz, 1H), 2.57 (br t, J = 11.2 Hz, 1H), 2.28 (m, 6H), 1.93 (br t, J = 10.8 Hz, 2H), 
1.64 (m, 2H), 1.41 (m, 2H).  13C NMR (100 MHz, DMSO-d6) d 153.6, 136.9, 130.1, 
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129.4, 129.2, 129.1, 128.3, 127.0, 125.5, 120.3, 108.8, 61.4, 60.2, 52.4, 49.9, 48.5, 45.8, 
40.7, 29.2, 27.9, 18.8; HRMS calc’d for C25H33N4O[M+H]; 405.2654 found   
405.2654 .   
 TBPB analog 1b (ethyl carbamate derivative).  To a stirred solution of 4-(2-
keto-1-benzimidazolinyl)piperidine (50 mg, 0.230 mmol) in CHCl2 (3 mL) was added 
ethyl 4-oxo-1-piperidinecarboxylate (43.3 mg, 0.253 mmol, 1.1 equivalents) and MP-
B(OAc)3H (285 mg, 0.691 mmol, 2.42 mmol/g, 3.0 equivalents).  The reaction was then 
monitored by analytical LCMS, and once judged complete, the reaction was filtered and 
concentrated.  Purification by mass-directed preparative HPLC afforded 32.50 mg (38%) 
of title compound as a beige-white solid.  Analytical LC/MS (J-Sphere80-C18, 3.0 x 50.0 
mm, 4.1 min gradient, 5%[0.05% TFA/CH3CN]:95%[0.05% TFA/H2O]:2.05 min, >99% 
(214 nm, 254 nm and ELSD) M+1 peak m/e 373.2;  1H NMR (400 MHz, DMSO-d6) d 
10.94 (s, 1H), 9.97 (br s, 1H), 7.31 (d. J = 4.4 hz, 1H), 7.00 (m, 3H), 4.57 (m, 1H), 4.12 
(br d, J = 11.6 Hz, 2H), 4.04 (q, J = 7.2 Hz, 2H), 3.59 (br d, J = 11.2 Hz, 2H), 3.47 (m, 
1H), 3.24 (m, 2H), 2.82 (m, 2H), 2.66 (m, 2H), 2.05 (m, 2H), 1.94 (br d, J = 12.4 Hz, 
2H), 1.59 (m, 2H), 1.19 (t, J = 6.8 Hz, 3H).  13C NMR (100 MHz, DMSO-d6) d 154.4, 
153.6, 128.7, 128.4, 120.9, 120.3, 109.1, 108.6, 62.5, 60.9, 48.1, 46.6, 42.1, 25.8, 14.5; 
HRMS calc’d for C20H29N4O3[M+H]; 373.2240 found 373.2235.   
 
 
M1 antagonist syntheses 
 
 General parallel analog library synthesis.  To a solution of 3-
(benzo[c][1,2,5]thiadiazole-4-sulfonamido)-propanoic acid (50 mg, 0.17 mmol) and 
DIPEA (46 mL, 0.34 mmol) in DCM (2 mL) in a 4-mL vial was added polymer-
supported DCC (283 mg, 0.34 mmol, 1.2 mmol/g), HOBt (27 mg, 0.2 mmol) and one of 
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24 amines (HNR1R2) and rotated at room temperature for 20 h. Then, MP-carbonate (151 
mg, 0.5 mmol, 3.3 mmol/g) was added to scavenge excess acid and the HOBt. The 
reactions were filtered into 13 x 100 mm test tubes, and the resin washed (3 x 5 mL) with 
DCM. The combined organic layers were dried down on a nitrogen evaporator and the 
compounds purified to >98% by preparative LCMS on an Agilent 1200 Prep mass-
directed LCMS purification system.  
 VU0255035 (compound 5b).  To a solution of 3-(benzo[c][1,2,5]thiadiazole-4-
sulfonamido)-propanoic acid (2.00 g, 6.94 mmol) and DIPEA (2.43 mL, 13.9 mmol) in 
DMF (10 mL) was added EDC (1.55 g, 8.33 mmol), HOBt (937 mg, 6.94 mmol) and 1-
(4-pyridyl)piperazine (1.36 g, 8.33 mmol) and stirred at room temperature for 20 h. The 
reaction was diluted with water (80 mL) and extracted with EtOAc (2 x 100 mL). The 
combined organic extracts were washed with water (2 x 80 mL) and brine (100 mL), 
dried over MgSO4 and concentrated under vacuum. The residue was triturated with 
CH2Cl2/hexanes (1:1, 40 mL) to afford amide VU0255035 as a light tan solid (1.45 g, 48 
%): mp 159.7-160.2 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 9.0 Hz, 1H), 8.20 
(d, J = 7.0 Hz, 1H), 8.16 (d, J = 6.0 Hz, 2H), 7.85 (dd, J = 9.0, 7.0 Hz, 1H), 7.71 (br s, 
1H), 6.80 (d, J = 6.0 Hz, 2H), 3.51-3.40 (m, 4H), 3.35-3.28 (m, 4H), 3.21-3.12 (m, 2H); 
13C NMR (100 MHz, DMSO-d6) δ 169.1, 155.4, 154.7, 149.5, 149.2, 132.5, 130.9, 129.3, 
126.3, 108.6, 45.6, 45.3, 44.2, 41.7, 41.4, 33.0; Analytical LCMS (J-Sphere80-C18, 3.0 x 
50.0 mm, 4.1 min gradient, 5%[0.05% TFA/CH3CN]:95%[0.05% TFA/H2O]: 1.95 min, 
>99%, (214 nM, 254 nm, ELSD), m/z [M+H] = 433.1; HRMS calc’d for C18H21N6O3S2 
[M+H]; 433.1117 found 433.1117. 
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Jetmilling/scale-up 
 For compounds used in in vivo behavioral and/or pharmacokinetic (PK)/plasma-
brain levels (PBL) studies, a large-scale synthesis was performed (generally 200 mg to 10 
g) to provide the required amount of material.  In such cases where compound solubility 
or other physiochemical properties imposed substantial challenges during vehicle 
formulation, the material was passed through a jet-milling device (Model 00 Jet-O-Mizer 
with a High-Yield® Collection Module from Fluid Energy Processing & Equipment 
Company), which afforded uniform nanoparticles with improved solubility and physical 
properties. 
 
In vitro Pharmacology 
 
Cell lines and cell culture 
 Rat M1 cDNA, provided by T.I. Bonner (National Institutes of Health, Bethesda, 
MD), was used to generate the orthosteric-site mutant rat M1Y381A using the QuikChange 
site-directed mutagenesis kit.  All tissue culture reagents were purchased from Invitrogen 
Corporation, Carlsbad, CA, unless otherwise noted.  Cell lines used for all WT-mAChR 
studies stably expressed rat M1, human M2 and Gqi5, human M3, rat M4 and Gqi5, or 
human M5 in the Chinese Hamster Ovary (CHO-K1) parental background.  The M1, M3, 
and M5 cell lines were cultured in HAM’s F12 medium with 10% FBS, 20 mM HEPES, 
and 50 µg/mL G418 (Mediatech, Inc., Herndon, VA).  M2/Gqi5 cells were cultured in the 
same media with 500 µg/mL hygromycin.  M4/Gqi5 cells were cultured in the same media 
400 µg/mL G418 and 500 µg/mL hygromycin.  Cells expressing the rat M1Y381A 
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orthosteric-site mutant receptor were cultured in the same medium, except without 
hygromycin.  Cell lines used for experiments performed with human M4 were generated 
and used by Millipore and co-expressed the promiscuous Gα16. 
 
Calcium mobilization assays 
 All functional cell-based calcium mobilization assays were performed essentially 
as previously described (Marlo et al., 2009; Brady et al., 2008) using either an FDSS or 
Flexstation according to the following protocols.  These protocols represent the general 
methods used for the M5 PAM, M4 PAM, and M1 PAM projects.  The M1 allosteric 
agonist and TBPB projects utilized similar methods with the exception that a single-add 
format was used wherein test compound is added at 2X alone with no second-add of 
ACh.  For the M1 antagonist project, similar methods were used as described for the M5 
PAM, M4 PAM, and M1 PAM projects with the exception that an ACh ~EC80 was used in 
the second-add instead of an ~EC20.  Likewise for M2-M5 antagonism screening in the M1 
allosteric agonist project, an ACh ~EC80 was used in the second-add instead of an ~EC20 
to assess functional antagonism. 
 For all FDSS screens/assays, cells (10,000 cells/20 µl/well) were plated in black-
walled, clear-bottomed, TC treated, 384 well plates (Greiner Bio-One, Monroe, North 
Carolina) in Ham’s F12 medium supplemented with 10% FBS and 20 mM HEPES.  The 
cells were grown overnight at 37 °C in the presence of 5% CO2.  The next day, the 
medium was removed and replaced with 20 µl of 2 µM Fluo-4AM in calcium assay 
buffer (Hank’s Balanced Salt Solution supplemented with 20 mM HEPES and 2.5 mM 
Probenecid) and the cell plates incubated for 60 minutes at 37 °C.  Dye solution was 
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removed and replaced with 20 µl of fresh assay buffer.  Test compounds were transferred 
from a 384-well source plate (10 mM DMSO, 30 µl/well) to 384-well daughter plates 
using an ECHO acoustic plate reformatter (Labcyte) and then diluted into assay buffer to 
20 µM stock concentration (2X).  Acetylcholine (Aldrich) was diluted in a 384-well plate 
containing submaximal (~EC10, determined empirically) and maximal (10 µM) stock 
concentrations (5X).  Mobilization of intracellular calcium was measured using the 
Functional Drug Screening System 6000 (FDSS6000, Hamamatsu).  Baseline readings 
were taken and then test compounds (30 µM final, 20 µl/well) were added using the 
FDSS’s integrated pipettor.  After 150 seconds of equilibration, acetylcholine (EC10 and 
maximal concentrations, 10 µl/well) was added using the FDSS’s integrated pipettor.  
Data were obtained as max-min fluorescent ratios and then normalized to percentage of 
maximum ACh response and represent mean values obtained from three independent 
determinations (error bars represent +/- SEM) unless otherwise specified.   
 For Flexstation screens/assays (which were primarily used to determine 
compound potency, ACh fold-shift efficacy, mAChR subtype-selectivity, etc...) the 
methods used were essentially the same as previously described (Marlo et al., 2009, 
Brady et al., 2008) and in a format similar to that described above using the same 
reagents.  CHO cells stably expressing rM1, hM3, hM5, rM4/Gqi5, or rM2/Gqi5 were plated 
in 100 mL of growth medium at 5 X 104 (rM1, hM3, and hM5) or 6 X 104 (hM2, and rM4) 
cells per well in Costar 96-well black-walled, TC-treated, clear-bottom plates (Fisher).  
Cells were incubated overnight at 37 °C under 5% CO2.  The next day, medium was 
removed from the cells, and they were incubated with 50 mL of 2 mM Fluo-4 AM diluted 
in assay buffer for 1 h at 37 °C.  Dye was then removed and replaced with 45 mL of fresh 
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assay buffer.  Test compounds were diluted in assay buffer at 2X concentration and 
acetylcholine was diluted in assay at a 10X concentration.  FLEXstation II (Molecular 
Devices) automated plate reader was used for assay execution and measurement of 
calcium flux.  After establishing baseline fluorescence, test compounds (45 mL) were 
added to the cells using the FLEXstation II’s integrated pipettor and allowed to 
equilibrate for 150 seconds before addition of acetylcholine (10 mL).  Data were obtained 
as max-min fluorescent ratios and then normalized to percentage of maximum ACh 
response.  For test compounds exhibiting intrinsic fluorescence (typically found only at 
30 µM final), adjustment of analysis time window for max-min values was sometimes 
performed in order to obtain more accurate baseline readings.  Calculation of potentiation 
EC50 and fold-shift of ACh CRC was performed using the curve-fitting software 
GraphPad Prism (version 4.0c).  Data shown represent mean values obtained from at least 
three independent determinations performed in duplicate or greater (error bars represent 
+/- SEM) unless otherwise specified. 
 
Radioligand binding assays 
 M4 PAMs (all) competition binding assays.  M4 cells were washed once with 
ice-cold phosphate-buffered saline, pH 7.4.  Cells were then harvested with a cell scraper, 
resuspended in ice-cold buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2, pH 7.4), 
and homogenized using a glass homogenizer (Dounce).  The homogenate was centrifuged 
at 20,000g for 20 min at 4 °C.  This final step was repeated twice more with 
homogenization between centrifugations, and the final pellets were resuspended and 
homogenized in ice-cold buffer in aliquots at a final protein concentration of 1-3 mg mL–
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1 and stored at -80 °C until use.  Protein concentrations were measured using the Bio-Rad 
Protein Assay Kit (Bio-Rad, Hercules, CA) with serum albumin (Pierce Chemical, 
Rockford, IL) as the standard.  For each binding experiment, membranes were 
resuspended and homogenized in ice-cold buffer.  Non-specific binding, calculated in the 
presence of 1 µM atropine, was never greater than 10% of total binding; in both 
saturation and competition binding experiments, bound radioligand did not exceed 10%.  
 For competition binding experiments, test compounds and atropine were 
dissolved in 100% DMSO, diluted in assay buffer to make a 3x stock, and then added to 
the assay plate for a final maximum DMSO concentration of 0.3% for test compounds 
and 0.01% for atropine.  Vehicle for each condition was DMSO-matched control made in 
assay buffer.  For ACh competition experiments, test compound was diluted in assay 
buffer to make a 5x stock and then added to the assay plate for a maximum final DMSO 
concentration of 0.1%.  Binding reactions were incubated at room temperature for 2 h on 
a Titer Plate Shaker (Lab-Line Instruments, Melrose, IL), and equilibrium binding was 
terminated by rapid filtration through Unifilter-96 GF/B filter plates presoaked for at least 
2 h with 0.1% polyethylenimine (PEI, Sigma).  Filter plates were washed three times with 
ice-cold harvesting buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) using a 96-well 
Brandel harvester (Brandel Inc., Gaithersburg, MD).  Plates were then dried overnight, 
and 35 µl MicroScint-20 was added to each well the following day.  Radioactivity was 
counted using a TopCount NXT microplate scintillation and luminescence counter 
(PerkinElmer Life and Analytical Sciences, Downers Grove, IL).  
 M5 PAM VU0238429 and M1/M3/M5 PAM VU0119498 competition binding 
assays.  Membranes were prepared from M5-CHO cells according to the previously 
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described protocol.  Binding reactions contained 0.09 nM [3H]-NMS (obtained 
commercially from Amersham), 15-20 µg of membrane protein, and test compound or 
atropine in a total volume of 500 µl assay buffer (100 mM NaCl, 10 mM MgCl2, 20 mM 
HEPES, pH 7.4).  1 µM (final) atropine was used to determine non-specific binding.  The 
KD of [3H]-NMS was determined empirically to be 0.264 nM.  Binding reactions were 
incubated for 2 hours at room temperature on a Lab-Line Titer plate shaker at setting 7 
(~750 rpm).  Reactions were stopped and membranes collected onto 96-well Barex 
microplates with GF/B filter (1µm pore size) using a Brandel harvester and washed 3X 
with ice-cold harvesting buffer (50mM Tris-HCl, 0.9% NaCl, pH 7.4).  Filter plates were 
dried overnight and counted in a PerkinElmer TopCount scintillation counter 
(PerkinElmer Life and Analytical Sciences).  True [3H]-NMS concentration was back-
calculated after counting aliquots of 5X [3H]-NMS used in the reaction.  Atropine Ki 
determined to be 0.21 by Cheng-Prusoff equation.  For all assays, radioligand depletion 
was kept to approximately 10% or less.  Data shown represent mean values obtained 
from at least three independent determinations performed using three or more replicates 
(error bars represent +/- SEM). 
 ACh +/- M5 PAM VU0238429 competition binding assays.  Membranes were 
prepared from M5-CHO cells according to a previously described protocol.  Binding 
reactions contained 0.09 nM [3H]-NMS (obtained commercially from Amersham), 20 µg 
of membrane protein, and ACh plus vehicle or test compound in a total volume of 500 µl 
assay buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4).  1 µM (final) 
atropine was used to determine non-specific binding.  The KD of [3H]-NMS was 
determined empirically to be 0.264 nM.  Binding reactions were incubated for 2 hours at 
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room temperature on a Lab-Line Titer plate shaker at setting 7 (~750 rpm).  Reactions 
were stopped and membranes collected onto 96-well Barex microplates with GF/B filter 
(1µm pore size) using a Brandel harvester and washed 3X with ice-cold harvesting buffer 
(50mM Tris-HCl, 0.9% NaCl, pH 7.4).  Filter plates were dried overnight and counted in 
a PerkinElmer TopCount scintillation counter (PerkinElmer Life and Analytical 
Sciences).  True [3H]-NMS concentration was back-calculated after counting aliquots of 
5X [3H]-NMS used in the reaction.  Radioligand depletion was kept to approximately 
10% or less.  Data shown represent mean values obtained from at least three independent 
determinations performed using three or more replicates (error bars represent +/- SEM). 
 M1 PAM VU HTS hits competition binding assays.  Membranes were prepared 
from M1-expressing CHO cells as described.  Binding reactions contained 0.1 nM [3H]-
NMS, 20 µg of membranes and compound or vehicle (0.3% DMSO, final, to define total 
binding) or 1 µM atropine (to define nonspecific binding) in a total volume of 500 µl. The 
KD of [3H]-NMS was determined empirically to be 0.21 nM.  Compounds were serially 
diluted in DMSO and then diluted in assay buffer (100 mM NaCl, 10 mM MgCl2, 20 mM 
HEPES, pH 7.4) to give a final DMSO concentration of 0.3% in the binding reaction.  
Binding reactions were incubated for 2 hours at room temperature on a Lab-Line Titer 
plate shaker at setting 7 (~750 rpm).  Reactions were stopped and membranes collected 
onto 96-well Barex microplates with GF/B filter (1µm pore size) using a Brandel 
harvester and washed 3X with ice-cold harvesting buffer (50mM Tris-HCl, 0.9% NaCl, 
pH 7.4).  Filter plates were dried overnight and counted in a PerkinElmer TopCount 
scintillation Counter (PerkinElmer Life and Analytical Sciences).  For ACh affinity 
experiments, the KI of an ACh competition curve was determined in the absence and 
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presence of fixed concentrations (3 to 30 µM, final) of test compound.  Actual [3H]-NMS 
concentrations were back-calculated after counting aliquots of 5X [3H]-NMS added to the 
reaction.  Radioligand depletion was routinely kept to approximately 5% or less.   
 M1 allosteric agonist competition binding assays. Membranes were prepared 
from M1, M2, M3, M4, and M5-expressing CHO cells as previously described.  Binding 
reactions contained 0.1 nM [3H]-NMS, 20 µg of membrane and compound or 1 µM 
atropine (to define nonspecific binding) in a total volume of 500 µl.  Compounds were 
serially diluted in DMSO-matched assay buffer (100 mM NaCl, 10 mM MgCl2, 20 mM 
HEPES, pH 7.4) to give a final DMSO concentration of 0.3% in the binding reaction.  
Binding reactions were incubated for 2 hours at room temperature on a Lab-Line Titer 
plate shaker at setting 7 (~750 rpm).  Reactions were stopped and membranes collected 
onto 96-well Barex microplates with GF/B filter (1µm pore size) using a Brandel 
harvester and washed 3X with ice-cold harvesting buffer (50mM Tris-HCl, 0.9% NaCl, 
pH 7.4).  Filter plates were dried overnight and counted in a PerkinElmer TopCount 
scintillation counter (PerkinElmer Life and Analytical Sciences).  Actual [3H]-NMS 
concentrations were back-calculated after counting aliquots of 5X [3H]-NMS added to the 
reaction.  Radioligand depletion was routinely kept to approximately 10% or less. 
 Merck M1 PAM BQCA and M1 Antagonist VU0255035 competition binding 
studies.  Full methods are not described due to redundancy, as details are essentially the 
same as described previously for M4 PAM and M5 PAM projects.  Binding reactions used 
15-25 mg of membrane protein prepared from rM1 receptor expressing CHO cells and 0.1 
nM [3H]-NMS (GE Healthcare) in a final volume of 1 mL.  Non-specific binding was 
determined in the presence of 1 µM atropine.   
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Ancillary/off-target screening assays 
 Millipore functional screening.  Prior to conducting in vivo experiments with M1 
PAM BQCA, M4 PAM VU0152099, and M4 PAM VU0152100, the compounds were 
submitted to Millipore’s GPCR Profiler™ Service where it was evaluated for agonist, 
antagonist, and allosteric potentiator activity against a panel of 16 GPCRs in a functional 
screening paradigm (N=2).  Calcium mobilization assays were used to obtain full 
compound CRCs, and for PAM screens a standard orthosteric agonist was used for each 
target. 
 MDS Pharma/Ricerca binding screening.  M4 PAM VU0152099, M4 PAM 
VU0152100 (as reported in Chapter III), numerous M5 PAMs (as reported in Chapter 
IV), and M1 allosteric agonists (as reported in Chapter V) were submitted to MDS 
Pharma (now Ricerca) for LeadProfile screening across a panel of 67 different GPCRs, 
ion channels, enzymes, transporters, and nuclear hormone receptors.  Competition 
binding assays were performed using standard orthosteric radioligands for each target 
(N=2) with test compounds at 10 µM.  Results are reported as % inhibition of radioligand 
binding caused by the test compound, with >50% inhibition signifying substantial 
activity at a given target. 
 
In vivo Pharmacology 
 
 All experiments were conducted in accordance with the National Institutes of 
Health regulations of animal care covered in Principles of Laboratory Animal Care 
(National Institutes of Health publication 85-23, revised 1985) and were approved by the 
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Institutional Animal Care and Use Committee.  Methods for studies performed for the M5 
PAM and M4 PAM projects are described below, all other behavioral and PK studies 
associated with M1 PAM, M1 allosteric agonist, TBPB, and M1 antagonist projects are 
similar to those described below, and in cases where data from a study is discussed in the 
associated text/figures (i.e. in Chapter V) that is not described below, the full 
methodology can be found in the associated references. 
 
Amphetamine-induced hyperlocomotion behavioral rat studies 
 All behavioral studies were conducted using male Sprague-Dawley rats (Harlan 
Sprague-Dawley, Inc.; Indianapolis, IN) weighing 270 to 300 grams.  Subjects were 
housed in pairs in a large colony room under a 12-h light/dark cycle (lights on at 6:00 
a.m.) with food and water provided ad libitum.  Test sessions were performed between 
6:00 a.m. and 6:00 p.m.  Dose groups consisted of 8-16 rats per dose group.  All doses of 
VU0152099 and VU0152100 refer to the salt form and were injected in a 1.0 mL/kg 
volume.  Each compound was dissolved in 10% Tween 80 and double deionized water 
with the pH adjusted to approximately 7.0 using 1N NaOH. 
 Studies were conducted using a SmartFrame Open Field System (Kinder 
Scientific., San Diego, CA) equipped with 32 horizontal (x- and y-axes) infrared 
photobeams located 1 cm above the floor of the chamber. Changes in ambulation or 
locomotor activity were measured as the number of total photobeam breaks as expressed 
in 5 min intervals and were recorded with a Pentium I computer equipped with the Motor 
monitor system software (Kinder Scientific).  
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 Rats were placed in the open field chambers for a 30 min habituation interval 
(data not shown), followed by a pretreatment with vehicle or a 56.6 mg/kg dose of either 
VU0152099 or VU0152100 (I.P.) for an additional 30 min.  Next, all rats received an 
injection of 1 mg/kg (subcutaneous [S.C.]) of amphetamine and locomotor activity was 
measured for an additional 60 min.  Data were analyzed by a one-way ANOVA with 
comparison with the vehicle+amphetamine control group using Dunnett's test.  
Calculations were performed using JMP v5.1.2 (SAS Institute Inc., Cary, NC) statistical 
software. 
 
Roto-rod behavioral rat studies 
 The effects of VU0152100 on motor performance were evaluated using a Rotorod 
(Columbus Instruments, Columbus, OH).  All rats were given an initial training trial of 
120 s, followed by 2 additional training trials of 85s approximately 10 min apart, using a 
rotarod (7.5cm in diameter) rotating at a constant speed of 20 revolutions/minute.  After 
initial training trials, a baseline trial of 85s was conducted, and any rats that did reach the 
85s criteria were excluded from the study.  Rats were then pretreated for 30 minutes i.p. 
with vehicle or dose of VU0152100, specifically 30, 56.6 or 100 mg/kg, and then the 
time each animal remained on the rotorod was recorded; animals not falling off the 
rotorod were given a maximum score of 85s. Data were analyzed by a one-way ANOVA, 
with comparison to the vehicle control group using Dunnett's test.  Calculations were 
performed using JMP v5.1.2 (SAS Institute Inc., Cary, NC) statistical software. 
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Pharmacokinetic/PBL rat studies 
 M4 PAMs.  Male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc.; 
Indianapolis, IN) weighing 225-250g, were fasted overnight prior to dosing.  Compounds 
were dissolved 10% Tween 80 and double deionized water with the pH adjusted to 
approximately 7.0 using 1N NaOH at a concentration of 56.6 mg/mL and sonicated until 
a uniform homogenous solution was obtained.  The dose was administered ip at 56.6 
mg/kg per compound.  Three animals were used for each time point. The rat blood and 
brain were collected at 0.5, 1, 2 and 4h.  Animals were euthanized, decapitated and the 
brains removed and frozen on dry ice.  Trunk blood was collected in ethylenediamine 
tetra-acetic acid (EDTA) Vacutainer tubes and plasma was separated by centrifugation 
and stored at -80 °C until analysis. 
 For the brain sample preparation, frozen whole rat brains were weighed (1.5 to 
1.8g) and placed in 3 mL of ice-cold solution of acetonitrile and methanol (1:1, volume) 
with a synthetic internal standard (50 ng/mL) and homogenized using a Sonic 
Dismembrator Model 100 (Fischer Scientific) at maximal speed for 2 min.  Next, a 1ml 
aliquot of each homogenate was placed into 1.5 mL centrifuge tubes and centrifuged at 
16,000 rpm for 5 min. Finally 100 mL of supernatant was injected into LC-MS-MS.  
Plasma samples (100ml) were combined with 200ml of ice-cold solution of the internal 
standard (100ng/mL) in acetonitrile with 0.1% formic acid.  After vortexing for one 
minute, the mixture was centrifuged at 16,000 rpm for 5 min in a bench-top Spectrafuge 
16M Microcentrifuge (Labnet, Woodbridge, NJ).  Again, 100 mL of the supernatant was 
injected into LC-MS-MS. 
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 For the LCMS Analysis, the LC separation was carried out on a Phenomenex 
Luna ODS, 5 micron, 2.1 mm x 5 cm column (Torrance, CA) at a flow rate of 0.3 
mL/min.  The gradient started with 80% solvent A (0.1% Formic acid in water) and 20% 
solvent B (0.1% Formic acid in CH3CN), held for 1 min and increasing to 100% B in 4 
min and held for 1 min.  Mass spectrometry was carried out using a ThermoFinnigan 
TSQ Quantum ultra (Thermo Scientific, Waltham, MA) mass spectrometer in positive 
ion mode.  The software Xcalibur version 2.0 was used to control the instrument and 
collect data.  The ESI source was fitted with a stainless steel capillary (100µm i.d.). 
Nitrogen was used as both the sheath gas and the auxiliary gas.  The ion transfer tube 
temperature was 300ºC.  The spray voltage, tube lens voltage, pressure of sheath gas and 
auxiliary gas were optimized to achieve maximal response using the test compounds 
mixing with the mobile phase A (50%) and B (50%) at a flow rat of 0.3 mL/min.  
Collision-induced dissociation (CID) was performed on the test compounds and internal 
standards under 1.0 mTorr of argon. Selected reaction monitoring (SRM) was carried out 
using the transitions from, m/z 356 to 205 @ 30 eV for VU0152099, m/z 342 to 205 @ 
27 eV for VU0152100, and m/z 310 to 223 @ 25 eV for our internal standard. 
 The calibration curves were constructed by spiking known amounts of test 
compounds in blank brain homogenates and plasma.  The samples went through the same 
extraction steps as described above.  A linear response was achieved from 50ng/mL to 
100ug/mL in both matrices.  Compound exposure following administration was 
determined by calculating AUC (0-∞) using the trapezoidal method.   
 M5 PAMs.  VU0238429 was formulated as a 10% Tween 80 micro-suspension in 
sterile water at the concentration of 5 mg/mL and administered intraperitoneally to male 
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Sprague-Dawley rats weighing 225 to 250 g (Harlan Sprague-Dawley, Inc., Indianapolis, 
IN) at the dose of 10 mg/kg.  The rat blood and brain were collected at 0.5, 1, 3, and 6 h.  
Animals were euthanized and decapitated, and the brains were removed, thoroughly 
washed in cold phosphate buffered saline and immediately frozen on dry ice.  Trunk 
blood was collected in EDTA Vacutainer tubes, and plasma was separated by 
centrifugation and stored at -80 °C until analysis.  Three animals were used for each time 
point.  On the day of analysis, frozen whole-rat brains were weighed and homogenized in 
1:3 (w/w) volumes of ice-cold phosphate buffered saline (pH 7.4).  The sample extraction 
of plasma (100µl) and brain homogenate (250 µl) was performed by a method based on 
protein precipitation, using three volumes of cold acetonitrile containing 0.1% formic 
acid and an internal standard (VU-178) having final concentration of 50 ng/mL.  Extracts 
were vortex mixed for 5 min. followed by centrifugation at 14000 rpm for 10 min.   
 The supernatants of plasma and brain homogenate extracts were analyzed by 
means of HPLC/MS/MS, using a ThermoFinnigan TSQ Quantum Ultra (Thermo Fisher 
Scientific, Waltham, MA) mass spectrometer in positive ion mode.  The chromatographic 
separation was achieved on an Acquity UPLC BEH C18 column (1.7um; 2.1x50mm) at a 
flow rate of 0.8 mL/min.  The gradient program was used with the mobile phase, 
combining solvent A (95: 5: 0.1% formic acid in water: acetonitrile) and solvent B (95: 5: 
acetonitrile: 0.1% formic acid in water) as follows: 20% B (0.5 min), 20–95% B 
(0.5 min), 95% B (1 min), 95–20% B (0.2 min), 20% B (2.8 min).  The column 
temperature was set at 50 °C.  The software Xcalibur version 2.0 was used to control the 
instrument and collect data.  The electrospray ionization source was fitted with a stainless 
steel capillary (100 µm i.d.).  Nitrogen was used as both the sheath gas and the auxiliary 
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gas.  The ion transfer tube temperature was 300 °C.  The spray voltage, tube lens voltage, 
and pressure of sheath gas and auxiliary gas were optimized to achieve maximal response 
using the test compounds mixing with the mobile phase A (50%) and B (50%) at a flow 
rate of 0.8 mL/min.  Collision-induced dissociation was performed on compound 
VU0238429 and internal standard under 1.0 mTorr of argon.  Selected reaction 
monitoring was carried out using the transitions from m/z 352 to 121 for VU0238429, 
and m/z 310 to 223 for VU-178 (internal standard).  The calibration curves were 
constructed and linear response was obtained in the range of 10- 2000 ng/mL by spiking 
known amounts of VU0238429 in blank brain homogenates and plasma.  Brain 
concentrations were corrected for dilution in PBS and for residual blood volume using 
15µl/g as the vascular space (Brown et al., 1986).  The final PK parameters were 
calculated by non-compartmental analysis using WinNonlin software (version 5.1, 
Pharsight Inc.).  
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Chapter III 
 
DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL                   
SUBTYPE-SELECTIVE MACHR4 POSITIVE ALLOSTERIC MODULATORS 
 
 
 
Discovery of M4 PAM VU010010 
 
 As discussed in the Introduction (Chapter I), a lack of M4-selective small 
molecule tools has precluded thorough investigation into the role of M4 in basic 
neurobiology and in target validation for therapeutic discovery.  Based on  M4 
localization data and on results from studies with M4-KO mice, selective activation of M4 
may represent an attractive strategy for treatment of various CNS disorders such as 
schizophrenia44.  A disclosure by Eli Lilly revealed the first potentially M4-selective 
small molecule, an M4 PAM termed LY2033298 that was reported to possess high 
potency (EC50 < 100 nM) and efficacy at the human receptor with no activity at any other 
mAChR subtype at high concentrations using cell-based functional assays (Fig. 1)123.  At 
the time, no data was presented for activity of LY2033298 at rat or mouse M4, and since 
preclinical research typically relies on rodent studies, the utility of this compound for our 
own experiments depended largely on its pharmacology in rodents.  Thus, we re-
synthesized LY2033298 and determined its potency in the presence of an ACh ~EC20 by 
Ca2+ mobilization assay in rM4/Gqi5 cells.  Importantly, this compound exhibited an 
approximately two-order of magnitude loss of potency at rM4 (EC50 > 1 µM, data not 
shown), rendering it sub-optimal as an rM4 research tool. 
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Figure 1.  Structures of Eli Lilly hM4 PAM LY2033298 (1) and Vanderbilt rM4 PAM VU010010 (2) 
 
 Therefore, we sought to identify novel M4 PAMs with pharmacological profiles 
suitable for rodent studies124-126.  Rather than execute a full HTS (as was done for other 
mAChR PAM projects described in Chapters IV and V), we used a cheminformatic 
approach wherein a structure similarity search based on LY2033298 was performed on a 
large commercial drug-like chemical collection.  This database screen provided 232 
virtual hits, which were then ordered and subsequently screened for rM4 PAM activity in 
a single concentration-point format using Ca2+ mobilization assays.  Ultimately, three 
structurally similar hits were identified that exhibited concentration-dependent M4 PAM 
activity with sub- to low-micromolar potencies (data not shown).  However, these 
compounds suffered from poor solubility in assay buffer, resulting in incomplete CRC 
plateaus at higher concentrations.  A limited medicinal chemical optimization of the 
eastern amide side chain in the form of alternative benzyl substitutions identified 
VU010010 (Fig. 1, compound 2), which possessed relatively greater solubility, an rM4 
EC50 of approximately 400 nM, and an rM4 ACh CRC fold-shift of 47x at 30 µM. 
 Characterization of VU010010 in a number of in vitro experiments revealed that it 
was highly selective for M4 and that its potentiation was mediated by enhancement of 
both ACh affinity and G-protein coupling efficiency (data not shown).  Although this 
early compound represented the first potent and selective rM4 PAM tool useful for in 
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vitro cell-based and ex-vivo electrophysiology experiments, it still suffered from sub-
optimal physiochemical properties that precluded acceptable vehicle formulation for in 
vivo studies and likely contributed to a lack of central brain penetration in a single-dose 
rat PK/PBL study (data not shown).  Therefore, we began a comprehensive chemical 
optimization project aimed at exploring structure-activity relationships (SAR) around the 
VU010010 scaffold in order to obtain a compound universally suitable for systemic 
dosing in a wide range of in vivo studies. 
 
Optimization of M4 PAM VU010010 to obtain VU0152099 and VU0152100 
 
 Optimization began with a diversity-oriented synthesis (DOS) approach to 
explode SAR with a variety of hypothesis-driven, structural changes to the lead 
compound.  The rationale for this approach for the optimization of VU010010 is that 
SAR for allosteric ligands is often ‘flat’ or ‘shallow’, with subtle structural modifications 
leading to a complete loss of activity, and often only one portion of an allosteric ligand is 
amenable to change.  Therefore, a multi-dimensional, DOS library approach provides the 
best opportunity to quickly identify productive SAR as opposed to a lead optimization 
strategy based on classical, single compound synthesis.  One explanation for the lack of 
central activity observed with VU010010 could be the result of the poor physiochemical 
properties alone, or in combination with efflux through a BBB transporter such as P-
glycoprotein (P-gp).  The β-aminoamide motif (Fig. 2a) present in VU010010 represents 
a potential P-gp liability, which could be removed by cyclization to analogs such as 
compounds 4 (Fig. 2a).  Alternatively, P-gp susceptibility could also be diminished by 
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electronically attenuating the basicity of the amine moieties by the incorporation of distal 
fluorine atoms.   
 
 
Figure 2.  Chemical optimization of VU010010.  Each of the ten scaffolds (5, 7-15) were derivatized with 
diverse amide side chains in 12-24 member libraries using standard amide-coupling reaction conditions.  
Syntheses jointly performed with P. Kennedy. 
  
 Utilizing solution phase parallel synthesis, we synthesized small, 12- to 24-
member focused libraries around each of the 10 scaffolds 5 and 7-15 (Fig. 2b-c), which 
were then purified by mass-directed preparative HPLC to analytical purity (>98%).  This 
collection of VU010010 analogs incorporated CF3 moieties (scaffolds 9 and 10) to 
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electronically attenuate potential P-gp susceptibility, deletion of the β-amino moiety 
(scaffold 14), or replacement of the β-amino moiety with an isosteric methyl group 
(scaffold 13).  Other scaffolds explored the deletion of substituents on the pyridine 
nucleus (scaffold 11), incorporation of an additional nitrogen atom to afford a pyrimidine 
nucleus (scaffold 12) or removal of the pyridine nitrogen atom in VU010010 (scaffold 
15).  Finally, a library around scaffold 7 focused on maintaining the core structure of 
VU010010, but explored alternative amides, selected to improve physiochemical 
properties and lower the logP value. 
 As observed with positive allosteric modulators of Class C GPCRs, SAR around 
VU010010 was relatively flat, possibly due to a shallow binding pocket.  An ACh EC20 
triage screen, employing a functional, fluorescence-based Ca2+ assay in CHO cells stably 
co-expressing the rat M4 mACh receptor and the chimeric G protein, Gqi5, quickly 
eliminated all VU010010 analogs except those in library 7 (Fig. 3).  Within library 7, all 
aliphatic and non-benzyl amides were inactive, and only benzyl and heteroaryl methyl 
congeners of VU010010, 7a-7p, retained M4 PAM activity (Table 1).  The potency of 
each compound was determined by pre-incubating cells with vehicle or increasing 
concentrations of test compound followed by the addition of an ACh EC20 to yield CRCs.  
Subtle substitution changes on the arene ring lost activity 5-10-fold in terms of M4 EC50 
and/or fold-shift of the ACh CRC (Table 1).  For instance, analog 7d, in which the 4-Cl 
moiety of VU0100010 is moved to the 3-position results in a loss in potency of over 9-
fold (EC50 = 3.7 µM).  Similarly, the unsubstituted phenyl congener 7a retains M4 PAM 
activity (EC50 = 630 nM), but the fold-shift diminishes to 8.6-fold, versus the 47-fold 
shift observed for VU010010.  In general, functionalized benzyl amides and pyridyl 
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methyl congeners (7f and 7g) were well tolerated, providing selective M4 PAMs with 
EC50 values ranging from 380 nM to 3.7 µM and with fold-shifts of the ACh CRC from 
8.6- to 70-fold.   
 
 
Figure 3.  Singlepoint screen of M4 PAM VU010010 analogs based on scaffold 7 bearing eastern amide 
side chain substitutions.  Ca2+ mobilization was used to obtain singlepoint (10 µM) potentiation responses 
for each compound in the presence of an ACh ~EC20 in rM4 cells.  Data represent Mean +/-SEM of at least 
three independent determinations.  Experiments performed by A. Brady. 
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Table 1.  M4 PAM potency and ACh CRC fold-shift SAR for VU010010 analogs based on scaffold 7.  
Ca2+ mobilization was used to obtain CRCs of test compounds in the presence of an ACh ~EC20 using rM4 
cells.  Similar assays determined the fold-shift of an ACh CRC in the presence of 30 µM test compound 
(N.D. = not determined).  Data represent Mean +/-SEM from at least three independent determinations.  
Experiments performed by A. Brady. 
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 Two compounds were selected for further evaluation based on their ability to 
potentiate the M4-mediated Ca2+ response to ACh.  VU0152099 (7o), (Fig. 4a) and 
VU0152100 (7p), (Fig. 4d) retained M4 PAM activity (EC50 values of 403 ± 117 nM and 
380 ± 93 nM, respectively) comparable to VU010010, and in the absence of an ACh 
EC20, neither VU0152099 nor VU0152100 elicited a response (Fig. 4b,e).   
 
 
Figure 4.  Structures, potency CRCs, and ACh CRC fold-shifts for M4 PAM leads A.) VU0152099 (7o) 
and B.) VU0152100 (7p).  Ca2+ mobilization was used to obtain: B., E.) CRCs of test compound in the 
absence and presence of an ACh ~EC20, (EC50 values: VU0152099 = 403 nM, VU0152100 = 380 nM) C., 
F.) CRCs of ACh in the absence or presence and of increasing fixed concentrations of test compound (fold-
shift values: VU0152099 = 30x, VU0152100 = 70x).  Data represent Mean +/-SEM from at least three 
independent determinations.  Experiments performed by A. Brady.  
 
 
91 
 We next determined the effects of maximal concentrations of each compound on 
the CRC of ACh.  Cells were pre-incubated with a fixed concentration (0.1-30 µM) of 
test compound and subsequently stimulated with increasing concentrations of ACh.  Both 
VU0152099 and VU0152100 induced a concentration-dependent left-shift of the ACh 
CRC with maximal shifts of 30-fold observed with 30 µM VU0152099 (Fig. 4c) and 70-
fold observed with 10 µM VU0152100 (Fig. 4f). 
 
In vitro characterization of M4 PAMs VU0152099 and VU0152100 
 
 Using Ca2+ mobilization to assess the functional activity of VU0152099 and 
VU0152100 at the M4 receptor requires co-expression of the chimeric G protein, Gqi5, in 
order to link the Gi/o-coupled M4 receptor to the PLCβ/Ca2+ pathway.  As an alternative 
approach to measure M4 PAM activity, we chose to take advantage of a novel functional 
assay recently developed in our lab that takes advantage of the ability of endogenous Gβγ 
subunits of Gi/o-coupled GPCRs to alter the kinetics of GIRK channels to conduct the ion, 
thallium.  For these studies, HEK293 cells stably co-expressing heteromeric GIRK1/2 
channels and the human M4 muscarinic receptor were pre-incubated with test compound 
and then stimulated with agonist (ACh) in the presence of thallium ion.  Both 
VU0152099 and VU0152100 concentration-dependently potentiated the response to an 
EC20 concentration of ACh with EC50 values of 1.2 ± 0.3 µM and 1.9 ± 0.2 µM, 
respectively, and increased the maximal response to ACh to approximately 130% (Fig. 
5a).  As observed in the Ca2+ mobilization assays described above, both VU0152099 and 
VU0152100 (10 µM) also enhanced the potency of ACh to induce GIRK-mediated 
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thallium flux, as manifest by a robust (≈30-fold) left-shift of the ACh CRC from 77 ± 1.2 
nM to 2.09 ± 0.3 nM and 2.35 ± 0.5 nM, respectively (Fig. 5a).  Taken together, these in 
vitro studies suggest that VU0152099 and VU0152100 are potent positive allosteric 
modulators that enhance the response of the M4 receptor to the endogenous agonist, ACh. 
 
 
Figure 5.  GIRK-mediated thallium flux M4 PAM assays with lead compounds VU0152099 and 
VU0152100.  A.) CRCs of test compounds in the presence of an ACh ~EC20 (EC50 values: VU0152099 = 
1.2 µM, VU0152100 = 1.9 µM) and B.) CRCs of ACh in the absence and presence of a fixed 10 µM 
concentration of test compound (fold-shift values: VU0152099 and VU0152100 both = ~30x).  Data 
represent Mean +/-SEM from at least three independent determinations.  Experiments performed by A. 
Brady. 
 
 To further confirm an allosteric mechanism of action by the novel M4 PAMs, we 
evaluated the effect of VU0152099 and VU0152100 on equilibrium radioligand binding 
studies using membranes prepared from cells expressing the rM4 receptor.  We first 
assessed the ability of increasing concentrations of the two M4 PAMs to displace the 
orthosteric radioligand, [3H]-N-methylscopolamine ([3H]-NMS) (0.1 nM).  Unlike the 
orthosteric antagonist, atropine, which potently inhibited [3H]-NMS binding (Ki= 0.54 ± 
0.1 nM), neither M4 PAM displaced [3H]-NMS at concentrations up to 30 µM (Fig. 6a), 
strongly suggesting that VU0152099 and VU0152100 act at a site on the M4 receptor that 
is distinct from the orthosteric binding site.   
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 In addition, we evaluated the effect of VU0152099 and VU0152100 on the 
affinity of ACh for the M4 receptor by assessing the ability of an increasing concentration 
of ACh to displace [3H]-NMS (0.1 nM) binding in the absence or presence of the M4 
potentiators.  VU0152099 and VU0152100 were found to induce a 20-25x leftward shift 
in the potency of ACh to displace [3H]-NMS binding to M4 as manifest by a reduction in 
the ACh Ki from 252 ± 17.9 nM (veh) to 10.4 ± 0.91 nM (VU0152099) and 12.2 ± 0.49 
nM (VU0152100) (Fig. 6a). These data present a possible mechanism whereby these 
compounds could enhance receptor activation by increasing the affinity of M4 for 
acetylcholine, and are in agreement with data previously determined for VU010010, 
where a 14 fold decrease in the ACh Ki was reported. 
 
 
Figure 6.  [3H]-NMS competition binding experiments with M4 PAMs VU0152099 and VU0152100 at rM4 
cell membranes.  A) CRCs of test compound and atropine positive control (atropine Ki  = 0.54 nM). B.) 
CRCs of ACh in the absence (vehicle) and presence of  (10 µM) test compounds (ACh Ki values: vehicle = 
252 nM, VU0152099 = 10.4 nM [25x left-shift], VU0152100 = 12.2 nM [21x left-shift]).  Data represent 
Mean +/-SEM from at least three independent determinations.  Experiments performed by A. Brady. 
 
 We next evaluated VU0152099 and VU0152100 in Ca2+ mobilization assays for 
effects at all mAChR subtypes to determine whether these compounds are selective for 
M4.  Both VU0152099 and VU0152100 were selective for M4 relative to M1, M2, M3 and 
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M5.  Neither VU0152099 (Fig. 7a) nor VU152100 (Fig. 7b) had any effect on the ACh 
CRCs at these other mAChR subtypes at concentrations up to 30 µM.  To further assess 
selectivity of these compounds for M4 relative to other potential targets, the activity of 
VU0152099 and VU0152100 also were evaluated in radioligand binding assays against a 
large panel of 67 discrete GPCRs, ion channels, transporters, nuclear hormone receptors, 
and enzymes (Table 2).  These compounds were largely inactive at each of the targets in 
this panel screen.  At concentrations of 10 µM, both compounds were completely inactive 
at most targets and induced less than 50% displacement of binding for all targets tested, 
with the single exception of GABAA receptors (assessed by flunitrazepam binding), 
where VU0152099 displayed 51% displacement.  This suggested that VU0152099 may 
interact with the flunitrazepam binding site with an IC50 value of approximately 10 µM, 
which still provides high selectivity for M4 relative to GABAA receptors. 
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Figure 7.  mAChR subtype-selectivity profiles for M4 PAMs A.) VU0152099 and B.) VU0152100 
determined by ACh CRC fold-shift.  Ca2+ mobilization was used to obtain CRCs of ACh in the presence 
and absence of 30 µM test compound using M1, M2, M3, and M5 cells.  Data represent Mean +/-SEM from 
at least three independent determinations.  Experiments performed by A. Brady. 
 
 
 
96 
Table 2.  Ancillary pharmacological activity of M4 PAMs VU0152099 and VU0152100 in singlepoint (10 
µM) competition binding assays across a large panel of off-targets.  Experiments performed by MDS 
Pharma/Ricerca. 
 
 
 
 Since VU0152099 and VU0152100 are allosteric modulators of M4, it is possible 
that they have activity at similar allosteric sites on other GPCRs.  If so, this would not be 
apparent in the radioligand binding assays of Table 2.  The finding that these compounds 
are completely inactive at other mAChR subtypes makes this less likely since M4 is more 
closely related to the other mAChR subtypes than to other GPCRs.  However, to further 
evaluate the selectivity of VU0152099 for M4 relative to other family A GPCRs, we 
contracted with Millipore to determine the effects of these compounds on functional 
responses of a panel of 15 other GPCRs to activation by their respective agonists (Fig. 8).  
For these studies, we chose family A GPCR subtypes that are among the closest relatives 
of mAChRs.   
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Figure 8.  Functional GPCR off-target activity screening for M4 PAMs VU0152099 and VU0152100.  Ca2+ 
mobilization assays using multiple cell lines expressing each of the GPCR targets and promiscuous G 
protein, Gα15/16 were used to obtain CRCs of orthosteric agonists in the absence and presence of test 
compound at 10 µM.  VU0152099 exhibited no agonist activity at any of the targets tested, and was found 
to possess antagonist activity only at the 5HT2B receptor (as indicated by an ≈16 fold right-shift in the 
agonist CRC in the presence of VU0152099).  At the human M4 mAChR, VU0152099 elicited a robust ≈80 
fold left-shift in the carbachol CRC (EC50s:  CCh alone = 800 nM, CCh +VU0152099= 10 nM).  Similar 
CRC curves were generated for additional GPCRs: Muscarinic M1, Adenosine A2B, α1A-, 2A-, 2B-
Adrenergic, Dopamine D1 ,D2L, D5, Histamine H1, H2, H3, and Serotonin 5HT1A, 2A, 2B, 2C, with no 
comparable left-shift observed at any other target tested.  All data represent Mean of two independent 
determinations.  Experiments performed by Millipore GPCR Profiler Service service. 
 
 
 We first determined the effects of VU0152099 alone on each receptor and found 
that these compounds had no agonist activity at any receptor studied (data not shown).  
We then determined the effects of VU0152099 on full CRCs of agonists of each of these 
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receptors (Fig. 8).  This allows unambiguous evaluation of whether the compounds 
possess antagonist activity (either allosteric or orthosteric) or allosteric potentiator 
activity at these other GPCRs.  Consistent with our internal studies, VU0152099 induced 
a robust potentiation of ACh-induced activation of M4, but had no potentiator activity at 
M1 (Fig. 8).  In addition, VU0152099 had no allosteric potentiator activity at any of the 
other GPCR subtypes tested (Fig. 8).  The only significant activity detected for 
VU0152099 in this functional panel screen was weak antagonist activity at the serotonin 
5HT2B receptor (Fig. 8).  Together, these data suggested that VU0152099 and 
VU0152100 possess clean ancillary pharmacology profiles, which would allow us to 
pursue the behavioral effects of selective M4 activation in vivo. 
 
In vivo pharmacokinetics of M4 PAMs VU0152099 and VU0152100 
 
 Prior to conducting in vivo studies with VU0152099 and VU0152100, 
pharmacokinetic studies were undertaken to assess brain/plasma ratios following 
systemic dosing of these compounds.  In contrast, to the high log partition coefficient 
(logP) of VU010010 (4.5), both VU0152099 and VU0152100 possessed logP values of 
3.7 and 3.6, respectively, a full order of magnitude less lipophilic than VU010010.  As a 
consequence, both VU0152099 and VU0152100 displayed improved physiochemical 
properties and afforded homogeneous dosing solutions in multiple vehicles acceptable for 
in vivo studies.  Further, we conducted in vivo PK/PBL studies in rats at the dose of 56.6 
mg/kg (intraperitoneal [I.P.]).  Both compounds exhibited substantial systemic absorption 
and brain penetration (Fig. 9).  After administration, peak brain concentrations for both 
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compounds were in the range of 3-5 µg/ml (Table 3).  VU0152100 (Fig. 9b, Table 3) 
was far superior to VU0152099 (Fig. 9a, Table 3) in terms of brain penetration, as 
evident from area under the curve (AUC) (0-∞) values.  The AUC brain/AUC plasma 
ratio for VU0152099 was calculated to be 0.39 ± 0.01, while the ratio for VU0152100 
was determined to be 0.86 ± 0.08 (Table 3).  The half-life of the compounds in brain was 
1.25 ± 0.02 h (VU0152099) and 1.12 ± 0.01 h (VU0152100) (Table 3).  Therefore, our 
earlier concern of P-gp susceptibility within this series was likely unwarranted, and the 
lack of central activity for VU010010 was most likely due solely to physiochemical 
properties.  
 
 
Figure 9.  In vivo rat pharmacokinetic/PBL studies with M4 PAMs VU0152099 and VU0152100.  
Concentrations were measured over time in brain and plasma following a single 56.6 mg/kg (IP) dose using 
male Sprague-Dawley rats (N=3 per compound).  Experiments performed by S. Jadhav. 
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Table 3.  Pharmacokinetic parameters calculated for M4 PAMs VU0152099 and VU0152100 from a rat 
PK/PBL study using a single 56.6 mg/kg (IP) dose each compound. 
 
 
 
In vivo behavioral studies with VU0152099 and VU0152100 
 
 Previous studies using the M1/M4-preferring muscarinic agonist xanomeline 
produced robust effects in several preclinical models predictive of antipsychotic-like 
activity, including reversal of amphetamine-induced hyperlocomotion in rats, as 
discussed in the Introduction (Chapter I).  Based on our initial PK studies suggesting that 
systemic administration of VU0152099 and VU0152100 provides robust brain levels of 
these compounds, the effects of VU0152099 and VU0152100 were evaluated in reversing 
amphetamine-induced hyperlocomotion using a dose of 56.6 mg/kg (I.P.) for each 
compound with a 30 min pretreatment interval.  As shown in Fig. 10a, both VU0152099 
and VU0152100 produced robust decreases in amphetamine-induced hyperlocomotion 
over the time course tested.  In addition, to provide further confirmation that the M4 
PAMs have no effect on baseline levels of motor performance, which could complicate 
the interpretation of the amphetamine-induced hyperlocomotion data, we evaluated the 
effects of one of the M4 PAMs, specifically VU0152100, after administration alone on 
performance in the rotorod test (Fig. 10b). As shown, VU0152100 had no effect on 
performance in the rotorod test, even when tested at a dose of 100 mg/kg, which was 
higher than that required to observe reversal of amphetamine-induced hyperlocomotion. 
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Figure 10.  Reversal of amphetamine-induced hyperlocomotion and absence of sedation in vivo by M4 
PAMs VU0152099 and VU0152100. A.) Rats were pretreated for 30 min with vehicle or a 56.6 mg/kg 
dose of either VU0152099 or VU0152100 (IP).  Next, all rats received an injection of 1 mg/kg (SC) of 
amphetamine and locomotor activity was measured for an additional 60 min.  Each point represents the 
Mean +/-SEM of eight-sixteen rats. *, P < 0.05 versus veh+amphetamine control group, Dunnett's test. B.) 
Lack of effect of VU0152100 on motor performance on the Rotorod.  After initial training, rats were 
pretreated for 30 minutes (IP) with vehicle or VU0152100 (30, 56.6 or 100 mg/kg), and time each animal 
remained on rotorod was recorded; Each bar graph represents the Mean +/-SEM of eight-ten rats.  
Experiments performed by C. Jones. 
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 These behavioral findings represented the first published direct in vivo 
pharmacological evidence that selective M4-modulation may be efficacious in the 
treatment of psychosis.  Although much is known about the relationship between M4 and 
regulation of central DA signaling based on  M4 localization and KO-mouse studies, 
which suggest that activation or positive allosteric modulation of M4 is likely to inhibit 
DA-mediated motor activity, no potent, selective, and CNS penetrant M4 activators were 
available to test this hypothesis in rodents, prior to our discovery of VU0152099 and 
VU0152100.  Furthermore, these results shed important light on questions raised from 
clinical trials with xanomeline, the M1/M4-preferring orthosteric agonist that 
demonstrated robust anti-psychotic efficacy in multiple human trials (Chapter I)100,110.  
Specifically, our data support the hypothesis that the mechanism(s) of action underlying 
xanomeline’s effects were mediated at least in-part by activation of M4.  However, it is 
possible, perhaps even likely, that xanomeline-induced M1 activation also contributed to 
the drug candidate’s broad clinical efficacy across multiple symptom clusters.  
Nonetheless, further investigation into the neurochemistry and neurocircuitry involved in 
mediating the observed in vivo effects (Fig. 10) of M4 PAMs VU0152099 and 
VU0152100 is required.  
 
Optimization of M4 PAMs VU0152099 and VU0152100 
 
 Although the novel M4 PAMs VU0152099 and VU0152100 represented 
important advances over both LY2033298 and our first generation compound VU010010 
and served as highly useful in vivo probes of selective M4 modulation, we opted to 
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continue our optimization campaign in order to further improve upon these leads (Fig. 
11).  Both VU0152099 and VU0152100 possessed high potency, efficacy, and subtype-
selectivity, with acceptable in vivo PK profiles, and were devoid of ancillary 
pharmacological activity; however, in vitro metabolic stability experiments revealed that 
these compounds readily underwent phase-I oxidative metabolism with <10% of parent 
compound remaining after 90 min incubation with rat liver microsomes (data not shown).  
Subsequent metabolite identification experiments indicated that hydroxylation of the 
pyridine ring was the major oxidative metabolite.  In order to prevent this metabolic 
liability and further explore SAR around the lead scaffold, we employed an iterative 
parallel library synthesis approach for new analog generation. 
 
 
Figure 11.  Structures of first- and second-generation M4 PAMs based on optimization of the 
dimethylamino-thienopyridine amide scaffold.  All three compounds possess approximately ~400 nM rM4 
potency with 30-70x ACh CRC fold-shift, yet suffer from poor in vitro metabolic stability. 
 
 Having tentatively designated the p-methoxybenzamide moiety of lead compound 
3 as the most-favored substituent (of those screened in the initial amide side chain scan 
described previously) based on its functional activity at rat M4, we first held this side 
chain constant while exploring alternative substituents at the 6-position to prevent 
formation of the hydroxy metabolite.  Synthesis of initial 20-member alkylamine and 20-
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member ether libraries, as shown in Figure 12, began with condensation between 3-
aminocrotonitrile 4 and 2-cyanothioacetamide 5 to furnish the aminopyridyl core 6.  This 
was cyclized with a-chloro-p-methoxybenzamide 7 to give the diaminothieno[2,3-
b]pyridine scaffold with the p-methoxybenzamide 8.  To produce the 20-member amine 
library, 8 was reacted with various alkyl chlorides to generate 9a-s.  The ether library was 
synthesized in a similar fashion by reacting ethylacetoacetate 10 with 2-
cyanothioacetamide 5 to provide the core pyridone 11, which was then cyclized with 7 at 
0 °C then allowed to warm to r.t. overnight.  Once pure, 12 was alkylated to obtain 
analogs 13a-s.   
 
 
Figure 12. Synthesis of M4 PAM analog libraries 9a-s and 13a-s. Reagents and conditions: a) Piperidine, 
EtOH, MW 160 °C, 12 min. 42%; b) K2CO3, MW 160 °C, 10 min., 75%; c) R1-Cl, KI, Cs2CO3, DMF, MW 
160 °C, 30 min. 15-80%; d) Morpholine, EtOH, MW 160 °C, 10 min. 62%; e) K2CO3, DMF, 0 °C->r.t., 
24h 65%; f)  R1-Cl, KI, Cs2CO3, DMF, MW 160 °C, 30 min. 15-80%. 
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 These libraries were first screened in a singlepoint Ca2+ mobilization assay using 
a fixed 10 µM concentration of test compound added to rat M4/Gqi5-cells prior to addition 
of a submaximal concentration (~EC20) of ACh.  This allowed efficient triage of analogs 
for further characterization.  In general, alkylamine library 9a-s showed weak efficacy 
with elevation of the ACh response ranging from none (inactive) to modest (<50% ACh 
max).  However, ether library 13a-s contained a number of robust potentiators (~60-90% 
ACh max).  The EC50 values for compounds selected from both libraries based on their 
potentiation efficacy and structural characteristics were then obtained from full CRCs in 
similar Ca2+ assays testing for potentiation of an ACh ~EC20 (Table 4).   
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Table 4.  M4 PAM SAR for select analogs from alkylamine library 9a-s and ether library 13a-s chosen 
based on an initial singlepoint triage screen.  Ca2+ mobilization was used to obtain CRCs of each 
compound in the presence of an ACh ~EC20 using rM4 cells.  Similar assays were used to obtain CRCs of 
ACh in the presence and absence of 30 µM of each test compound to determine fold-shift values (- denotes 
not determined).  Data represent Means from at least three independent determinations. 
 
Compound R1 EC50 (µM) Fold-shift 
9a  >10 - 
9b  >10 - 
9c  9.1 1x 
9e  >10 - 
9l  >10 - 
9n  >10 - 
9o  >10 - 
9p  >10 1x 
13a  >10 1x 
13b  >10 - 
13c  6.5 37x 
13d  8.2 25x 
13e  >10 - 
13f  >10 - 
13g  >10 - 
13k  2.0 50x 
13l  2.2 9x 
13m  1.8 5x 
13p  >10 - 
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 More than half of these compounds possessed EC50 values over 10 µM with 
potentiation effects emerging only at the 10 µM and 30 µM concentrations.  Among 
alkylamines 9a-s, only the ethyl morpholine congener 9c had an EC50 just below 10 µM, 
reflecting relatively weak activity of this library.  In contrast, compounds from the ether 
library 13a-s possessed improved potencies.  Particularly, picolyl analogs 13k, 13l, and 
13m each exhibited an EC50 of approximately 2 µM.  A concentration-response curve for 
13k in the presence of fixed ACh EC20 is presented in Figure 13a.  Analog 13k elicited a 
robust potentiation of M4 activation, elevating the submaximal ACh response to over 
130% of the maximum response induced by a high concentration of ACh alone.  Looking 
ahead to in vivo studies, the structure of 13k was particularly attractive, as the presence of 
a basic amine would allow for an HCl salt to confer greater aqueous solubility for vehicle 
formulation.  Based on these potency data, compounds having EC50 values below 10 µM 
were examined for their ability to shift a full ACh CRC to the left when applied at a fixed 
30 µM concentration in a similar functional Ca2+ assay with rM4/Gqi5-cells (Table 4).  
The ACh CRC fold-shift data for analog 13k is shown in Figure 13b.  In the case of 
other allosteric modulators of GPCRs, compound potency often fails to correlate tightly 
with fold-shift magnitude.  For example, a PAM with high potency but low efficacy can 
exhibit next to no fold-shift effect, and conversely one with low potency but high efficacy 
may induce a substantial fold-shift.  Hence, evaluation of fold-shift for novel potentiators 
having upper single-digit micromolar potencies can sometimes uncover helpful SAR that 
would have otherwise been missed. 
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Figure 13.  CRCs and ACh fold-shift for analog 13k in rat M4 cells by Ca2+ mobilization assay. A.) CRC 
for 13k in the presence of an ACh ~EC20 (EC50 = 2.0 µM).  B.) CRC for ACh in the presence and absence 
of a 30 µM concentration of 13k (fold-shift = 50x).  Data represent Mean +/-SEM from at least three 
independent determinations.  
 
 
 As shown in Table 4, neither morpholino compound 9c nor ethyl compound 9p 
caused a left-shift in the ACh CRC, demonstrating the compromised activity found with 
alkylamine modification at the 6-position of the scaffold.  The same lack of effect was 
seen with the tertiary amine analog 13a from the ether library.  However, the ether-linked 
morpholino 13c and pyrrolidine 13d analogs demonstrated strong ACh left-shifts of 37x 
and 25x, respectively.  Interestingly, movement of the nitrogen from the 2-position or 3-
position of the picolyl ethers 13m and 13l to the 4-position of 13k progressively 
increased the fold-shift from 5x to 9x and ultimately 50x, respectively (Fig. 13b).  
 Taken together, these data suggested ether-linked modifications to the 6-position 
of the scaffold were more tolerated and optimal than alkylamine-linked changes.  
However, despite retention of robust PAM properties in terms of ACh CRC fold-shift for 
13c, 13d, and particularly 13k, the potency of these analogs was moderately diminished 
relative to the parent compound 3 (EC50 = 380 nM) (Fig 13).  Furthermore, the SAR for 
these two libraries underlines the importance of considering both fold-shift and potency 
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when optimizing allosteric modulators.  Although each of the three picolyl ether analogs 
had ~2 µM EC50 values, their left-shift effects on the ACh CRC revealed dramatic 
differences in maximal PAM efficacy.  
 For the next library iteration, we postulated that with the picolyl or ethyl 
morpholine ether moieties on the left-hand side of the molecule, the p-methoxybenzyl of 
the right-hand side might no longer be optimal for M4 potency.  Therefore, we opted to 
re-scan the amide with 18 side chain groups while holding constant each of the three 
picolyl ether modifications, the morpholino ether, and the dimethylpropylamine ether 
(Fig. 14).  The morpholino and 4-picolyl were clear choices based on their degree of ACh 
CRC fold-shift, but the 2-picolyl and 3-picolyl were also included to be comprehensive.  
The dimethylpropylamine ether was chosen to provide for the possibility that a different 
amide side chain may rescue the activity of 13a (i.e. a matrix-like approach to broaden 
SAR).  These libraries began with the cyclization between pyridone 11 and ethyl 
chloroacetate 14 to produce thienopyridone ethyl ester 15.  To obtain the five alkyl ethers 
16a-e, material 15 was reacted with the five selected side chains from our previously 
library.  These five scaffolds were saponified and immediately coupled with 18 amines to 
produce five alkyl ether libraries with different amide side chains 17a-p, 18a-r, 19a-o, 
20a-p, 21a-o (Fig. 14). 
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Figure 14.  Synthesis of M4 PAM analog libraries 17-21.  Reagents and conditions: a) TEA, DMF, 0 °C-
>r.t. 62%; b) R1-Cl, KI, Cs2CO3, DMF, MW 160 °C, 30 min. 75-95%; c) 1) 3:1 1M NaOH:EtOH, MW 120 
°C, 30 min. 2) R2-NH2, DIC, HOBt, 9:1 DMF:DIEA 20-80%. 
 
 
 As before, these libraries were screened first in a singlepoint 10 µM PAM assay 
that tested their ability to enhance the response of a submaximal (~EC20) concentration of 
ACh in rM4/Gqi5-cells (Fig. 15).  PAM activity ranged from absent to robust within each 
of these libraries, revealing generally consistent SAR across all of the five ether-linked 
modifications that were held constant on the left-hand side of the structure.  
 
 
Figure 15.  Singlepoint (10 µM) M4 PAM screen of analog sets 17-21.  Ca2+ mobilization was used to 
obtain % ACh max values for each compound in the presence of an ACh ~EC20.  Data represent Mean +/-
SEM from at least three independent determinations. 
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 From this screen, eleven compounds were selected for CRCs and ACh fold-shift 
assays based on their degree of potentiation.  The associated SAR data for the chosen 
compounds from libraries 17-21 obtained from these assays are shown in Table 5.  All 
selected compounds possessed an EC50 below 10 µM, except for 19n, the di-flurobenzyl 
substituted 2-picolyl analog.  Similar to earlier libraries, ACh CRC fold-shift magnitude 
did not track closely with potency, as shown for example in the case of compound 18h.  
This t-butyl substituted moropholine analog had near 9 µM potency but caused a robust 
62x foldshift of the ACh CRC.  Further, the two dimethylpropyl analogs 17a and 17o 
displayed approximately 3 µM potency yet induced only a moderate ACh fold-shift.  
Interestingly, this dimethylpropylamine motiety at R1 conferred poor potency (EC50 > 10 
µM) in its parent compound 9b that bore a p-methoxybenzyl group at R2, but the amide 
scan library 17a-p discovered side chains that rescued activity for this western side 
modification. 
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Table 5.  M4 PAM SAR for select compounds from second library iteration analogs 17-21.  Ca2+ 
mobilization was used to obtain CRCs of each compound in the presence of an ACh ~EC20 using rM4 cells.  
Similar assays were used to obtain CRCs of ACh in the presence and absence of 30 µM of each test 
compound to determine fold-shift values (- denotes not determined).  Data represent Means from at least 
three independent determinations. 
 
 
Compound R1 R2 EC50 (µM) Foldshift 
17a   2.58 7x 
17o   2.75 14x 
18a   7.42 40x 
18b   6.25 67x 
18c   5.81 51x 
18g   7.15 36x 
18h   8.73 62x 
19m   5.40 28x 
19n   >10 41x 
21n   2.44 44x 
21o   3.78 64x 
 
 
 In general, difluorinated benzylic substitutions at R2 were favored, providing 
analogs with EC50s in the 2-5 µM range at rat M4 and with large ACh CRC fold-shift 
values (Table 5).  The 4-picolyl moieties of R1 with the 2,3-difluoro and 2,5-difluoro 
substitutions at R2 of 21n and 21o proved most desired when seeking a balance of both 
potency and potentiation efficacy, consistent with previous SAR.  However, the 
moropholines at R1 of library 18a-r with bare alkyl and mono-oxygenated side chains at 
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R2 possessed strong fold-shift effects despite moderately weaker potency compared to 
21n and 21o.  Figure 16 presents the CRC for elevation of an ACh ~ EC20 and fold-shift 
effect on an ACh CRC for analog 21n.  Interestingly, this 2,3-difluorobenzyl substituted 
analog did not elevate the maximal response of ACh at the top of the CRC (Fig. 16b), 
which constrasts with 4-methoxybenzyl analog 13k (Fig. 13b). 
 
 
Figure 16.  M4 PAM characterization of analog 21n in rat M4/Gqi5-CHO cells by functional Ca2+ 
mobilization assay.  A.) CRC for compound 21n in the presence of an ACh ~EC20 (EC50 = 2.4 µM).  B.) 
ACh CRC in the presence and absence of a fixed 30 µM concentration of 21n (foldshift = 44x).  Data 
represent Mean +/-SEM from at least three independent determinations. 
 
 
 
 Despite generation of a multi-dimensional library of analogs varying both sides of 
the lead molecule’s scaffold, the approximately 400 nM rM4 potency of the first- and 
second- generation compounds 1-3 could not be maintained despite retention of robust 
PAM efficacy in terms of ACh CRC fold-shift (e.g. >50x).  Indeed, compounds 13k, 18b, 
and 21o each caused large left-shifts of ACh CRCs when applied at 30 µM, but were 
approximately an order of magnitude less potent than the earlier lead compounds.  These 
SAR suggest the presence of a possible ~ 2 µM potency floor for this chemotype with 6-
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position ether or amine modifications, as variation of the amide side chain failed to 
provide congers with EC50 values below this level.   
 We next evaluated the microsomal stability of novel analogs 13k, 21n, 21o, and 
18h in both rat and human fortified liver microsomes.  Replacement of the metabolically 
labile 6-Me group with the ether linkage did indeed improve metabolic stability for all 
four analogs 13k, 21n, 21o, and 18h (>90% parent remaining after 90 minutes) as 
compared to 1-3 (<10% parent remaining after 90 minutes).  Moreover, incorporation of 
the basic amine moieties in these four compounds also improved solubility providing 
either homogeneous solutions or uniform micro-suspensions, as the HCl salts, across a 
panel of pharmaceutically acceptable vehicles (β-cyclodextrin, PEG400/H2O, etc...) 
relative to initial lead compounds 2 (VU0152099) and 3 (VU0152100), which were only 
soluble in 10% Tween-80.   In particular, 21n afforded a homogeneous solution at 15 
mg/mL in pH 3 saline.   Thus, our optimization efforts revealed interesting and useful 
SAR that led to improved metabolic stability and physiochemical properties for this 
series of M4 PAMs. 
 
In vivo behavioral studies with 3rd-generation optimized M4 PAMs 
 
 Despite low micromolar potency at rat M4, we evaluated analogs 13k, 21n, 21o, 
and 18h in our standard amphetamine-induced hyperlocomotion in vivo model.  Recall, 
both 2 (VU0152099) and 3 (VU0152100) (EC50s ~400 nM, ACh CRC fold-shifts of 30x 
and 70x, respectively) were efficacious in this behavioral model predictive of 
antipsychotic efficacy.  In the event, 13k, 21n, 21o, and 18h all failed to reverse 
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amphetamine-induced hyperlocomotion following dosing at 56.6 mg/kg (I.P.), suggesting 
perhaps that the new compounds were too weak at rat M4 (data not shown).  This 
possibility is underlined by the fact that LY2033298 possesses similarly modest rM4 
potency and failed to achieve efficacy when dosed alone in recently disclosed in vivo rat 
behavioral studies, thereby requiring co-dosing of a muscarinic agonist (Oxotremorine) to 
achieve significant effects127. 
 
Species-specific differences in 3rd-generation M4 PAM potencies 
 
 Primarily, our efforts were aimed at exploring SAR at rat M4 and optimizing this 
series for beneficial DMPK and vehicle formulation properties suitable for in vivo rodent 
behavioral studies.  While stability and physiochemical properties were improved, 
potency at rM4 was diminished to a point where, most likely, in vivo efficacy was lost.  
However, rat and human mAChRs do diverge in structure (~95% amino acid sequence 
identity) and species-specific differences in on-target pharmacology have been noted for 
other mAChR PAMs.  Therefore, we opted to evaluate representative compounds 13k, 
21n, 21o, and 18h in analogous functional cell-based Ca2+ assays using cells expressing 
the human M4 receptor (and promiscous Gq15/16 for Ca2+ mobilization readout).  To this 
end, all four compounds were submitted to Millipore and assayed in their GPCR Profiler 
Service, which provided potency and ACh CRC fold-shift values with the human M4 
receptor.  Remarkably, each compound possessed EC50 values approximately in the 100-
200 nM range at human M4 (Fig. 17a), more than an order of magnitude greater potency 
than at the rat M4 receptor.  Each compound also elicited large left-shifts of the control 
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ACh CRC in human M4 cells (Fig. 17b) at 30 µM, similar to their fold-shifts at rat M4.  
In contrast, the prototypical M4 PAMs 1-3, displayed near equivalent EC50s on rat and 
human M4, suggesting the possibility that the basic residues in these newer analogs 
contact divergent residues in human M4.  
 
 
Figure 17. Effects of compounds 13k, 18h, 21n, and 21o in human M4/Gq15/16-expressing cells by 
functional Ca2+ mobilization assay.  A.) CRCs for potentiators in the presence of an ACh ~EC20 (13k EC50 
= 100 nM, 18h EC50 = 192 nM, 21n EC50 = 95 nM, 21o EC50 = 183 nM).  B.) for ACh in the presence and 
absence of a fixed 30 µM concentration of potentiator (13k foldshift = 63x, 18h foldshift = 44x, 21n 
foldshift = 60x, 21o foldshift = 49x).   
 
 
 
Potential for dual M4 PAM / H3 antagonist anti-psychotic activity 
 
 While M1 PAMs and allosteric agonists have the potential to affect multiple 
symptom clusters of schizophrenia, M4 PAMs may only prove efficacious in the 
treatment of positive symptoms.  If so, combination therapy or possibly a monotherapy 
possessing poly-pharmacology may be more clinically effective for comprehensive 
symptom treatment in psychotic patients.  For the cognitive symptom cluster specifically, 
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antagonism of the central histamine H3 receptor (H3) has been proposed as a potentially 
viable strategy128-130.   
 We observed that M4 PAMs 13k, 21n, 21o, and 18h possessed the general 
features of the refined H3 receptor antagonist pharmacophore (Fig. 18), and we therefore 
evaluated these compounds for their ability to function as H3 antagonists (using an in 
vitro binding assay), which may provide pro-cognitive attributes in vivo128.  Compounds 
13k, 21o and 18h were found to inhibit human H3 with IC50 values of ~10 µM, while 21n 
afforded an IC50 value of 6.3 µM.  Although weak, this result suggest that it may be 
possible to ‘dial in’ H3 antagonist activity to this new series of M4 PAMs via further 
optimization.  Testing of this hypothesis via additional syntheses and dual M4/H3 
screening will be required and has not yet been performed. 
 
 
 
Figure 18.  Alignment of M4 PAM lead compound 21n with the refined histamine H3 receptor antagonist 
pharmacophore. 
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Summary 
 
 Ultimately, a lead optimization campaign around M4 PAMs 1-3 provided novel 
analogs with substantially improved metabolic stability and physiochemical properties, 
but diminished potency at rat M4 (EC50s ~ 2 µM) while retaining comparable ACh CRC 
fold-shift (14x-67x) relative to early leads 1-3.  Surprisingly, we noted significant species 
differences within this series of M4 PAMs, where analogs such as 21n displayed an order 
of magnitude greater potency at human M4 (EC50 = 95 nM) than at the rat M4 receptor 
(EC50 = 2.4 µM) but with comparable ACh fold-shifts (human, 60x; rat, 44x).  
 To further expand the therapeutic relevance of M4 positive allosteric modulation 
for the treatment of schizophrenia beyond the positive symptom cluster, we evaluated 
analogs against the H3 receptor, as they align well with the refined H3 antagonist 
pharmacophore model.   M4 PAM 21n was found to provide modest inhibition of H3 
radioligand binding with an IC50 of 6.3 µM, suggesting that it might be possible to 
discover optimized analogs with dual M4 PAM and H3 antagonist activity.  Such 
compounds could be used to test the hypothesis that dual M4/H3 pharmacology would 
possess broad anti-psychotic potential across a range of preclinical behavioral studies 
aimed at predicting efficacy in treating different/multiple symptom clusters of 
schizophrenia. 
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Chapter IV 
 
DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF NOVEL 
SUBTYPE-SELECTIVE MACHR5 POSITIVE ALLOSTERIC MODULATORS 
 
 
 
Discovery of M1/M3/M5 PAM VU0119498 
 
 In order to identify novel M1 PAMs, an HTS of the VHTSC compound collection 
(~160,000 compounds total) was performed using a fluorescence-based Ca2+ mobilization 
assay27.  Test compounds were added to CHO-cells stably expressing the M1 receptor and 
allowed to equilibrate for approximately three minutes before addition of a submaximal 
(~EC20) concentration of the orthosteric agonist carbachol (CCh).  Compounds that 
potentiated the CCh response at least three standard deviations over the vehicle-control 
response were marked as primary hits (1,634 compounds).  Secondary screening 
(singlepoint or CRC assays) at M1 and counter-screening (CRC assays) at mGluR4 
identified a subset of hits (77 compounds), which exhibited concentration-dependent 
PAM activity at M1 with no activity at mGluR4.   
 
 
Figure 1.  Compounds identified by M1 PAM HTS chosen for in vitro characterization. 
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 Four of these hits (Fig. 1) were chosen for further characterization, including in 
vitro mAChR subtype-selectivity assays, which identified VU0119498 as a mAChR 
PAM with similar potencies (~3-6 µM) and efficacies (~45-65% CCh max) in M1, M3, 
and M5 CHO cell lines and with no PAM activity in M2/Gqi5 or M4/Gqi5 CHO cell lines, 
as shown in Fig. 2.  Subsequent functional and radioligand-binding assays demonstrated 
that VU0119498 (30 µM) induces a 14x left-shift of an ACh CRC at M1 by Ca2+ 
mobilization assay and does not compete with [3H]-NMS for binding to M1 cell 
membranes (Fig. 2), similar to the other three novel mAChR PAMs evaluated from the 
HTS and consistent with an allosteric mode of modulation. 
 
  
 
Figure 2.  In vitro characterization of VU0119498.  mAChR subtype-selectivity curves (top left panel) 
were obtained by Ca2+ mobilization assays in the presence of an ~EC20 of ACh at all five mAChR subtype 
cell lines.  ACh curves in the absence and presence of VU011948 (top right panel) were obtained by Ca2+ 
mobilization assays using M1 cells.  Competition curves (bottom panel) were obtained in the presence of 
0.1 nM [3H]-NMS using membranes from M1-expressing CHO cells.  Atropine Ki = 1.08 +/- 0.09 nM.  
Data represent the Mean ±S.E.M. of at least 3 independent experiments with similar results.  Experiments 
performed by J. Marlo. 
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 In light of the unprecedented mAChR PAM subtype-selectivity profile of 
VU0119498, we hypothesized that structural modification via chemical optimization of 
this novel compound would lead to the discovery of PAMs selective (either functionally 
or via binding specificity) for M5131,132.  As discussed in the introduction (Chapter I), the 
current and longstanding lack of available small molecules with selectivity for M5 made 
this an attractive endeavor with the possibility of providing a substantial contribution to 
the mAChR research community and thereby facilitating subsequent ex-vivo and/or in 
vivo M5 neurobiology studies.  To this end we executed an exploratory optimization 
project utilizing  (Chapter I) medicinal chemistry methods.  However, prior to 
synthesizing VU019498 analogs, the parent compound itself was resynthesized and 
retested in order to confirm the validity of the structure and associated pharmacological 
characteristics (Fig. 3).  N-alkylation of commercially available isatin with 4-
bromobenzyl bromide under standard conditions provided the desired compound with 
high yield (Fig. 3), which was then tested in mAChR subtype-selectivity CRC assays by 
Ca2+ mobilization. 
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Figure 3.  Resynthesis and retesting of HTS hit VU0119498.  Isatin was reacted with 4-bromobenzyl 
bromide in the presence of K2CO3, and KI, in ACN and stirred overnight at room temperature to provide 
desired compound (top panel).  Ca2+ mobilization assays with M1-M5 cells (M2 and M4 co-expressed Gqi5) 
were used to obtain CRCs (bottom panel) of resynthesized VU0119498 (EC50 values: M1 = 6.0 µM 82% 
ACh max, M3 = 6.4 µM 66% ACh max, M5 = 4.1 µM 74% ACh max).  Data represent the Mean ±S.E.M. 
of at least 3 independent experiments with similar results. 
 
 
 This was an important step because hits from HTS campaigns can sometimes fail 
to retest following resynthesis due to reasons such as incorrect structure assignment from 
the compound vendor or in-house management system, sample or assay plate/well 
contamination, etc...  Gratifyingly, the resynthesized batch of VU0119498 exhibited a 
virtually identical mAChR subtype-selectivity, potency, and efficacy profile as that of the 
parent batch obtained from the HTS (Fig. 3), which increased confidence that a 
subsequent optimization effort on this chemical scaffold would be worthwhile. 
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Optimization of VU0119498 to obtain M5 PAM VU0238429 
 
 Given SAR findings from other medicinal chemistry projects centered on GPCR 
allosteric modulators that demonstrated often pronounced effects of subtle structural 
modifications on subtype-selectivity and other pharmacological characteristics, we chose 
to initially and rapidly explore SAR around VU0119498 via synthesis of a 92-member 
analog library in matrix format wherein each of 8 commercially available isatins was 
reacted with approximately 12 benzyl halides under standard microwave alkylation 
conditions (Fig. 4).  Resulting analogs (compounds 21-112) were then screened in a 
singlepoint format at 30 µM in Ca2+ mobilization assays using M5 and M1 cells receiving 
a fixed submaximal (~EC20) concentration of ACh (Fig. 4).  This method was utilized to 
allow for efficient triage of analogs displaying high M1 vs. M5 or M5 vs. M1 preference.  
Interestingly, some analogs displayed robust potentiation effects at M5 (i.e. elevation of 
ACh ~EC20 to >50-60% of maximum ACh response) with absent or weak potentiation at 
M1, thus exhibiting strong preference for M5 versus M1 activity (Fig. 4).  
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Figure 4.  Synthesis and singlepoint screening of initial matrix library of VU0119498 analogs.  Different 
substituted isatins were each N-alkylated with various benzyl halides under microwave conditions in the 
presence of K2CO3 and KI in ACN to generate a 92-member library (top panel).  Ca2+ mobilization assays 
with M1 and M5 cells were used to obtain singlepoint (30 µM) potentiation responses for each analog in the 
presence of a submaximal (~EC20) concentration of ACh (middle and bottom panels). Data represent the 
Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
 
125 
Table 1.  Structures for compounds 21-112 and associated PAM activity data from the initial single 
concentration (30 µM) potentiator screen against M1 and M5.  Values shown for each compound are Ca2+ 
mobilization responses as percentages of maximum ACh response.  The synthetic method used to generate 
each compound is indicated by the following abbreviations: M, microwave; C, classical.  The molecular 
formula for each compound is also presented.  Data represent the Mean of at least 3 independent 
experiments with similar results. 
 
 
Structure Cmpd # Synthesis Formula M1 %Max M5 %Max 
 
21 M C16H13NO3 19.40 28.04 
 
22 M C16H13NO3 43.58 29.19 
 
23 M C16H12FNO3 32.32 41.61 
 
24 M C16H12FNO3 41.14 38.28 
 
25 M C15H9BrFNO2 62.67 51.69 
 
26 M C16H12FNO3 51.07 51.97 
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27 M C16H12FNO3 54.62 44.40 
 
28 M C15H9BrClNO2 26.13 32.03 
 
29 M C16H12ClNO3 16.94 27.87 
 
30 M C16H12ClNO3 20.31 32.61 
 
31 M C15H9BrClNO2 29.87 44.34 
 
32 M C16H12ClNO3 46.88 38.74 
 
33 M C16H12ClNO3 49.44 30.32 
 
34 M C16H12BrNO2 18.98 24.06 
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35 M C17H15NO3 14.49 29.57 
 
36 M C17H15NO3 14.09 21.18 
 
37 M C15H8BrCl2NO2 12.08 20.67 
 
38 M C16H11Cl2NO3 13.26 35.11 
 
39 M C16H11Cl2NO3 18.60 11.73 
 
40 M C16H9BrF3NO3 13.21 47.56 
 
41 M C17H12F3NO4 28.55 70.08 
 
42 M, C C17H12F3NO4 12.69 60.73 
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43 M C16H10F3NO2 37.89 40.23 
 
44 M C16H10F3NO2 73.26 61.99 
 
45 M C15H10ClNO2 43.42 41.96 
 
46 M C16H9F4NO2 47.78 36.15 
 
47 M C16H9F4NO2 67.30 59.76 
 
48 M C15H9ClFNO2 41.35 39.90 
 
49 M C16H9F4NO2 41.26 30.92 
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50 M C16H9F4NO2 60.86 71.10 
 
51 M C15H9ClFNO2 18.53 20.27 
 
52 M C16H9ClF3NO2 29.56 48.35 
 
53 M C16H9ClF3NO2 44.14 67.39 
 
54 M C15H9Cl2NO2 21.27 44.35 
 
55 M C16H9ClF3NO2 31.14 13.99 
 
56 M,C C16H9ClF3NO2 67.04 70.76 
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57 M C17H12F3NO2 17.81 30.57 
 
58 M C17H12F3NO2 22.89 35.45 
 
59 M C16H12ClNO2 16.80 24.30 
 
60 M C16H8Cl2F3NO2 21.09 16.02 
 
61 M C15H8Cl3NO2 13.06 18.94 
 
62 M C17H9F6NO3 22.63 56.54 
 
63 M C17H9F6NO3 25.69 67.22 
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64 M C16H9ClF3NO3 12.29 51.88 
 
65 M C15H10FNO2 38.87 24.49 
 
66 M C15H9F2NO2 44.84 40.38 
 
67 M C15H9F2NO2 36.65 17.44 
 
68 M C15H9F2NO2 40.11 46.18 
 
69 M C15H8F3NO2 47.31 60.32 
 
70 M C15H8F3NO2 27.59 31.11 
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71 M C15H9F2NO2 42.71 42.40 
 
72 M C15H8F3NO2 64.42 68.93 
 
73 M C15H8F3NO2 33.10 25.10 
 
74 M C15H9ClFNO2 22.98 36.33 
 
75 M C15H8ClF2NO2 32.39 44.90 
 
76 M C15H8ClF2NO2 27.34 31.82 
 
77 M C15H9ClFNO2 50.42 49.54 
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78 M C15H8ClF2NO2 64.64 61.59 
 
79 M C15H8ClF2NO2 38.83 23.59 
 
80 M C16H12FNO2 24.85 24.60 
 
81 M C16H11F2NO2 32.56 33.81 
 
82 M C16H11F2NO2 17.28 14.40 
 
83 M C15H8Cl2FNO2 12.36 14.70 
 
84 M C15H7Cl2F2NO2 17.23 19.10 
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85 M C15H7Cl2F2NO2 16.40 12.19 
 
86 M C16H9F4NO3 11.30 51.77 
 
87 M C16H8F5NO3 25.85 61.90 
 
88 M C16H8F5NO3 13.57 29.82 
 
89 M C16H10F3NO3 54.72 60.47 
 
90 M C16H13NO2 43.16 36.34 
 
91 M C15H9BrFNO2 49.20 48.52 
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92 M C16H9F4NO3 59.81 58.39 
 
93 M C16H12FNO2 37.72 40.76 
 
94 M C15H8BrF2NO2 70.54 63.96 
 
95 M C16H9F4NO3 51.78 57.70 
 
96 M C16H12FNO2 30.17 27.52 
 
97 M C15H8BrF2NO2 39.19 46.34 
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98 M C16H9ClF3NO3 31.28 47.07 
 
99 M C16H12ClNO2 27.65 47.26 
 
100 M C15H8BrClFNO2 29.89 30.39 
 
101 M C16H9ClF3NO3 43.65 72.32 
 
102 M C16H12ClNO2 32.83 32.56 
 
103 M C15H8BrClFNO2 46.52 60.75 
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104 M C17H12F3NO3 13.83 18.92 
 
105 M C17H15NO2 20.19 29.85 
 
106 M C16H11BrFNO2 22.32 27.77 
 
107 M C16H8Cl2F3NO3 16.03 23.24 
 
108 M C16H11Cl2NO2 13.68 16.42 
 
109 M C15H7BrCl2FNO2 9.93 12.38 
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110 M C17H9F6NO4 13.82 58.87 
 
111 M C17H12F3NO3 26.16 59.97 
 
112 M C16H8BrF4NO3 11.56 36.36 
 
 
  
 In terms of maximal potentiation efficacy, SAR from the initial 30 µM screen of 
the entire library suggested that 5-OCF3 substitution of the isatin core was generally 
favored for greater M5 versus M1 activity, while halogen substitutions at the 7- position 
conferred a more dual M1/M5 activity.  The % ACh max values for each compound at 
both M1 and M5 from the full singlepoint screen are show in Table 1.  Based on the 
results of this screen, 18 compounds were selected for follow-up CRCs at M1 and M5 to 
determine potencies (Table 2).  All 5-OCF3 substituted compounds chosen from the 
initial screen possessed 1-5 µM potencies at M5 and >30 µM potencies at M1 in CRC 
assays, with the exception of compounds 63 and 112, which nonetheless possessed 
greater M5 versus M1 activities (Table 2).  Numerous benzylic substitutions were 
tolerated for M1 and M5 activity (depending also on the isatin core), methoxybenzyl was 
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generally favored for M5 versus M1 activity, and trifluoromethylbenzyl was generally 
favored for dual M1/M5 PAM activity.  Most other simple congeners, including those 
with various methyl substitutions at R1 or R2 displayed weak or no potentiation activity at 
either receptor (Table 2).   
 
Table 2.  Potency SAR at M1 and M5 for 18 compounds selected from an initial singlepoint screen.  Ca2+ 
mobilization assays with M1 and M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh. Data represent the Mean of at least 3 independent experiments 
with similar results. 
 
 
 
Cmpd R1 R2 M1 EC50 (µM) M5 EC50 (µM) 
22 H 4-OMe >10 >30 
25 7-F 4-Br 3.99 1.93 
33 7-Cl 4-OMe 5.38 3.96 
38 4,7-Cl 3-OMe >30 7.15 
41 5-OCF3 3-OMe >30 1.70 
42 5-OCF3 4-OMe >30 1.16 
44 H 4-CF3 5.88 3.19 
46 5-F 2-CF3 6.21 4.09 
47 5-F 4-CF3 8.55 7.13 
49 7-F 2-CF3 >30 >30 
50 7-F 4-CF3 5.18 3.26 
56 7-Cl 4-CF3 3.20 2.11 
63 5-OCF3 4-CF3 7.09 1.85 
64 5-OCF3 2-Cl >30 4.07 
103 7-Cl 2-F, 4-Br 7.14 4.66 
110 5-OCF3 4-OCF3 >30 1.86 
111 5-OCF3 2-Me >30 3.28 
112 5-OCF3 2-F, 4-Br >30 >10 
 
 
 Based on these findings, specifically that subtle structural changes to VU0119498 
confer dramatic effects on mAChR subtype-selectivity, we also hypothesized that some 
of the compounds (of this 92-member library) that were inactive at M1 and M5 in the 
singlepoint screen may represent M3 PAMs.  Although identification of PAMs for M3 
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was not a priority of this project, we nonetheless tested this hypothesis by evaluating 13 
M1/M5 inactive compounds in a similar singlepoint (30 µM) screen at M3 by Ca2+ 
mobilization assay (Fig. 5).  Surprisingly, all were devoid of robust PAM activity at M3 
(Fig. 5).  With the exception of only two compounds (VU0238437 and VU0238469, 
which bore 7-F substitution at R1) all of these analogs contained either 5-Me or 4,7-Cl 
substitution at R1, suggesting that these modifications dial-out functional mAChR PAM 
activity from the VU0119498 scaffold or prevent mAChR binding altogether.  The 
structures and VU numbers for these 13 compounds are shown in Table 3. 
 
 
Figure 5.  Singlepoint screen at M3 of a subset of VU0119498 analogs chosen based on inactivity at M1 
and M5.  Ca2+ mobilization assays with M3 cells were used to obtain singlepoint (30 µM) potentiation 
responses for each analog in the presence of a submaximal (~EC20) concentration of ACh. Data represent 
results from a single experiment. 
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Table 3.  Structures and VU numbers for 13 VU0119498 analogs chosen for a M3 PAM singlepoint screen 
based on their inactivity at M1 and M5 in the initial singlepoint screen of 92-member matrix library. 
 
R1 R2 Compound 
5-Me 4-OMe VU0238423 
4,7-Cl 4-Br VU0238424 
4,7-Cl 4-OMe VU0238426 
7-Fl 2-Cl VU0238437 
4,7-Cl 2-CF3 VU0238446 
4,7-Cl 2-Cl VU0238448 
7-Fl 2-Fl VU0238469 
4,7-Cl 2-Fl VU0238470 
4,7-Cl 2,4-Fl VU0238471 
4,7-Cl 2,6-Fl VU0238472 
5-Me 4-OCF3 VU0238490 
4,7-Cl 2-Me VU0238494 
4,7-Cl 2-Fl,4-Br VU0238495 
 
 
In vitro characterization of M5 PAM VU0238429 
 
 In light of the high M5 versus M1 potentiation preference displayed by analog 42 
(1.16 µM M5 EC50 and >30 µM M1 EC50) in these assays, the full subtype-selectivity 
profile of this compound was obtained in similar Ca2+ assays using M2, M3, and M4 cells 
(Fig. 6).  Likewise, full subtype-selectivity determination was also performed with 
compound 56, which was the most potent dual M1/M5 potentiator in the initial evaluation 
at both receptors (2.11 µM M5 EC50 and 3.20 µM M1 EC50), as shown in Figure 7. 
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Figure 6.  mAChR subtype-selectivity of compound 42 (VU0238429) displaying high M5 PAM selectivity.  
Ca2+ mobilization assays with M1-M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh (EC50 values: M1 = >30 µM, M3 = >30 µM, M5 = 1.1 µM 91% 
ACh max).  Data represent the Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
Figure 7.  mAChR subtype-selectivity of compound 56 displaying pan-mAChR PAM activity.  Ca2+ 
mobilization assays with M1-M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh (EC50 values: M1 = 3.2 µM 87% ACh max, M3 = 2.2 µM 78% 
ACh max, M5 = 2.1 µM 86% ACh max, M2 = 2.8 µM 55% ACh max, M4 = >10 µM).  Data represent the 
Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 Remarkably, compound 42 (VU0238429) had similarly poor potency at M3 as at 
M1, with potentiation of the ACh ~EC20 beginning to emerge only in the double-digit 
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micromolar range (Fig. 6).  Gratifyingly, this compound maintained its lack of 
potentiation activity at M2 and M4 (in cells co-transfected with Gqi5) at up to 30 µM (Fig. 
6).  Given these data, the approximately 1.16 µM M5 potency of compound 42 provides 
>30x PAM selectivity for M5 versus the other four subtypes, thus representing the first 
highly M5-preferring M5 ligand ever reported.  Conversely, compound 56 (VU0238441) 
was found to retain the M1/M3/M5 potentiation profile of the parent HTS hit 113 and also 
interestingly possessed modest potentiation at M2 and M4 at higher concentrations (Fig. 
7).  Despite the high M5-preference of VU0238429 observed in these functional PAM 
assays, it is unknown if this compound (or any of the other analogs) possesses high M5-
binding specificity or if its selectivity is primarily functional with similar binding 
affinities for multiple subtypes.  Binding experiments aimed at answering this question 
are hindered by an absence of radioligand(s) for the putative allosteric site at which these 
PAMs bind; however, functional studies may be pursued, which are discussed later in this 
thesis (Chapter VI). 
 To further evaluate the ability of compound 42 (VU0238429) to potentiate ACh-
induced activation of M5, we obtained full CRCs for ACh in M5 cells in the presence of 
either vehicle or a fixed (30 µM) concentration of compound 42 (Fig. 8).  In these assays, 
compound 42 induced a robust 14x left-shift of the ACh CRC, which was virtually 
identical to that found with the parent HTS hit VU0119498 when evaluated in the similar 
assay at M1.  Moreover, compound 42 lacked intrinsic agonist activity at M5 when tested 
up to 30 µM in the absence of ACh (Fig. 8).    
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Figure 8.  Compound 42 (VU0238429) requires ACh to activate M5 and causes a robust increase in ACh 
potency at M5.  Ca2+ mobilization assays with M5 cells were used to obtain compound CRCs in the 
presence and absence of a submaximal (~EC20) concentration of ACh (left panel) and ACh CRCs in the 
presence and absence of compound (30 µM, right panel).  ACh EC50 was left-shifted 14x by compound 42 
(VU0238429).  Data represent the Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 We also evaluated HTS hit VU0119498 and the highly M5-preferring analog 42 
(VU0238429) in competition-binding experiments with M5-CHO membrane preparations 
using the orthosteric radioligand [3H]-NMS, a potent pan-mAChR antagonist.  At up to 
30 µM, compound 42 lacked competition with [3H]-NMS, consistent with an allosteric 
mode of binding to M5 (Fig. 9).  By contrast, VU0119498 exhibited approximately 50% 
inhibition of radioligand binding at 30 µM (Fig. 9).  This inhibition by VU0119498 could 
be due either to direct competitive orthosteric binding or to negative cooperativity via an 
allosteric site; however, further experiments to investigate these possibilities were not 
performed due to a greater focus on VU0238429.  When competition curves of ACh were 
obtained (Fig. 9) in the presence and absence of VU0238429 (30 µM) at M5 cell 
membranes, this PAM caused a pronounced increase in the Ki of the low affinity binding 
state of the receptor (~15x) with only a modest effect on the Ki of the high affinity 
binding state (~1.5x), which suggests that the primary mechanism of potentiation by 
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VU0238429 at M5 is by enhancement of ACh binding, possibly via stabilization of the 
high affinity receptor conformation (Fig. 9). 
 
 
 
Figure 9.  Competition binding experiments with VU0238429 and compound VU0119498.  [3H]-NMS (0.1 
nM) binding to M5 cell membranes was measured (top panel) in the presence of increasing concentrations 
of test compounds or atropine control (Ki = 0.21 nM). [3H]-NMS (0.1 nM) binding to M5 cell membranes 
was used to obtain CRCs of ACh in the presence and absence of compound 42 (30 µM, bottom panel). 
ACh curves exhibited two-site competition (+Vehicle: Ki high affinity = 123 nM, Ki low affinity = 22 µM; 
+VU0238429: Ki high affinity = 81 nM, Ki low affinity = 1.39 µM).  Data represent the Mean ±S.E.M. of at 
least 3 independent experiments with similar results. 
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In vivo rat pharmacokinetics of M5 PAM VU0238429 
 
 We then determined rat in vivo pharmacokinetics and brain penetration of the M5 
PAM to evaluate its ability to serve as an in vivo tool compound. Unfortunately, 
VU0238429 exhibited poor systemic absorption after I.P. administration with maximum 
concentration in plasma (161.7 ng/ml) being achieved within 1 hour (Fig. 10).  However, 
it was eliminated relatively slowly from systemic circulation with an elimination half-life 
of 4.7 hours, which is desirable for in vivo studies (Fig. 10).  Although quickly taken up 
in the brain, it displayed poor brain penetration with an AUC-brain/AUC-plasma value of 
0.2514 (Fig. 10). 
 
 
 
Figure 10.  Rat pharmacokinetic PBL study of VU0238429 and calculated PK parameters.  Concentration 
of compound in brain and plasma over a 6-hour time course was measured by LC/MS/MS following a 
single 10 mg/kg (IP) dose using male Spraque-Dawley rats.  Data represent the Mean ±S.E.M. with N=3.  
Study performed by S. Jadhav. 
PK Parameter Plasma Brain 
Cmax (ng/ml or g) (mean±SD) 161.7 ± 13.9 43.08 ± 15.68 
Tmax (h) 1 0.5 
Elimination half life (h) 4.7 3.69 
AUC (0-6h) (ng.h/ml or g) (mean±SD) 621.1 ± 39.9 158.62 ± 47.23 
CL/F (ml/min) 145  
V/F (L/kg) 59.6  
AUCbrain/AUC plasma 0.25  
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Optimization of M5 PAM VU0238429 
 
 Despite the relatively limited scope of the initial matrix analog library in terms of 
structural modification, we found clear SAR associated with this novel mAChR PAM 
chemotype, with 5-OCF3 modification of the isatin core and 3- or 4- position OMe 
substitutions of the benzyl ring conferring strong M5 PAM preference versus M1-M4.  In 
contrast, virtually all modifications conferring increased M1 PAM activity simultaneously 
increased M5 PAM activity.  As exemplified in the case of compound 56, 7-Cl 
substitution of the isatin core carried comparably high M1/M5 potency and efficacy, but 
also caused degeneration into a pan muscarinic potentiator as revealed by CRC profiling 
at all five subtypes.  Based on these initial findings from the matrix library and the 
identification of VU0238429 as the first M5-preferring PAM, we began a more 
comprehensive optimization campaign focused on VU0238429 as the lead structure.   
 The rationale for further optimization included a desire to improve potency, 
efficacy, and subtype-selectivity, as well as to decrease potential DMPK liabilities of the 
lead compound.  An iterative parallel analog synthesis approach was used to drive the 
VU0238429 optimization as this methodology provides a more focused and efficient 
route compared to generation of matrix libraries or singleton syntheses because global 
structural diversity and random SAR exploration was no longer a priority based on the 
results from the initial 92-member matrix library around VU0119498.  As introduced 
previously (Chapter I), iterative libraries are well suited to optimizations aimed at 
improving specific pharmacological or physiochemical characteristics of a lead 
compound because they are hypothesis-driven and less random than matrix-based or 
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other medicinal chemistry optimization strategies.  Based on the initial VU0119498 SAR 
and from consideration of chemistry/synthetic route accessibility and efficiency, we 
outlined a number of modifications to VU0238429 to explore (Fig. 11).   
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Figure 11.  Initial optimization strategy for M5 PAM VU0238429. 
 
 Given the importance of the 5-OCF3 moiety of the isatin core to M5 subtype-
selectivity, it was held constant while the N-alkyl chain was lengthened and while the 
benzyl ring was substituted at the para position with different aryl/heteroaryl rings in 
place of the methoxy group of the lead structure.  Libraries were prepared according to 
the scheme depicted in Figure 12, wherein commercial 5-(trifluoromethoxy)indoline-2,3-
dione (compound 4) was alkylated with p-bromobenzylbromide to deliver key 
intermediate (compound 5).  An 11-member Suzuki library was then prepared to explore 
the effect introducing the biaryl and heterobiaryl motifs into VU0238429 (compounds 6).  
In parallel, compound 4 was alkylated with functionalized phenethyl bromides 
(compounds 7) to probe the effect of chain homologation (compounds 8).  Compound 
libraries were then triaged by a singlepoint (10 µM) screen for their ability to potentiate 
an ~EC20 of ACh in M1 and M5 cells using Ca2+ mobilization assay with VU0238429 
included as a positive control (Fig 12).  
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Figure 12.    Synthesis and M1/M5 singlepoint screening of biaryl/heterobiaryl and phenethyl analogs of 
VU0238429.  13 compounds were synthesized (top panel) by a) p-bromobenzylbromide, K2CO3, KI, ACN, 
rt, 16 h (99%); b) R-B(OH)2, Pd(Pt-Bu3)2, Cs2CO3, THF:H2O, mw, 120 °C, 20 min (10-90%); c) K2CO3, 
KI, ACN, rt, 16 h (50-90%).  Ca2+ mobilization assays with M1 and M5 cells were used to obtain 
singlepoint (10 µM) potentiation responses for each analog in the presence of a submaximal (~EC20) 
concentration of ACh (middle and bottom panels). Data represent the Mean ±S.E.M. of at least 3 
independent experiments with similar results. 
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 From these singlepoint screens at M1 and M5, select compounds were assayed 
using full CRCs based on the general high M5 versus M1 potentiation in terms of % ACh 
max efficacy observed with numerous members of this library. The potency SAR and 
associated efficacy data from the singlepoint screens at M1 and M5 for this library is 
presented in Table 4.  In general, chain homologation (compounds 8, i.e. VU0365124 
and VU0365125) proved unsuccessful as potency and M5-selectivity was compromised 
despite retention of PAM efficacy at higher concentrations.  For example, the direct 
phenethyl analog of VU0238429 (compound 8a, i.e. VU0265124) possessed a M5 EC50 
of 4.9 µM and 78% ACh max response and a M1 EC50 >10 µM and 90 % ACh max 
response (Table 4).  Biaryl and heterobiaryl analogs (compounds 6) proved far more 
productive, affording a number of M5 PAMs with high selectivity versus M1 (>30 uM M1 
EC50s) and low micromolar M5 EC50s (Table 4).  All other analogs possessed M5 EC50s 
>10 µM.  In general, both 5- and 6-membered heterocycles were tolerated as was simple 
phenyl substitution (compound 6a).  Potency was very similar for most of these analogs 
(M5 EC50s 2.7 µM to 4.8 µM) as were % ACh max values (70-85%).  Shallow SAR was 
again noted with compounds either being active in this potency range or inactive as M5 
PAMs. 
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Table 4.  M1 and M5 potency SAR for biaryl/heterobiaryl and phenethyl analogs of VU0238429.  Ca2+ 
mobilization assays with M1 and M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh. n/d = potency not determined (no CRCs and the % ACh max 
values represent singlepoint screen data).  Data represent the Means of at least 3 independent experiments. 
 
N
O
O
O
FF
F
R
Chain Length
Cmpd VU# Chain Length R     M5 EC50, ACh max     M1 EC50, ACh max
6a       0365114           CH2
6b       0365115           CH2 
6c       0365116           CH2
6d       0365117           CH2
6e       0365118           CH2
6f        0365119           CH2
6g       0365120           CH2
6h       0365121           CH2
6i        0365122           CH2
6j        0365123           CH2
6k       0365138           CH2
8a       0365124          C2H4
8b       0365125          C2H4
Cl
Cl
S
N
Cl
F
F
N
F
OMe
N
N
O
Cl
OMe
Br
MeO
2.7 uM, 85%                   >30 uM, n/a
   n/d, 73%                        n/d, 30%
   n/d, 73%                        n/d, 22%
2.8 uM, 90%                   >30 uM, n/a
4.8 uM, 98%                   >30 uM, n/a
   n/d, 46%                        n/d, 23%
   n/d, 81%                        n/d, 18%
3.6 uM, 88%                   >30 uM, n/a
   n/d, 46%                        n/d, 25%
3.3 uM, 85%                   >30 uM, n/a
   n/d, 31%                        n/d, 21%
4.9 uM, 78%                   >10 uM, 90%
   n/d, 81%                        n/d, 42%
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 Given the relatively high potency and efficacy of compounds 6a and 6d, and the 
highest efficacy observed from compound 6e, these three analogs were chosen for 
characterization in ACh CRC fold-shift (Fig. 13) and M3 CRC selectivity (Fig. 13) via 
Ca2+ mobilization assays.  M3 selectivity was determined due to the lower likelihood that 
M2 and M4 activity would present itself in light of previous SAR for this chemical series 
and the fact that M5 shares highest amino acid sequence identity with M3, thus rendering 
it the most obvious of the remaining mAChR subtypes to check for selectivity first.  As 
seen in Figure 13, compound 6a (VU0365114) exhibits very high PAM selectivity for 
M5 versus M1 and M3, which is even greater than that of the parent compound 
VU0238429.  Interestingly, the 3-thiophene substitution of compound 6d, which is a 
common and well-recognized bio-isosteric replacement for a phenyl ring, exhibited a 
much more narrow selectivity window versus M3 than compound 6a (Fig. 13).  This 
serves as a clear example of the idiosyncratic and often-unpredictable SAR observed with 
many GPCR allosteric modulators.  Likewise, the chloropyridine moiety of compound 6e 
is electronically homologous (and modestly similar sterically) to the phenyl ring of 
compound 6a; however, it too confers an approximately equal loss of selectivity versus 
M3 as the thiophene of compound 6d (CRC data for compound 6e not shown). 
 In terms of ACh CRC fold-shift, these biaryl/heterobiaryl congeners proved far 
superior to VU0238429 with robust ACh potency left-shift of >50x compared to the 14x 
left-shift induced by VU0238429 (Fig. 13).  As observed with other mAChR PAMs such 
as BQCA (discussed in more detail in Chapter V), intrinsic agonist activity was present 
with both compound 6a and 6d, which is reflected by baselines that begin at (~25-50% 
ACh max) for the ACh CRCs obtained in the presence of 30 µM compound (Fig. 13). 
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Figure 13. M1, M3, and M5 subtype-selectivity and ACh CRC fold-shift of compound 6a (VU0365114) and 
6d (VU0365117).  Ca2+ mobilization assays with M1, M3, and M5 cells were used to obtain compound 
CRCs in the presence of a fixed submaximal (~EC20) concentration of ACh (top panels, VU0365114 EC50 
values: M5 = 2.7 µM 85% ACh max, M3 = >10 µM, M1 = >30 µM, VU0365117 EC50 values: M5 = 2.8 µM 
90% ACh max, M3 = >10 µM, M1 = >30 µM).  Ca2+ mobilization assays with M5 cells were used to obtain 
ACh CRCs in the presence and absence of test compounds (bottom panel).  Actual fold-shift values not 
determined due to intrinsic agonist activity of test compounds and therefore reported as >50x left-shift for 
both compounds.  Data represent the Mean ±S.E.M. of at least 3 independent experiments with similar 
results. 
 
 
 Encouraged by the potency, high ACh CRC fold-shift, and subtype-selectivity of 
VU0365114 (compound 6a), we hypothesized that a hybrid analog of this compound and 
the parent VU0238429 lead in the form of a bi-aryl ether on the southern portion of the 
scaffold may provide to a more optimal M5 PAM.  We also sought to explore bio-
isosteric replacements of the ketone at the 3-position of the isatin core or possibly 
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deletion/replacement of the entire keto-amide moiety, which is not a common drug-like 
structure and may represent a DMPK liability as an efflux pump (e.g. Pgp) substrate, 
potentially underlying the poor in vivo PK profile of VU0238429.  The strategy for this 
library iteration is presented in Figure 14. 
 
N
O
O
O
FF
F
O
Delete/replace keto-amide
Replace methyl with phenyl to
generate hybrid of VU0238429 
and VU0365114  
Figure 14.  Strategy for second round of M5 PAM analog library iterations. 
 
 The hybrid analog was synthesized according to the same general alkylation 
procedure described previously for earlier compounds (Fig. 4 and Fig. 12).  Briefly, 
commercial 5-trifluoromethoxyisatin was treated with p-phenoxybenzyl bromide in the 
presence of K2CO3 and subjected to microwave irradiation at 160 °C for 10 minutes to 
afford the desired compound as VU0400265 (68% yield).  This analog was then profiled 
in CRCs at M1-M5 (in the presence of an ~EC20 of ACh) using Ca2+ mobilization assays 
(Fig. 15).  The potency of VU0400265 (1.9 µM) and % ACh max (75%) for this analog 
was comparable to that of VU0238429 and VU0365114; however, it exhibited complete 
selectivity for M5 with no elevation of the ACh ~EC20 at any other mAChR subtype at up 
to 30 µM (Fig. 15).  This represented the most selective M5 PAM to date; however, it 
remains unknown whether or not this compound binds M1-M4. 
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Figure 15.  Structure, mAChR subtype-selectivity profile, and ACh CRC fold-shift for VU0400265, the 
first M5-selective PAM representing a hybrid of VU0238429 and VU0365114.  Ca2+ mobilization assays 
with M1-M5 cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) 
concentration of ACh (EC50 values: M5 = 1.9 µM, 75% ACh max, M1-M4: >30 µM). Data represent the 
Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
 During the preparation of this phenoxybenzyl analog (VU0400265), we 
simultaneously generated a library of substituted indole and oxindole analogs to test the 
importance of the keto-amide moiety (2-,3-position carbonyls) of the isatin headpiece as 
part of the strategy outlined in Figure 14.  To this end, 14 compounds were synthesized 
using previously described alkylation conditions (data not shown), which were then 
screened at 30 µM in M1 and M5 cells in the presence of an ACh ~EC20 by Ca2+ 
mobilization assay, similar to previous singlepoint screens (Fig. 16).  In both cell lines, 
VU0119498 and VU0238429 were used as positive controls. 
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Figure 16.  M1/M5 singlepoint screening of substituted indole and oxindole analogs.  Ca2+ mobilization 
assays with M1 and M5 cells were used to obtain singlepoint (30 µM) potentiation responses for each 
analog in the presence of a submaximal (~EC20) concentration of ACh.  M1/M3/M5 HTS hit VU0119498 
and M5 PAM lead VU0238429 were included as positive controls.  Data represent the Mean ±S.E.M. of at 
least 3 independent experiments with similar results. 
 
  
 However, none of these modifications were tolerated for PAM activity at either 
receptor subtype (regardless of the southern benzyl substitution present), and some 
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appeared to induce modest inhibition of the ACh response at M5, suggesting possible 
antagonism or negative allosteric modulation.  Other attempts at replacing the 2-position 
carbonyl by introducing an eastern carboxylic acid in this position included synthesis of a 
small set of benzylated scaffolds (data not shown); however, these compounds were 
extremely unstable and degraded quickly at room temperature, thus they were not tested 
for mAChR PAM activity. 
 Having then established the importance of the keto-amide structure of the isatin 
core, we turned to specific bio-isoteric replacements for the 3-position ketone, which 
included gem di-fluoro, spirocyclopropyl, and a chiral tertiary alcohol.  These structural 
changes are well-known mimetics for ketones as they retain the general electronic and 
steric characteristics of a ketone carbonyl, with the exception of the tertiary alcohol due 
to its hydrogen bond donation property (as compared to the hydrogen bond accepting 
property of a ketone).  These three analogs were synthesized using the VU0238429 
template (i.e. retention of p-methoxybenzyl on the southern portion) as shown in the 
scheme of Figure 17.   
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Figure 17.  Synthesis of oxindole M5 PAM analogs VU0402733, VU0402734, VU0402735. 
 
 Each compound was then tested via Ca2+ mobilization in CRCs at M5 in the 
presence of an ACh ~EC20 (Fig. 18).  Gem-difluoro substitution (VU0402734) was 
extremely well tolerated and provided a modest increase in M5 PAM potency, whereas 
spirocyclopropyl substitution (VU0402735) completely abolished M5 PAM activity (Fig. 
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18).  Interestingly, the chiral tertiary alcohol analog (VU0402733) exhibited an 
approximately ~10x right-shift in potency compared to that of the parent M5 PAM 
VU0238429 (Fig. 18).  These SAR data indicated that gem-difluoro would be ideal for 
subsequent analog generation, and it may confer an improved in vivo PK profile to this 
M5 PAM series in contrast to retention of the isatin-based headpiece of VU0238429.  
Furthermore, this modification was synthetically favorable as any isatin-containing 
analog could be fluorinated in a simple one-step manner (Fig. 17). 
 
 
 
Figure 18.  Structures and CRCs for M5 PAM analogs bearing 3-position ketone replacements. Ca2+ 
mobilization assays with M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh (EC50 values: VU0402734 = 870 nM, 90% ACh max, 
VU0402733 = >10 µM, VU0402735 = >30 µM). Data represent the Mean ±S.E.M. of at least 3 
independent experiments with similar results. 
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 Following this, VU0402734 was profiled in CRCs assays at M1 and M3 in the 
presence of an ACh ~EC20 to determine if this modification altered subtype-selectivity 
(Fig. 19).  Not only did gem-difluorination of the M5 PAM scaffold result in greater 
potency, it also decreased PAM activity at M1 (relative to the VU0238429 parent 
subtype-selectivity profile) and exhibited similarly low activity at M3 (Fig. 19), which 
provided further confidence that this modification would be worth retaining for a final 
optimized scaffold. 
 
 
Figure 19.  M1, M3, and M5 subtype-selectivity profile for VU0402734, the gem-difluoro analog of M5 
PAM VU0238429.  Ca2+ mobilization assays with M1, M3, and M5 cells were used to obtain compound 
CRCs in the presence of a fixed submaximal (~EC20) concentration of ACh (EC50 values: M5 = 870 nM, 
90% ACh max, M1 = >30 µM, M3 = >30 µM). Data represent the Mean ±S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
 Having completed the optimization strategy outlined in Figure 14 and 
establishing important SAR demonstrating the favorable effect of the southern bi-aryl 
ether on M5 PAM subtype-selectivity with no loss of potency as well as the northern 
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gem-difluoro substitution on both M5 PAM subtype-selectivity and potency, a third 
iteration of parallel synthesis was planned (Fig. 20).  At this point, movement of the 5-
position OCF3 group on the isatin core, introduction of mono or difluorines to the ortho 
position(s) on the southern benzyl ring, and southern 3-position biaryl/heterobiaryl 
extensions were planned in order to further investigate SAR around the M5 PAM scaffold 
(Fig. 20).  Rotation from the 5- to 6-position of the OCF3 moiety was specifically 
investigated due to the fact that no 6-position substitutions were present in the initial 92-
member matrix library around VU0119498.  Impetus for fluorination of the southern 
benzyl ring in the ortho position(s) stemmed from SAR findings with M1 PAMs derived 
from BQCA and from VU0119498 as part of a parallel but separate optimization project 
(discussed in Chapter V), which revealed an increase in PAM potency via fluorination in 
this position.  Finally, biaryl/heterobiaryl extension at the 3-position of the southern 
benzyl ring was sought due to the fact that 3-methoxybenzyl (compound 41 from the 92-
member matrix library) was well tolerated based on its M5 versus M1 PAM potency 
(Table 2) as well as the finding that a piperonyl group (VU0366628, synthesized using 
one-step N-alkylation method as previously described) in the southern region was well-
tolerated for M5 PAM activity (Fig. 21).  Given that the gem-difluoro or ketone of the 3-
position on the core both appear similar in pharmacology, the latter was maintained 
temporarily to increase speed of synthesis (i.e. reduce by one step). 
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fluorination
3-position biaryl/heterobiaryl
Maintain isatin/3-position ketone temporarily
 
Figure 20.  Optimization strategy for third round of M5 PAM library iterations. 
 
 
  
 
Figure 21.  Structure and M5 PAM activity of piperonyl analog VU0366628.  Ca2+ mobilization assays 
with M5 cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) 
concentration of ACh (EC50 values: M5 = 3.2 µM, 87% ACh max). Data represent the Mean ±S.E.M. of at 
least 3 independent experiments with similar results. 
 
 
 Synthesis of mono and di-ortho fluorinated analogs was carried out using the 
same general alkylation conditions described previously with the naked 4-bromobenzyl 
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halide reactant(s) being replaced by the fluorine substituted congeners that were then 
Suzuki coupled with phenyl boronic acid (Fig. 12) to afford the desired products as 
VU0366625 and VU0366626 (Fig. 22).  The p-phenylbenzyl southern moiety was used 
due to better commercial availability of the fluorinated bromobenzyl halide in lieu of the 
corresponding fluorinated methoxybenzyl and also because this moiety (based on 
VU0365114) is comparable if not superior to that of VU0238429.  Both new fluorinated 
analogs were evaluated in CRCs at M5 by Ca2+ mobilization assay in the presence of an 
ACh ~EC20 (Fig. 22).  Remarkably, di-fluorination of the benzyl ring in the ortho 
positions completely abolished M5 PAM activity while mono-fluorination resulted in a 
substantial decrease in both potency and efficacy.  
  
 
 
Figure 22.  Structures and CRCs for ortho-fluorinated M5 PAMs based on VU0365114 lead structure.  
Ca2+ mobilization assays M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh (EC50 values: VU0366625 = 5.9 µM 60% ACh max, 
VU0366626 = >30 µM). Data represent the Mean ±S.E.M. of at least 3 independent experiments with 
similar results. 
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 Fluorine atoms, which are approximately the same size in as hydrogen atoms, 
exhibit partial hydrogen-bond accepting properties, withdraw electron density from 
aromatic rings, and increase lipophilicity (i.e. calculated logP [cLogP]).  One or more of 
these properties carried by these specific fluorinations compromises either binding to M5 
and/or functional PAM activity, although it is difficult to ascertain the exact reason(s) 
underlying this effect given an absence of structural knowledge for the putative allosteric 
site at which this M5 PAM series binds.  Given these SAR data, no subsequent libraries 
were generated with ortho-fluorine substitution(s). 
 Returning temporarily to the biaryl/heterobiaryl extension investigation, we 
simultaneously prepared analogs bearing direct phenyl, 2-thiophene, 3-thiophene, or 
phenoxy substitutions at the meta position of the southern benzyl ring, as outlined in the 
strategy presented in Figure 20.  These analogs were synthesized according to the same 
alkylation procedure described previously using commercially available benzyl halides 
bearing the desired meta-substitutions, thus Suzuki couplings were not necessary.  All of 
these analogs were devoid of M5 PAM activity up to 10 µM and showed only a moderate 
elevation of an ACh ~EC20 at 30 µM in Ca2+ mobilization assays with M5 cells (data not 
shown, N=1).  Based on these results, further derivatizations in the form of alternate 
heterocycles in this meta-benzyl position were not performed. 
 In parallel and again in accordance with the aims of the third round of SAR 
exploration as outlined in Figure 20, 6-OCF3 analogs of VU0365114 and VU0238429 
(the two lead M5 PAMs containing the isatin headpiece) were prepared using the same 
synthetic route described previously, starting in this case with the commercially available 
6-substituted isatin material.  Both compounds were then tested in CRCs at M5 in the 
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presence of an ACh ~EC20 by Ca2+ mobilization assays (Fig. 23).  M5 potency was 
moderately decreased in the case of VU0400267 (5.7 µM) but unchanged in the case 
VU0400266 (2.7 µM); however, efficacy was enhanced, with % ACh max values 
approaching 95-100% for both analogs (Fig. 23).  Interestingly, subtype-selectivity 
eroded (Fig. 23) when these compounds were tested in similar CRC assays at M1-M4.   
 
 
 
Figure 23.  Subtype-selectivity profiles for VU0400266 and VU0400267.  Ca2+ mobilization assays with 
M1-M5 cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) 
concentration of ACh (EC50 values: VU0400266 M5 = 2.7 µM, 95% ACh max, M1-M4 >10 µM; 
VU0400267 M5 = 5.7 µM 98% ACh max, M1-M4 >10 µM). Data represent the Mean ±S.E.M. of at least 3 
independent experiments with similar results. 
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 These SAR clearly suggested that 6-position migration of the OCF3 group was not 
favored going forward, yet it was unknown whether or not the phenoxybenzyl southern 
moiety of earlier analogs could rescue the selectivity of a 6-OCF3 template given that it 
provided a completely M5-selective PAM (VU0400265, Fig. 15).  To test this hypothesis, 
we synthesized a small 2x2 matrix library containing 5-OCF3 and 6-OCF3 substituted 
headpieces with gem-difluorines at the core’s 3-position and each bearing either 3- or 4-
phenxoxybenzyl southern moieties.  The gem-difluoro versions were prepared because 
they too increased subtype-selectivity (although only modestly) and because the 
phenoxybenzyl analog VU0400265 had never been di-fluorinated.  The 3-phenoxybenzyl 
substitutions were made due to the possibility that rotation of the OCF3 from the 5- to 6-
position may no longer be favored with southern para-substitution (e.g. due to rotation of 
the scaffold in the binding site).  Again, synthesis proceeded as described previously 
using N-alkylation conditions on the respective commercially available starting materials 
with the substituted benzyl halides.  These four analogs were tested in CRCs at M5 in the 
presence of an ACh ~EC20 via Ca2+ mobilization assays (Fig. 24).  As expected, the gem-
difluorinated 5-OCF3 headpiece bearing a southern 4-phenoxybenzyl substitution 
(VU0403751) exhibited potent M5 PAM activity with an EC50 of 1.6 µM and a 69% ACh 
max (Fig. 24).  Likewise, the corresponding 6-OCF3 analog (VU0403753) exhibited an 
EC50 of 3.6 µM and an 81% ACh max (Fig. 24).  In contrast, both meta-phenoxybenzyl 
analogs (VU0403752 and VU0403754) were devoid of M5 PAM activity at up to 30 µM 
(Fig. 24), further confirming that the para-position is more optimal for the southern 
benzyl substitutions. 
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Figure 24.  Structures and M5 CRCs for 2x2 matrix library of phenoxybenzyl gem-difluoro analogs.  Ca2+ 
mobilization assays with M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh (EC50 values: VU0403751 = 1.6 µM, 69% ACh max; 
VU0403753 = 3.6 µM, 81% ACh max; VU0403752 = >30 µM; VU0403754 = >30 µM).  Data represent 
the Mean ±S.E.M. of at least 3 independent experiments with similar results. 
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 Next, both VU0403751 and VU0403753 were profiled for subtype-selectivity in 
CRCs at M1 and M3 (Fig. 25), with the former maintaining its high M5-selectivity 
comparable to the parent VU0400265 isatin-based compound and the latter exhibiting an 
increase in M5-selectivity engendered by the gem-difluoro and phenoxybenzyl 
substitutions.  However, because the 6-OCF3 group in VU0403753 still introduced M1 
and M3 potentiation at higher concentrations despite the selectivity-engendering 
substitutions made to its core and southern portions, further optimization did not utilize 
the 6-position of the core headpiece despite its favorable effect on M5 PAM efficacy.   
 
 
Figure 25.  M1, M3, and M5 CRCs for VU0403751 and VU0403753. Ca2+ mobilization assays with M1, M3, 
and M5 cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) 
concentration of ACh (EC50 values: VU0403751 M5 = 1.6 µM, 69% ACh max; VU0403751 M1-M4 >30 
µM; VU0403753 M5 = 3.6 µM, 81% ACh max; VU0403753 M1 and M3 = >10 µM). Data represent the 
Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 
 Having then further established the favorable effect of gem-difluoro substitution 
at the 3-position of the scaffold’s core on M5 PAM potency and subtype-selectivity, the 
VU0403751 and earlier VU0402734 lead analogs bearing gem-difluorines were tested in 
ACh CRC fold-shift experiments by Ca2+ mobilization assays with M5 cells (Fig. 26).  At 
30 µM, these compounds induced approximately 6x and 23x left-shifts of the ACh curve, 
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respectively, with the stronger potentiator VU0402734 inducing moderate intrinsic 
agonist activity (Fig. 26).  These results agreed well with previous SAR from the 
homologous isatin sister analogs of these two compounds and added additional 
confirmation that gem-difluorination conferred increased PAM efficacy. 
 
 
Figure 26.  ACh CRC fold-shift effect of gem-difluoro lead analogs VU0403751 and VU0402734.  Ca2+ 
mobilization assays with M5 cells were used to obtain ACh CRCs in the presence and absence of test 
compounds.  VU0403751 induced an approximately 6x left-shift and VU0402734 induced an 
approximately 23x left-shift with moderate intrinsic agonism at 30 µM.  Data represent the Mean ±S.E.M. 
of at least 3 independent experiments with similar results. 
 
 To be comprehensive and before concluding that only 5-position substitution on 
the core was favorable, we synthesized two tricyclic di-fluoromethyldioxylene analogs, 
which represented hybrids of 5-OCF3 and 6-OCF3 groups in terms of general electronics, 
lipophilicity, and to a lesser extent steric bulk.  These compounds were synthesized using  
one-step alkylation methods utilizing commercial 2,2-difluoro[1,3]dioxolo[4,5-f]indole-
6,7-dione as starting material, again with 4- and 3-phenoxybenzyl halides.  The structures 
and M5 CRCs for these compounds in Ca2+ mobilization assays in the presence of an 
ACh ~EC20 are shown in Figure 27.  Neither compound exhibited robust PAM activity 
and therefore this tricyclic template was abandoned (Fig. 27). 
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Figure 27.  M5 CRCs for tricyclic analogs VU0403897 and VU0403898.  Ca2+ mobilization assays with M5 
cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) concentration of 
ACh (EC50 values: VU0403897 and VU0403898 = >10 µM). Data represent the results of one experiment. 
 
 
 For the fourth iteration of parallel libraries, the western 5-OCF3 group was chosen 
as a point of derivation (Fig. 28).  Although movement of this moiety to the 6-position of 
the core was found to erode subtype-selectivity (despite enhancement of M5 PAM 
efficacy), other substitutions beyond those present in the initial 92-member matrix library 
(5-OCF3, 5-Cl, 5-F, 5-Me) to the 5-position had not been explored.  In particular, alkyl 
extensions of the trifluoro group in the form of an ethoxy or propoxy ether and deletion 
of the trifluoro group altogether via synthesis of the 5-methoxy analog was planned.  
These structures would provide important insight to the significance of the OCF3 group.  
Beyond these three specific changes, we also sought an extensive SAR survey though 
synthesis of a diverse set of benzyl, heteroaryl, alkyl, substituted alkylamine, etc... off of 
a 5-position ether.  Most of these analogs could be accessed synthetically via generation 
of the 5-hydroxy starting material, which would involve methyl-deprotection of a 5-
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methoxy substrate.  In light of this synthetic route, the p-phenylbenzyl moiety of 
VU0365114 was chosen as the southern piece to be held constant for these libraries, since 
its mAChR pharmacology confers it with “lead” status comparable or perhaps greater 
than that of the methoxybenzyl southern moiety in VU0238429, and its use would not 
result in problematic bis-hydroxyl production during the methyl-deprotection step, unlike 
VU0238429.  The synthetic scheme for this set of libraries is presented in Figure 28, and 
a complete list of structures generated is shown in Table 5.  The rationale for the broad 
range of substituents was simply to increase the likelihood of uncovering useful SAR 
since no previous analogs investigated such modification in the western region of this 
general M5 PAM scaffold. 
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a.: R-X, CS2CO3, KI, DMF, 120oC 30 min, (avg. 20%), R = 27 analogs
b.: (1) ethylchloroacetate, CS2CO3, KI, DMF, 120oC 30 min, (16%)
     then (2) LiOH, THF, H2O, 120oC 10 min, (43%)
c.: R-OH, PS-PPh3, DIAD, THF, RT 16 hr, (avg. 4%), R = 10 analogs
d.: 4-(2-chloroethyl)morpholine HCl, NaH, KI, DMF, 55oC 24 hr (4%)
e.: 3-chloromethyl-1-methylpiperidine HCl, CS2CO3, KI, DMF 180oC 30 min, (1%)
f.: 1,1,1-trifluoro2-iodoethane, K2CO3, DMF, 160oC 10 min, (4%)
g.: 2-fluoropyridine, CS2CO3, DMF, 160oC 20 min, (3%)
h.: 2-chloropyridine, K2CO3, DMF, 100oC 30 min, (14%)
(43 total analogs across multiple sub-libraries)
 
Figure 28.  Synthetic scheme for generation of a diverse set of M5 PAM analogs based on VU0365114 
bearing western ethers.  Analogs were synthesized by utilization of eight sub-library/singleton chemistry 
routes (a.-h.) using the 5-hydroxy(N-substituted)isatin starting material following methyl-deprotection. 
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Table 5.  Structures of western ether analog library based on M5 PAM VU0365114.  All analogs were 
devoid of robust M5 PAM activity in 10 µM singlepoint screen (Fig. 29). 
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 Following synthesis and purification, the compounds were evaluated in a 
singlepoint PAM (10 µM) Ca2+ mobilization assay in the presence of an ACh ~EC20 with 
M5 cells (Fig. 29).  Remarkably, all analogs were devoid of any considerable PAM 
activity, suggesting in agreement with all previous SAR that the 5-OCF3 group is 
absolutely required for activity at M5 and even the subtle derivation to trifluoroethoxy in 
this position causes loss of the PAM effects (Fig. 29).  Intriguingly, a subset of analogs in 
this screen induced partial inhibition of the submaximal ACh concentration, which may 
reflect either orthosteric antagonism or possible NAM activity (Fig. 29).  Each of these 
analogs bore basic amines on similarly long alkyl tethers to the oxygen at the 5-position 
of the isatin core, with the three most basic analogs inducing the greatest inhibition (Fig. 
30).  
 
 
Figure 29.  M5 singlepoint screening of western ether analogs (Table 5).  Ca2+ mobilization assays with M5 
cells were used to obtain singlepoint (10 µM) potentiation responses for each analog in the presence of a 
submaximal (~EC20) concentration of ACh. Data represent the Mean ±S.E.M. of at least 3 independent 
experiments with similar results. 
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Figure 30.  Basic-amine containing western ether analogs that partially inhibited an ACh ~EC20 response in 
M5 PAM screen shown in Figure 29, suggesting potential M5 NAM or antagonism.   
 
 
  
 Based on these data, an exploratory optimization project was launched in hopes of 
discovering M5 NAMs or antagonists (of which there are none at present reported in the 
international scientific or patent literature), which has identified a number of additional 
compounds maintaining the western basic alkylamine that exhibit complete inhibition of 
an ACh ~EC80 with upper micromolar-level potency in CRCs using M5 cells by Ca2+ 
mobilization.  Although not a focus of this thesis, this discovery may eventually lead to 
M5-preferring or selective NAMs or antagonists suitable as research tools, which would 
provide invaluable insight to M5 neurobiology across a range of possible studies 
(discussed further in Chapter VI).  However, given the structure of ACh itself, it is 
possible that the basic amines of these putative M5 NAMs/antagonists may be inhibiting 
the ACh response via orthosteric antagonism, especially due to the comparable distance 
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between the nitrogen and the oxygen of the ether.  If orthosteric antagonism does in fact 
underly these data, M5-preference or selectivity may still be achievable due to the 
remainder of the scaffold.  Whether or not such a mechanism for selectivity is present 
with these analogs is currently unknown, as no radioligand binding studies have been 
performed to assess allosteric versus orthosteric modes of modulation. 
 Returning to the M5 PAM SAR revealed by this large library, we opted to 
maintain the 5-OCF3 moiety of the scaffold’s core indefinitely, as it alone appeared to 
provide the M5 potentiation effect.  This extremely flat SAR (around the western area of 
the scaffold) is common with many GPCR allosteric modulators and can be a difficult 
impediment to optimization projects.  In the case of these western ether analogs, a 
number of modifications were explored and importantly the crucial 5-methoxy analog 
(VU0366627), which was synthesized and also tested separately in Ca2+ mobilization 
CRCs at M5 (Fig. 31).  This compound provided a stark example of the narrow steric and 
electronic tolerance(s) of the receptor-binding interaction of the scaffold as this analog 
lacked M5 PAM activity at up to 10 µM with only modest potentiation occurring at 30 
µM (Fig. 31).  Whether the hydrophobic properties of the three fluorines, their electronic 
attenuation of the hydrogen-bond accepting potential of the neighboring oxygen, and/or 
their own partial hydrogen-bond accepting characteristics underlies this tight SAR 
remains unknown. 
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Figure 31.  Synthesis and M5 CRC for 5-methoxy analog VU0366627.  Ca2+ mobilization assays with M5 
cells were used to obtain compound CRC in the presence of a fixed submaximal (~EC20) concentration of 
ACh (EC50 = >10 µM).  Data represent the Mean ±S.E.M. of at least 3 independent experiments with 
similar results. 
 
 
 
 
Ancillary pharmacology and physiochemical optimization of M5 PAMs 
 
 Having investigated a large number of structural modifications to the general 
VU0238429 M5 PAM scaffold across four rounds of targeted libraries and uncovering 
important SAR to obtain a set of optimized lead compounds, we temporarily halted the 
medicinal chemistry efforts and determined ancillary off-target pharmacological activity 
via radioligand binding screens at MDS Pharma/Ricerca.  Both the isatin containing and 
gem-difluoro congeners of the two most potent and most subtype-selective compounds 
(VU0238429, VU0402734, VU0400265, VU0403751, respectively), as well as the 
moderately potent and highly subtype-selective intermediate lead VU0365114 were 
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chosen for testing, which involved N=2 singlepoint (10 µM) screening across 
approximately 75 different GPCRs, ion channels, transporters, nuclear hormone 
receptors, enzymes, and RTKs.  For any off-target binding that resulted in >50% 
inhibition, the protein and % inhibition is reported for each compound in Table 6. 
 
Table 6.  Ancillary/off-target binding screening results for five M5 PAM leads (10 µM). Data represent the 
Mean of 2 independent experiments with similar results.  Experiments performed by MDS Pharma/Ricerca. 
 
N
O
O
OF3C
OMe
VU0238429   
Target/Protein Species % Inhibition 
Adenosine A3 Human 65 
Adrenergic α2A Human 99 
NE Transporter Human 66 
Cannabinoid CB1 Human 84 
Dopamine D4.2 Human 61 
Histamine H1 Human 62 
Histamine H2 Human 55 
Opiate µ Human 70 
hERG K+ Channel Human 60 
 
 
 
Target/Protein Species % Inhibition 
Adenosine A3 Human 68 
Adrenergic α2A Human 98 
NE Transporter Human 71 
Cannabinoid CB1 Human 64 
Dopamine D3 Human 58 
N
O
OF3C
OMe
VU0402734
F F
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Dopamine D4.2 Human 57 
Histamine H1 Human 68 
Histamine H2 Human 59 
Opiate µ Human 73 
hERG K+ Channel Human 65 
PDE-4/Rolipram Rat 60 
Na+ Channel Site-2 Rat 60 
 
N
O
O
OF3C
O
VU0400265  
Target/Protein Species % Inhibition 
Adenosine A1 Human 50 
Adenosine A3 Human 97 
Adrenergic α1A Rat 79 
Adrenergic α1D Human 66 
Adrenergic α2A Human 100 
Adrenergic β1 Human 89 
NE Transporter Human 93 
Bradykinin B1 Human 52 
Ca2+ L-Type Channel Rat 74 
Cannabinoid CB1 Human 109 
Dopamine D1 Human 99 
Dopamine D2S Human 85 
Dopamine D3 Human 79 
DA Transporter Human 90 
GABA Transporter Rat 56 
Histamine H1 Human 99 
Histamine H2 Human 101 
Imidazoline I2 Rat 50 
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F F
 
Target/Protein Species % Inhibition 
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Adenosine A1 Human 55 
Adenosine A2A Human 51 
Adenosine A3 Human 97 
Adrenergic α1A Rat 62 
Adrenergic α1D Human 67 
Adrenergic α2A Human 98 
Adrenergic β1 Human 86 
NE Transporter Human 91 
Bradykinin B1 Human 60 
Ca2+ L-Type Channel Rat 79 
Cannabinoid CB1 Human 106 
Dopamine D1 Human 100 
Dopamine D2S Human 86 
Dopamine D3 Human 76 
DA Transporter Human 86 
GABA Transporter Rat 56 
Histamine H1 Human 93 
Histamine H2 Human 96 
 
N
O
O
O
FF
F
VU0365114  
Target/Protein Species % Inhibition 
Adenosine A3 Human 98 
Adrenergic α1B Rat 51 
Adrenergic α1D Human 70 
Adrenergic α2A Human 99 
Adrenergic β1 Human 86 
NE Transporter Human 86 
Ca2+ L-Type Channel Rat 73 
Cannabinoid CB1 Human 68 
Dopamine D1 Human 104 
Dopamine D2S Human 89 
Dopamine D3 Human 75 
DA Transporter Human 74 
Endothelin ETA Human 92 
Endothelin ETB Human 51 
 
 
181 
Histamine H1 Human 102 
Histamine H2 Human 103 
Leukotriene CysLT1 Human 104 
Muscarinic M1 Human 78 
 
Muscarinic M2 Human 96 
 
Muscarinic M3 Human 62 
 
Opidate κ Human 98 
Opidate µ Human 100 
hERG K+ Channel Human 69 
Prostanoid EP4 Human 72 
Serotonin 5-HT2B Human 67 
Serotonin Transporter Human 64 
 
 
 These ancillary pharmacology data clearly indicated that the southern 
methoxybenzyl moiety (VU0238429 and VU0402734) was favored over the 
phenoxybenzyl (VU0400265 and VU0403751), as the latter introduced a large number of 
off-target activities, including pronounced binding to DAT and multiple DA receptors, 
which would pose serious difficulties in many M5 neurobiology experiments (particularly 
those focused on the VTA, SNc, and/or striatum).  Gem di-fluorination (VU0402734 and 
VU0403751) dialed in modest D3 receptor (58% inhib.), PDE-4 (60% inhib.), and sodium 
channel site-2 (60% inhib.) activity, which did not raise substantial concerns for most 
potential M5 studies.  VU0365114, bearing the highly lipophilic linear bi-phenyl southern 
motif on the 5-OCF3 isatin core, suffered from the highest number of off-target activities. 
 Given these results, further optimization of the southern biaryl ether moiety was 
performed in order to reduce/eliminate its associated off-target activities and further 
explore SAR.  Specifically, introduction of more polar and heteroatomic moieties to the 
southern ether would likely reduce off-target activities that may be due to the increased 
lipophilicity of the distal phenyl ring in VU0400265 and VU0403751 as compared to the 
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methyl group of VU0238429 and VU0402734.  Furthermore, a reduction in the relatively 
high cLogPs of these compounds would likely aid in the overall physiochemical and 
drug-like properties of the scaffold, particularly if introducing basic amines to allow HCl 
salt formation is tolerated. 
 To this end, we replaced the distal phenyl ring with various 5- or 6-member naked 
or mono-substituted heterocyclic rings while holding constant the remainder of the M5 
PAM scaffold.  Due to the challenging synthesis of these analogs (Fig. 32), which 
required derivatization at the first rather than the last step as well as laborious reaction 
conditions and purifications, only four compounds were generated to explore this SAR 
(Fig. 32). 
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Figure 32.  Synthesis of four southern heterobiaryl ether analogs based on VU0400265. 
 
 These four southern heterobiaryl ether analogs were then evaluated in CRCs at M5 
in the presence of an ACh ~EC20 by Ca2+ mobilization assay and exhibited PAM activity 
with comparable potency (1.5 µM to 3.2 µM) to the phenoxybenzyl analog VU0400265 
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(Fig. 33).  These compounds proved advantageous given our goal of improving the 
physiochemical properties of VU0400265 (cLogP = 5.8, true logP = 4.6) as lipophilicity 
was decreased approximately by a full order of magnitude (cLogPs = 4.1-5.1) and the 
presence of a basic amine afforded HCl salt formation.  However, their efficacies (46-
62% ACh max) were moderately lower than that of the parent VU0400265 (75% ACh 
max) compound (Fig. 33).   
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Figure 33.  Structures, lipophilicities, and M5 potency/efficacy for four heterobiaryl ether M5 PAMs.  Ca2+ 
mobilization assays with M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh.  Data represent the Mean of at least 3 independent experiments 
with similar results. 
 
 
 The fluoropyridine ether analog VU0414747 was selected as the most potent and 
efficacious compound from this small 4-member library for evaluation in ACh CRC fold-
shift assays (Fig. 34).  At 30 µM, VU0414747 induced a modest 6x left-shift of the ACh 
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CRC and was devoid of intrinsic agonism, similar to the parent VU0400265 (Fig. 34).  
Although this degree of maximal potentiation is significant, previous analogs bearing 
straight biaryl/heterobiaryl southern motifs (i.e. without the ether linkage, such as 
VU0365114) exhibited much broader fold-shift values and %ACh max responses at 30 
µM (Fig. 13).   
 
 
Figure 34.  M5 ACh CRC foldshift assay with analog VU0414747. Ca2+ mobilization assays with M5 cells 
were used to obtain ACh CRCs in the presence and absence of test compound (6x left-shift).  Data 
represent the Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 
 Therefore we returned to the straight biaryl/heterobiaryl southern scaffold and 
likewise explored introduction of basic amines in the form of un-substituted pyridines in 
the proximal and/or distal locations of the linear southern motif (Fig. 35).  In order to 
survey multiple combinations of regio-isomeric pyridines, a matrix-like library approach 
was utilized for this synthesis (Fig. 35).  Standard N-alkyation conditions provided the 
para –Cl or –Br intermediates, which were then subjected to Suzuki-couplings with the 
various heterocyclic boronic acids to afford the final products (Fig. 35).  A similar route 
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was utilized to obtain VU0415485 as a singleton, which contained a distal 3,5-pyrimidyl 
para substitution off of a proximal benzyl ring (Fig. 35).  The final compounds (as well 
as the Cl-bearing intermediate VU0414754) were then profiled in M5 CRCs in the 
presence of an ACh ~EC20 by Ca2+ mobilization assay to obtain potency and efficacy data 
(Fig. 35). 
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Compound Y, Z R M5 EC50, ACh max 
VU0415483 CH, CH 3-pyridyl 1.6 µM, 51% 
VU0415484 CH, CH 4-pyridyl 2.8 µM, 60% 
VU0415485 CH, CH 3,5-pyrimidyl 2.1 µM, 53% 
VU0414754 CH, N Cl 2.4 µM, 80% 
VU0415478 CH, N phenyl 3.8 µM, 76% 
VU0415479 CH, N 3-pyridyl 4.0 µM, 53% 
VU0415480 CH, N 4-pyridyl 4.4 µM, 50% 
VU0415481 N, CH phenyl 3.1 µM, 47% 
VU0415487 N, CH 3-pyridyl >30 µM, n/a 
VU0415482 N, CH 4-pyridyl >30 µM, n/a 
 
Figure 35.  Synthesis and SAR for southern heterobiaryl amine-containing M5 PAM analogs. Reagents and 
conditions: (a) 4-bromobenzyl bromide, K2CO3, KI, DMF, rt, 48 h (99%), OR 5-bromo-2-(bromomethyl) 
pyridine OR 5-(bromomethyl)2-chloropyridine, K2CO3, KI, DMF, rt, 48 h (98%); (b) Het-B(OH)2, 5 mol % 
Pd(PPh3)4, 1.0 M aq. Cs2CO3, THF, mw, 120 oC, 20 min (5-18%).  Ca2+ mobilization assays with M5 cells 
were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20) concentration of ACh.  
Data represent the Mean of at least 3 independent experiments with similar results. 
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 This effort produced a number of moderately-highly potent M5 PAM compounds 
with a wide range of efficacies (Fig. 35).  Importantly, these SAR data suggested that 3-
pyridyl in the proximal ring location was uniformly favored over 2-pyridyl in the same 
position, as the former exhibited compounds with the best balance of potency/efficacy (of 
this library) while the latter was virtually inactive regardless of the distal ring substitution 
present (Fig. 35).  This provided success similar to that of the heterobiaryl ether analog 
library in that M5 PAM potency/efficacy was generally retained while cLogP values were 
simultaneously reduced by 1-1.5 orders of magnitude (true logP for VU0415478 = 3.6), 
and likewise providing the ability to formulate HCl salts. 
 Furthermore, the p-phenyl substituted 3-pyridyl analog VU0415478 exhibited a 
robust 14x left-shift of an M5 ACh CRC at 30 µM in Ca2+ mobilization assays and 
displayed modest intrinsic agonist activity, which agreed well with previous SAR 
suggesting that a linear biaryl/heterobiaryl southern moiety confers greater ACh CRC 
fold-shift (and associated % ACh max values in CRC assays) than related analogs 
containing a biaryl/heterobiaryl ether (Fig. 36). 
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Figure 36.  M5 ACh CRC fold-shift assay with analog VU0415478. Ca2+ mobilization assays with M5 cells 
were used to obtain ACh CRCs in the presence and absence of test compound (14x left-shift).  Data 
represent the Mean ±S.E.M. of at least 3 independent experiments with similar results. 
 
 In light of the well-tolerated 3-pyridyl replacement for the southern benzyl ring, 
which increased polarity and thereby decreased lipophilicity for the heterobiaryl sub-
series of compounds, we hypothesized that this nitrogen substitution would be similarly 
tolerated in the original M5 PAM lead VU0238429 structure bearing a southern p-
methoxy moiety.  Thus the 3-pyridyl congener was synthesized via one-step standard 
microwave alkylation conditions with the commercially available chloromethyl-
methoxypyridine and with the 5-trifluromethoxyisatin starting material as previously 
described, although the final yield (4%) was very low due to poor recovery from reverse-
phase HPLC purification (i.e. not due to poor % conversion of starting material to 
product) (Fig. 37).  This compound (VU0415486) exhibited 3.2 µM M5 potency and 47% 
ACh max efficacy in CRC assays using Ca2+ mobilization (Fig. 37).  Due to the relatively 
low efficacy, VU0415486 was not further characterized in the form of ACh CRC fold-
shift or subtype-selectivity assays was not performed. 
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Figure 37.  Synthesis and M5 potency/efficacy of VU0415486, the 3-pyridyl congener of VU0238429. 
Ca2+ mobilization assays with M5 cells were used to obtain compound CRCs in the presence of a fixed 
submaximal (~EC20) concentration of ACh.  Data represent the Mean of at least 3 independent experiments 
with similar results. 
 
 
 Finally, to more comprehensively explore SAR in the southern region of the M5 
PAM scaffold for the purpose of identifying additional compounds with improved 
physiochemical properties and reduced ancillary/off-target activities, we synthesized a 
small library of analogs bearing either acidic or basic moieties at R shown in Figure 38, 
as well as the de-methylated phenol congener of the original p-methoxybenzyl motif.  For 
each of these analogs, the gem-difluorinated core was used for reasons of convenience 
related to starting material availability at the time.  Starting with the methoxybenzyl-
bearing VU0402734, methyl de-protection afforded the phenol (VU0414750), which was 
used as starting material for subsequent O-alkylations (detailed conditions described in 
Chapter II) with the corresponding alkyl halides to obtain the three compounds of Figure 
38.  Each analog was profiled in M5 CRCs with an ACh ~EC20 by Ca2+ mobilization 
assays (Fig. 38).  However, the ethylpyrrolidine (VU0414751) exhibited a fully 
efficacious (~100% ACh max) agonist effect at 30 µM despite absence of any 
potentiation of the ACh ~EC20, which suggests possible orthosteric agonism that may be 
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conferred by the ACh-like structure of this particular motif (i.e. basic amine with ethyl 
tether to oxygen).  By contrast, the morpholine (VU0414752) and carboxylic acid 
(VU0414753) analogs lacked both agonism and PAM activity.  Interestingly, the phenol 
(VU0414750) exhibited concentration-dependent inhibition of the ACh ~EC20, 
suggesting potential NAM or antagonist activity. 
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Figure 38.  Structures and M5 potency/efficacy of acidic and basic moieties in the distal southern region of 
the M5 PAM scaffold. Ca2+ mobilization assays with M5 cells were used to obtain compound CRCs in the 
presence of a fixed submaximal (~EC20) concentration of ACh.  Data represent the Mean of at least 3 
independent experiments with similar results. 
 
 
 In order to further investigate the potential NAM activity of VU0414750, similar 
CRC assays were performed using Ca2+ mobilization with M5 cells in the presence of an 
~EC50 and ~EC80 of ACh (Fig. 39).  These experiments revealed similar concentration-
dependent inhibition of the ACh response, which is consistent but not necessarily 
suggestive of true NAM activity for this phenol compound.  Due to the greater focus on 
optimizing M5 PAMs, further examination of this compound in radioligand-binding or 
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other assays was not performed.  However, given these present data and in light of the 
compound’s structure, VU0414750 may represent the first M5 NAM.   
 
 
Figure 39.  M5 ACh inhibition CRCs for VU0414750, a potential M5 NAM.  Ca2+ mobilization assays with 
M5 cells were used to obtain compound CRCs in the presence of a fixed submaximal (~EC20, ~EC50, and 
~EC80) concentrations of ACh.  Data represent the Mean ±S.E.M. or results of 1-3 experiments. 
 
 
 The switch in VU0414750 from methoxy to hydroxy at the para benzylic position 
is relatively modest; however, a growing number of “molecular switches” that confer 
dramatic changes to the pharmacological mode of modulation of a given scaffold have 
appeared in recent GPCR allosteric modulator medicinal chemistry literature133,134.  
Given that the methoxy moiety possesses hydrogen-bond accepting properties while the 
phenol is a hydrogen-bond donor, it is possible that hydrogen-bond mediated attraction or 
repulsion of a key residue/motif in the M5 receptor allosteric binding site is responsible 
for switching this PAM scaffold into a NAM scaffold.  This hypothesis will require 
further experimental exploration, as discussed in more detail in Chapter VI. 
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 Having thus surveyed a wide range of modifications to the southern region of the 
M5 PAM scaffold with the aim of decreasing lipophilicity/cLogP while simultaneously 
maintaining potency, efficacy, and subtype-selectivity, we re-assessed ancillary off-target 
activity for VU0414747 and VU0415478.  These were chosen because they represented 
the most potent and efficacious compounds with reduced cLogP values from the most 
recently discussed heterobiaryl ether and straight heterobiaryl libraries, respectively.  
Unfortunately, in the same assays described previously for ancillary pharmacology 
screening (performed by MDS Pharma/Ricerca, Table 6), which used a large panel of 
off-targets in competition binding at 10 µM, both compounds exhibited a wide range of 
activities (Table 7). 
 
Table 7.  Ancillary/off-target binding screening results for physiochemically-optimized M5 PAMs 
VU0414747 and VU0415478 (10 µM). Data represent the Mean of 2 independent experiments with similar 
results.  Experiments performed by MDS Pharma/Ricerca. 
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VU0414747  
Target/Protein Species % Inhibition 
Adenosine A3 Human 75 
Adrenergic α1D Human 61 
Adrenergic α2A Human 101 
Adrenergic β1 Human 70 
NE Transporter Human 106 
Ca2+ L-Type Channel Rat 68 
Cannabinoid CB1 Human 93 
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Dopamine D1 Human 89 
Dopamine D2S Human 58 
Dopamine D3 Human 78 
Dopamine D4.2 Human 53 
Endothelin ETA Human 79 
Histamine H1 Human 100 
Histamine H2 Human 96 
Leukotriene CysLT1 Human 99 
Muscarinic M1 Human 51 
 
Muscarinic M2 Human 75 
 
Tachykinin NK1 Human -72 
Opiate κ Human 61 
Opidate µ Human 91 
hERG K+ Channel Human 69 
Serotonin 5-HT2B Human 56 
Na+ Channel Site-2 Rat 64 
 
N
O
O
O
FF
F
N
VU0415478  
Target/Protein Species % Inhibition 
Adenosine A3 Human 73 
Adrenergic α1D Human 76 
Adrenergic α2A Human 97 
Adrenergic β1 Human 59 
NE Transporter Human 106 
Bradykinin B2 Human -53 
Ca2+ L-Type Channel Rat 56 
Cannabinoid CB1 Human 70 
Dopamine D1 Human 88 
Dopamine D2S Human 66 
Dopamine D3 Human 87 
Endothelin ETA Human 79 
GABA Transporter Rat 57 
Histamine H1 Human 88 
Histamine H2 Human 92 
Leukotriene CysLT1 Human 86 
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Muscarinic M2 Human 78 
 
Opidate µ Human 90 
hERG K+ Channel Human 63 
Na+ Channel Site-2 Rat 51 
 
 
 Despite the substantially reduced cLogP values for these analogs versus earlier 
leads within the series, broad off-target activity was observed (Table 7), which suggests, 
in light of the previous ancillary pharmacology SAR shown in Table 6, that the southern 
heterobiaryl moiety (with or without an internal ether linkage) engenders promiscuous 
off-target binding.  These results, and the dopamine D1 and D2 receptor binding in 
particular, were surprising and present an impediment to utilization of these two 
advanced lead compounds in M5-related neurobiology studies.  Nonetheless, both 
compounds (VU0414747 and VU0415478) and their parent libraries revealed useful SAR 
and may serve as starting points for a more exhaustive optimization effort to survey a 
larger range of heterobiaryl and heterobiaryl substitutions that may be devoid of some or 
ideally all of these off-target liabilities (discussed in more detail in Chapter VI). 
 
In vitro characterization of M5 PAMs at rat M5 receptor 
 
 For all in vitro M5 assays performed throughout this optimization, cell lines 
expressing the human receptor were used.  Because species-specific differences in PAM 
activity have been found with other mAChR allosteric modulators (e.g. M4 PAMs 
described in Chapter III)126, and because future M5 electrophysiology experiments and in 
vivo studies will be performed using rats, we determined the effect of early lead 
compound VU0238429 at the rat M5 receptor.  Increasing fixed concentrations of 
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VU0238429 resulted in concentration-dependent left-shifting of an ACh CRC in rM5 
cells by Ca2+ mobilization assay (Fig. 40), with a maximum fold-shift of approximately 
30x at the top concentration (30 µM).   
 
 
Figure 40.  Rat M5 ACh CRC fold-shift assay with early lead compound VU0238429.  Ca2+ mobilization 
was used to obtain CRCs of ACh in the absence and presence of increasing fixed concentrations of test 
compound (30 µM maximum fold-shift = 30x).  Data represent Mean +/-SEM from at least three 
independent determinations.  Experiments performed by Dan Foster. 
 
 These data suggest that this novel series of M5 PAMs is not only active at the rat 
M5 receptor but may also be more efficacious, as the maximum fold-shift observed for 
VU0238429 at hM5 was 14x.  Further examination of VU0238429 and other lead 
compounds in rM5 assays, including CRCs to determine potencies, will be required to 
confirm this possibility.  Likewise, subtype-selectivity across all rat mAChRs will be 
important to confirm prior to initiation of neurobiology experiments.  Nonetheless, it was 
gratifying to find that VU0238429 was active in this rM5 PAM experiment.   
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 It is possible that differences in receptor expression/reserve between our rat and 
human mAChR cell lines could influence the relative activity of a given PAM, resulting 
in an illusory greater or lesser activity.  In the case of our findings with VU0238429 at 
rM5 and hM5, it is unlikely that differences in receptor expression/reserve between cell 
lines have confounded the data interpretation for several reasons.  First, Ca2+ mobilization 
readouts under the assay conditions used with our mAChR CHO cells, which have been 
generated using identical stable transfection techniques, are typically less sensitive to 
such effects because receptor expression is extremely high (i.e. large reserve) across each 
cell line.  Correspondingly, the potency of ACh in parallel CRC assays using rat versus 
human M5 cells is essentially identical (0.5-3 nM ACh EC50 for both), which further 
supports the hypothesis that the larger ACh CRC fold-shift observed at rM5 reflects truly 
comparable or perhaps greater PAM efficacy at the rat versus human receptor. 
 
 
 
Summary 
 
 In summary, this first and presently only class of highly subtype-selective M5 
positive allosteric modulators was discovered from the optimization of an M1 PAM HTS 
hit (VU0119498).  A large matrix-analog library was generated around VU0119498, 
which quickly provided SAR that conferred M5-preference.  This led to discovery of an 
early lead compound, VU0238429, which displayed approximately 1 µM M5 PAM 
potency with >30x subtype-selectivity versus M1-M4 by in vitro Ca2+ mobilization assay.  
This compound was found to potentiate ACh activation of M5 via allosteric enhancement 
of agonist affinity in radioligand binding studies using M5 cell membranes and induced 
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an approximately 14x left-shift of an ACh CRC in M5 cells by Ca2+ mobilization.  
However, VU0238429 possessed relatively poor in vivo PK properties and required 
further optimization to confer more drug-like characteristics.  Ultimately, a number of 
subsequent lead compounds were discovered, which maintained low micromolar to sub-
micromolar M5 potency and high subtype-selectivity but with improved DMPK and 
physiochemical properties.  However, problematic ancillary off-target binding for many 
of these compounds will require that future neurobiological experiments be carefully 
planned and controlled (such as evaluation of the M5 PAM alone in the absence of 
agonist).  In initial experiments using the rat M5 receptor, this series of PAMs retained 
equal or possibly greater ACh CRC fold-shift efficacy than at human M5, suggesting that 
these compounds are suitable for future rat neurobiology studies as they do not exhibit an 
undesirably loss of activity between the two species. 
 At present, these novel compounds represent the only tools available to the 
mAChR research field to pharmacologically investigate the role(s) of selective M5 
activation in native/WT neurobiological systems.  Furthermore, this optimization effort 
represents part of the unprecedented finding that selective M5 or M1 (as discussed in 
Chapter III) PAM activity can be engendered via structural modification of the same lead 
compound displaying multiple mAChR PAM activities (VU0119498).  Future 
experiments and potential optimization efforts are presented in detail in Chapter VI. 
 
 
 
 
 
 
197 
Chapter V 
 
DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF  
NOVEL SUBTYPE-SELECTIVE MACHR1 LIGANDS 
 
 
 
M1 PAMs derived from VU0119498 
 
 Based on the successful discovery of numerous M5-preferring and selective PAMs 
from SAR exploration and optimization of the M1/M3/M5 PAM HTS hit VU0119498 
(Chapter IV), we hypothesized that this N-benzyl isatin scaffold could likewise be used as 
a starting point for discovery of novel M1-preferring or selective PAMs135.  The broad 
SAR observed, for example in the initial 92-member matrix library, which explored the 
effect of various simple substitutions to the isatin core and southern benzyl moiety, as 
well as the structural similarity between VU0119498 and the Merck M1 PAM series 
based on BQCA (discussed later in this Chapter), provided further rationale for this 
hypothesis. 
 Our initial optimization strategy is outlined in Figure 1, and as SAR with 
allosteric ligands is often shallow, we employed an iterative parallel synthesis approach.  
From our M5 PAM optimization work where we often counter-screened on M1, we 
quickly learned that most substitutions (with the exception of 5-OCF3) on the isatin ring 
led to either loss of activity or pan-mAChR activation profiles with various degrees of 
potency, efficacy, and subtype-selectivity (Chapter IV).  Thus, our first libraries 
employed a naked isatin core and surveyed diversity on the southern benzyl moiety.  
Modification of chain length from benzyl to phenethyl linkage as well as 
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biaryl/heterobiaryl extension in the para position was performed based primarily on SAR 
findings from the M5 PAM series (Chapter IV). 
 
 
Figure 1.  Initial optimization strategy for VU0119498 aimed at discovering modifications that engender 
increased M1 PAM activity and subtype-selectivity. 
 
 
 Libraries were prepared according to the scheme shown in Figure 2, wherein 
commercial indoline-2,3-dione (compound 7) was alkylated with p-bromobenzylbromide 
to deliver key intermediate (compound 8).  A 10-member Suzuki library was then 
prepared to explore the effect of introduction of biaryl and heterobiaryl motifs into 
VU0119498 providing analogs (compounds 9).  In parallel, the isatin starting material 
(compound 7) was also alkylated with functionalized phenethyl bromides (compounds 
10) to probe the effect of chain homologation (compound 11). 
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Figure 2. Synthesis of initial biaryl/heterobiaryl library based on VU0119498.  Reagents and conditions: a) 
p-bromobenzylbromide, K2CO3, KI, ACN, rt, 16 h (97%); b) RB(OH)2, Pd(Pt-Bu3)2, Cs2CO3, THF:H2O, 
mw, 120oC, 20 min (15-90%); c) K2CO3, KI, ACN, rt, 16 h (50-90%).  B(OH)2 reactants used to generate 
10-member parallel library in b): 2,5-difluorophenyl, 6-fluoropyridin-3-yl, 4-methoxyphenyl, pyrazole, N-
methylpyrazole, 3,4-dichlorphenyl, 2-methoxyphenyl, 6-chloropyridin-3-yl, 4-propoxypheyl, and 4-
chlorophenyl.  Br-ethyl-Ar reactants used in c): 4-methoxyphenyl and 4-bromophenyl. 
 
 
 This 12-member (total) library was then triaged by a singlepoint (10 µM) screen 
that examined the compounds’ ability to potentiate an ~EC20 concentration of ACh by 
Ca2+ mobilization assay with M1 and M5 CHO cells (Fig. 3).  Only one analog 
(VU0365137, compound 9a) demonstrated robust M1 versus M5 potentiation.  All other 
analogs exhibited weak M1 potentiation and/or comparable activity at M5, with the 
exception of VU0365110 (the 2,5-difluorophenyl congener), which exhibited robust dual 
M1/M5 activity.  In follow-up CRC assays at M1, M3, and M5, VU0365137 (compound 
9a), which possessed an N-methylpyrazole in the 4-position of the southern benzyl ring, 
displayed an M1 EC50 of 2.3 µM, and high selectivity versus M3 and M5 (Fig. 4).  
Moreover, this analog afforded a ~5-x left-shift of the M1 ACh CRC at 10 µM, and a 
larger ~14x left-shift at 30 µM, with ~30% intrinsic allosteric agonism by Ca2+ 
mobilization assay.   
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Figure 3.  Singlepoint (10 µM) M1/M5 screen of initial 12-member biaryl/heterobiaryl and phenethyl 
analog library based on VU0119498.  Ca2+ mobilization assays were performed to obtain % ACh max 
values induced by each test compound in the presence of an ACh ~EC20 with M1 (top panel) and M5 
(bottom panel) CHO cells.  Data represent Means +/- SEM from at least three independent determinations. 
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Figure 4.  A) Structure and PAM activity of VU0365137; B) CRCs for VU0365137 in the presence of a 
ACh ~EC20 at M1, M3 and M5; C) ACh CRC fold-shift assay at M5 with 10 µM and 30 µM VU0365137, 
providing an ~5x and ~14x left-shift, respectively.  Data represent means of at least three independent 
determinations with similar results using mobilization of intracellular calcium in M1, M3, or M5 CHO cells. 
 
 
 Intriguingly, the 5-OCF3 congener of VU0365137 (compound 9a) was an 
equipotent M5-preferring PAM (as reported in Chapter IV), highlighting the  ‘molecular 
switch’ to engender M5 preference.  Despite this shallow SAR, it was exciting to see that 
we could rapidly obtain an M1-preferring PAM from our initial M1, M3, M5 PAM lead via 
this small analog library. 
 We next incorporated subtle changes, in the form of fluorine atoms, to the lead 
VU0365137 scaffold.  The rationale for these modifications stemmed in part from SAR 
around the Merck M1 PAM BQCA series, which demonstrated that mono- or di-fluoro 
substitution in the ortho positions(s) of the southern benzyl ring and/or on the western 
aryl ring of the core headpiece conferred increased potency/efficacy (discussed later in 
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this chapter).  Following the synthetic route outlined previously in Figure 2, analogs with 
fluorine on both the isatin core and the southern benzyl ring were readily prepared and 
evaluated for their ability to potentiate an ~EC20 of ACh at M1 via Ca2+ mobilization.  
 This SAR revealed that fluorine substitution was well tolerated on both the isatin 
core (4,7-difluoro or 7-fluoro) and on the benzyl ring (2-fluoro and 2,6-difluoro), as 
shown in Table 1.   The addition of a single fluorine atom to the 2-position of the benzyl 
ring delivered VU0366369 with an M1 EC50 of 830 nM (65% ACh max) – comparable to 
BQCA (M1 EC50 = 845 nM) and advantageously without the problematic carboxylic acid 
moiety (Table 1).  This single change caused an approximately 3-fold increase in potency 
over VU0365137.  A 2,6-difluorobenzyl congener (VU0366368) provided equivalent M1 
potency with a slightly diminished ACh max response (60%), as shown in Table 1.  
However, as fluorine content increased (compounds 12c-12e; fluoro-substitutions on both 
the isatin core and benzyl ring) ACh max values decreased (40-55%) despite retention of 
comparable potencies (Table 1). 
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Table 1.  SAR of fluorine-bearing analogs of lead compound VU0365137.  Ca2+ mobilization assays were 
used to obtain CRCs for each analog in M1 cells in the presence of an ACh ~EC20.  Data represent Mean 
values from at least three independent determinations. 
 
 
 
 Gratifyingly, VU0366369 was found to be a highly selective M1 PAM, with 
minimal/no activation of M2-M5 up to 30 µM (Fig. 5a-b).   However, in M1 ACh CRC 
fold-shift experiments, this compound as well as the di-fluoro congener (compound 12b) 
displayed only a subtle effect, increasing the potency of ACh by only 3x and 2x 
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respectively, at 30 µM (Fig. 5c).  Lack of correlation between PAM potency and fold-
shift is commonly observed within series of mAChR allosteric modulators and 
underscores the importance of determining both parameters when establishing SAR.  
 
 
 
Figure 5. A) and B) CRCs for VU0366368 (compound 12b) and VU0366369 (compound 12a) in the 
presence of a ACh ~EC20 at M1, M2/Gqi5, M3, M4/Gqi5 and M5; C) M1 ACh CRC fold-shift assay with 30 
µM of VU0366369 and VU0366368, providing an approximately 3- and 2-fold-shift, respectively.  Data 
represent Mean of at least two independent determinations with similar results using mobilization of 
intracellular calcium in M1, M2/Gqi5, M3, M4/Gqi5 and M5 CHO cells. 
 
 
 
205 
  Thus, optimization of the M1, M3, M5 PAM HTS hit VU0119498, which 
previously led to the discovery of the first selective M5 PAM (VU0400265), provided 
VU0366369, a highly selective and potent M1 PAM, which represented only the second 
known M1 PAM chemotype; however, it has modest efficacy.  Furthermore, the ability to 
dial in or out M1 and M5 PAM activity within a single scaffold is unprecedented.   
 Interestingly, gem-difluorination of the 3-position on the isatin core within this 
series of M1 PAMs resulted in substantially reduced potency and efficacy (data not 
shown), in stark contrast with the increased potency, efficacy, and subtype-selectivity 
conferred by this modification in the related M5 PAM series (Chapter IV).  However, 
replacement of the naked isatin core with a homologous cyclic carbamate ring system 
within the original VU0365137 M1 PAM lead scaffold using the same alkylation 
conditions shown in Figure 2 provided VU0366367.  In Ca2+ mobilization CRC 
experiments at M1 in the presence of an ACh ~EC20, this analog exhibited similar 
potency and efficacy as the isatin-bearing parent, with an EC50 of 1.4 µM and 65% ACh 
max response (Fig. 6).  This is a highly desirable modification to the scaffold as the 
cyclic carbamate core is more drug-like and does not carry the DMPK-related liabilities 
of the isatin core.  Further optimization of this cyclic carbamate series in the form of 
additional southern biaryl/heterobiaryl substitutions is currently underway; however, 
early data suggest that SAR around this series is relatively flat and no subtype-selectivity 
is known. 
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Figure 6.  Structure and M1 PAM CRC for VU03663657.  Ca2+ mobilization assays were performed to 
obtain a CRC of VU0366367 in the presence of an ACh ~EC20 with M1 cells.  Data represent Means +/- 
SEM from at least three independent determinations. 
 
 
M1 PAMs VU0028767 and VU0090157 
 
 As in Chapter IV, other novel M1 PAMs such as VU0028767 and VU0090157 
were identified by same HTS that identified VU0119498 (Fig. 7)27.  Optimization of 
these compounds was of lesser priority and a limited investigation into SAR around these 
two hits found extremely shallow SAR.  Any change to the VU0028767 structure resulted 
in a complete loss of M1 PAM activity (data not shown), and resynthesis of the hit itself 
following HTS identification produced spurious results that may have been due to 
chemical instability of the structure (Fig. 7).  For these reasons, further attempts at 
VU0028767 optimization were not pursued.  In a similar vein, SAR revealed by a series 
of VU0090157 analogs was quite flat; however, replacement of the nitro group on 
VU0090157 with bromine was tolerated for M1 PAM activity, as was deletion of the 
southern N-methyl moiety (data not shown).  
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Figure 7.  SAR summary for M1 PAM HTS hits VU0029767 and VU0090157. 
 
 Any changes to the eastern ester side-chain in the form of alternative linear alkyl 
(e.g. ethyl, propyl, etc…) or cyclo alkyl (e.g. cyclobutyl, cyclohexyl, etc…) substituents 
resulted in complete loss of M1 PAM activity (data not shown).  Likewise a more 
exhaustive exploration of replacements for the nitro-piperonyl headpiece in the form a 
diverse 17-member library revealed that modification to this northern region 
compromises M1 PAM activity (Fig. 8, Fig. 9). 
 
 
Figure 8.  Singlepoint (10 µM) M1 PAM screen of VU0090157 analogs bearing diverse northern 
substitutions.  Ca2+ mobilization assays with M1 cells were used to obtain % ACh max values for each 
compound in the presence of an ACh ~EC20.  Parent hit compound included as positive control.  Data 
represent Mean +/- SEM from at least three independent determinations. 
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Figure 9.  Structures of VU0090157 analogs generated to explore SAR at the northern headpiece. 
 
 
M1 PAM BQCA and analogs 
 
 Concomitant with discovery of the novel and diverse M1 PAM scaffolds from the 
VU HTS campaign and the subsequent optimization of the VU0119898 to obtain the 
series of M1 PAMs (e.g. VU0365137 and VU0366369), Merck disclosed a series of novel 
M1 PAMs based on a substituted benzyl quinolone carboxylic acid template136.  The main 
exemplified compound bore a p-methoxybenzyl substitution on the naked quinolone 
carboxylic acid core and was subsequently termed BQCA137.  This compound was 
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reported to exhibit robust PAM activity at human M1 with an EC50 of 845 nM and a 50% 
ACh max intrinsic agonist activity at 100 µM in Ca2+ mobilization assays performed in 
the presence of a fixed ACh ~EC20137.  In similar assays with human M1 cells, BQCA was 
reported to induce a 130x left-shift of an ACh CRC at 100 µM137.  However, GPCR 
PAMs can display species specificity (as exemplified in the case of the M4 PAM series 
discussed in Chapter III), and the activity of BQCA at the rat M1 receptor were not 
initially reported.  As discussed in the Introduction (Chapter I), a lack of truly-subtype 
selective M1 activators with drug-like properties has precluded in vivo investigations into 
the role M1 in both basic neurobiology and in the context of various CNS disorders such 
as Alzheimer’s disease and schizophrenia.  Therefore, attainment of an M1 PAM suitable 
as an in vivo tool for use in basic and pre-clinical rodent studies would provide a major 
advancement to the field. 
 Thus, in order to determine whether BQCA and/or related compounds have 
properties needed for use in rodent studies, we resynthesized BQCA and a panel of 20 
analogs to identify selective PAMs for the rat M1 receptor138.  Three libraries were 
generated each consisting of seven compounds possessing the same N-benzyl 
substitutions on either an 8-fluorinated quinolone carboxylic acid (compounds Ia-Ig), a 
quinolone carboxylic acid (compounds IIa-IIg, including BQCA), or a 5,8-difluorinated 
quinolone carboxylic acid (compounds IIIa-IIIg) template, respectively (Fig. 10). 
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Figure 10. Synthesis and screening of BQCA and BQCA analogs at rat M1. a.) reagents and conditions: a. 
K2CO3, KI, R-Br, DMF, 24 hr. at  r.t., b. LiOH, 9:1 THF:H2O 10 min. 120 °C µwave.  Ca2+ mobilization 
assays with rat M1 cells were used to obtain singlepoint % ACh max values for each compound at b.) 10 
µM, c.) 1 µM, or d.) 0.3 µM in the presence of an ACh ~EC20.  Four compounds, denoted by an asterisk 
(*), were selected for further evaluation based on their structural diversity and efficacy at 0.3 µM.  Data 
represent the mean ± S.E.M. of 3 independent determinations.  Experiments performed by A. Brady. 
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 The activity of BQCA and related compounds was evaluated by measuring effects 
on Ca2+ mobilization of each compound at 10, 1, or 0.3 µM (Fig. 10b-d) prior to the 
addition of an ~EC20 concentration of ACh.  From the panel, four compounds (one of 
which was parent BQCA) that exhibited robust potentiator activity at 0.3 µM were 
selected for further evaluation based on their structural diversity (Fig. 10d).  All four 
compounds had similar potencies at the rM1 receptor, with EC50 values in the 200-400 
nM range as determined by CRCs of each compound in the presence of an ACh ~EC20 by 
Ca2+ mobilization assay (Fig. 11a).  Each of these four compounds elicited a robust 
increase in ACh potency at rat M1, as manifest by 10-23x left-shifts of an ACh CRC 
when applied at 3 µM in Ca2+ mobilization assays (Fig. 11b) 
 
 
Figure 11. a) CRCs of BQCA and three analogs in the presence of an ACh ~EC20 at rat M1 in Ca2+ 
mobilization assays (EC50 values: VU0238389 = 187 ± 39 nM; VU0238393 = 404 ± 59 nM; BQCA = 316 
± 102 nM; and VU0238387 = 284 ± 32 nM.  b.) Ca2+ mobilization was used to obtain ACh CRCs in the 
absence and presence of each compound at 3 µM (fold-shifts: VU0238389 = 23x, VU0238393 = 10x, 
BQCA = 16x, and VU0238387 = 19x).  Data represent the Mean ± S.E.M. of 3 independent determinations.  
Experiments performed by A. Brady. 
 
 Following this survey of BQCA analog SAR at rat M1, which found a number of 
well tolerated southern benzylic substitutions as well as mono- and di-fluoro substitutions 
to the quinolone core, further in vitro, ex-vivo, and in vivo experiments were performed 
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using the parent BQCA compound due to the comparable potency/efficacy across these 
analogs.  In radioligand binding experiments using rat M1 cell membranes, BQCA lacked 
competition with the orthosteric antagonist [3H]-NMS at up to 10 µM and increased the 
affinity of ACh for rat M1 by 31x at 3 µM (data not shown).  These data provide strong 
evidence that BQCA potentiates ACh-induced M1 activation via an allosteric 
enhancement of ACh affinity.  Furthermore, BQCA lacked any agonist, PAM, or 
antagonist activity at a panel of 15 other GPCRs (including M2-M5) in Ca2+ mobilization 
assays performed by Millipore’s GPCR Profiler Service (data not shown).  In a single-
dose (10 mg/kg IP) rat PK/PBL study, BQCA exhibited sub-optimal yet satisfactory 
pharmacokinetics with a brain:plasma AUC ratio of 0.09, a brain Cmax of 1181 ng/mL at 
Tmax 1 hr, and a brain T1/2 of 2 hr (data not shown). 
 Having thus determined that BQCA possessed acceptable rat M1 potency/efficacy, 
selectivity, and systemic pharmacokinetics rendering it suitable for rodent 
electrophysiology experiments and behavioral studies, no further optimization or 
investigation into additional SAR for this series was performed.  Nonetheless, these 
analogs and initial characterization experiments provided crucial evidence and rationale 
for the utility of BQCA as an acceptable small molecule tool for selective activation of 
rat M1.  A large-scale (30 g) batch of BQCA was prepared according to the scheme in 
Figure 10a as the Na+-salt, which was jet-milled and made available to collaborators in 
order to facilitate a range of M1 neurobiology studies.  Such investigations found that 
activation of M1 induced a robust inward current and increased spontaneous excitatory 
post-syanptic currents (EPSCs) in medial pre-frontal cortical (mPFC) pyramidal cells in 
rodent brain slices, and that BQCA-mediated M1 activation increased firing of mPFC 
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pyramidal cells and restored discrimination reversal learning in a transgenic mouse model 
of AD in vivo138. 
 The BQCA M1 PAM medicinal chemistry work was primarily focused on 
screening/assays with M1 cells with the exception of subtype-selectivity confirmation at 
M2-M5 for BQCA itself.  Analogs generated in the 20-member panel were not screened at 
any of the other mAChRs and it remained a question as to whether any structural 
modifications to the BQCA scaffold could confer PAM activity for subtypes other than 
M1, similar to SAR findings with the VU0119498 N-benzyl isatin series of mAChR 
PAMs.  Moreover, the fact that M1-preferring/selective compounds as well as M5-
preferring/selective compounds could be obtained by subtle modification to the 
VU0119498 structure (Chapter IV), which is itself highly similar to the BQCA scaffold 
apart from the latter’s carboxylic acid moiety, suggested that it may be possible to dial-in 
BQCA activity at other mAChRs.  Specifically, we hypothesized that appending a 
western –OCF3 group to the 6-position of the BQCA quinolone core would engender M5 
PAM activity in a manner analogous to its effect on the VU0119498-derived PAMs 
(Chapter IV). 
 To test this hypothesis, two singleton BQCA analogs were synthesized according 
to the scheme in Figure 10a, starting with the commercial 6-trifluoromethoxy quinolone 
carboxylate, which was then N-alkylated with p-methoxy and p-phenoxy benzyl halides 
to afford VU0400268 and VU0400269 (Fig. 12).  These benzyl groups were selected 
because they represented two of the most favored/optimal southern moieties within the 
VU0238429-based M5 PAM series.  Each compound was then profiled in CRCs at M5 in 
the presence of an ACh ~EC20 by Ca2+ mobilization assay (Fig. 12).  Surprisingly, 
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essentially no PAM activity was observed at up to 30 µM for either compound, 
suggesting that the BQCA template is poorly compatible with M5 binding and/or 
functional activity (Fig. 12). 
 
 
Figure 12.  Structure and M5 CRCs for BQCA-based analogs VU0400268 and VU0400269.  Ca2+ 
mobilization was used to obtain CRCs of each compound in the presence of an ACh ~EC20 using M5 cells.  
Data represent Mean +/-SEM from at least three independent determinations. 
 
 
M1 PAMs derived from MLPCN probe project 
 
 As part of the NIH Roadmap Initiative, the MLSCN/MLPCN comprises a 
nationwide consortium of small molecule screening and medicinal chemistry centers 
aimed at discovering and optimizing novel small molecules for molecular targets that 
lack known and/or acceptable tool compounds by which to study their role(s) in biology 
and disease.  Given the  scarcity of selective mAChR small molecules possessing drug-
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like characteristics (Chapter I), an HTS of the then 65,000-member MLSCN/MLPCN 
compound collection was performed to identify novel M1 ligands.  This screen was 
performed while the mAChR PAM projects (Chapters III-V) were underway and prior to 
most of the associated publications/disclosures arising from our M1 PAM discovery and 
optimization efforts.  Utilizing a functional cell-based fluorescence assay that measured 
Ca2+ mobilization in rat M1 CHO cells during first addition of a test compound followed 
by an ACh or CCh ~EC80, this screen was originally designed to identify M1 antagonist 
hits.  Indeed, a number of novel M1 antagonist series were obtained139-141, which 
ultimately led to the discovery of the highly M1-selective antagonist probe compound 
VU0255035 (discussed later in this Chapter)140. 
 Following the HTS and subsequent M1 antagonist medicinal chemistry work, the 
screening data were re-analyzed to look for compounds that elevated the ACh ~EC80.  
Although this was not an ideal assay format for identification of PAMs, the data mining 
proved fruitful as approximately 200 compounds flagged as possible potentiators.  These 
putative M1 PAM hits were re-ordered from the commercial vendor and then screened in 
a singlepoint 30 µM PAM assay in the presence of an ACh ~EC20 by Ca2+ mobilization in 
M1 cells (Fig. 13). From this screen, only two compounds exhibited robust potentiation 
activity (VU0165202 and VU0108370) and were thus carried forward to further 
characterization (Fig. 13).  Interestingly, both hits were based on the same benzyl-
substituted indole sulfonyl amide bearing a distal methyloxazole and differed only a 
single halogen substitution on the southern benzyl ring (Fig. 13). 
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Figure 13.  Structure of two M1 PAM hits identified by 30 µM singlepoint screen of approximately 200 re-
ordered putative PAMs identified from a functional M1 antagonist HTS campaign.  Ca2+ mobilization was 
used to obtain % ACh max values for each test compound at 30 µM in the presence of an ACh ~EC20 using 
M1 cells.  Data represent a single determination performed in triplicate. 
 
 In follow-up CRCs of each compound at M1 in the presence of an ACh ~EC20, the 
3-fluoro VU0165202 and the 2-chloro VU0108370 exhibited EC50 values of 5.5 µM and 
>10 µM, respectively (Fig. 14).  These were exciting results as both compounds 
exhibited clear concentration-dependent potentiation of ACh at M1. 
 
 
Figure 14.  M1 CRCs of PAM hits VU0108370 and VU0165202.  Ca2+ mobilization was used to CRCs for 
each test compound in the presence of an ACh ~EC20 using M1 cells (VU0165202 EC50 = 5.5 µM, 
VU0108370 EC50 = >10 µM).  Data represent Mean +/-SEM from at least two independent determinations. 
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  Initial optimization efforts focused on a wide range of modifications to the 
scaffold, including sequential truncation from both the southern and northern termini, as 
well as a number of diverse benzyl substitutions (Fig. 15).  A total of 19 analogs as well 
as parent hit VU0108370 were prepared according to the scheme shown in Figure 16, 
which were then triaged for M1 PAM activity at 10 µM in the presence of an ACh ~EC20 
by Ca2+ mobilization (data not shown). 
 
 
Figure 15.  Initial optimization strategy for M1 PAM hit VU0108370. 
 
 
 
 
 
Figure 16.  Synthesis of M1 PAM hit VU0108370 used to generate southern benzyl-derivatized library.  
Syntheses performed by P. Reid. 
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 Ultimately, three compounds were chosen for M1 CRC assays to determine 
potencies (Fig. 17).  These SAR data revealed that substitution of the meta position on 
the southern benzyl ring was favored, with the m-Cl analog specifically exhibiting the 
highest potency and efficacy (Fig. 17).   
 
 
Figure 17.  Structures and M1 PAM CRCs of southern benzyl analogs based on the VU0108370 / 
VU0165202 scaffold identified from a larger singlepoint triage assay.  Ca2+ mobilization was used to obtain 
CRCs each compound in the presence of an ACh ~EC20 using M1 cells.  Data represent Mean +/-SEM from 
at least three independent determinations. 
 
 
 Therefore, additional compounds containing m-bromine or m-N-methylpyrazine 
substitutions (the latter was chosen based on previous VU0119498-based M1 PAM SAR) 
on the benzyl ring were synthesized as singletons using the general scheme presented in 
Figure 16.  Simultaneously, sulfoxide and thioester congeners of the m-bromo 
compounds were prepared to explore the effect of sequential oxygen deletion from the 
central linker’s sulfone (Fig. 18).  Each of these compounds were then profiled in CRCs 
at M1 in the presence of an ACh ~EC20 by Ca2+ mobilization assay (Fig. 18).  
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Gratifyingly, the N-methylpyrazole (VU0402606, EC50 = 3.2 µM) increased potency by 
approximately ~2x over the chlorine-bearing lead (VU0366368, EC50 = 5.8 µM) and 
exhibited a notable 102% maximal ACh response at M1 (Fig. 18).  The bromine-bearing 
analog (VU0402604, EC50 = 3.8 µM) was only slightly less potent, whereas the sulfoxide 
and thioether analogs (VU0402605 and VU040260) exhibited moderately weaker 
potency and inactivity, respectively (Fig. 18). 
 
 
Figure 18. Structures and M1 PAM CRCs of meta-substituted southern benzyl analogs based on the 
VU0108370 / VU0165202 scaffold.  Ca2+ mobilization was used to obtain CRCs each compound in the 
presence of an ACh ~EC20 using M1 cells (EC50 values: VU0402604 = 3.8 µM, VU0402605 = 5.2 µM, 
VU0402606 = 3.2 µM, VU0402607 = >30 µM, VU0165202 included as positive control).  Data represent 
Mean +/-SEM from at least three independent determinations. 
  
 
 
220 
 These SAR data suggested that, like the VU0119498- and BQCA-related M1 
PAMs, biaryl/heterobiaryl southern motifs are favored for increased potency/efficacy.  To 
further explore such substitutions, the m-bromo compound was used as starting material 
for microwave-assisted Suzuki couplings to obtain a small parallel library of 
biaryl/heterobiaryl analogs using standard conditions.  These were then evaluated in 
CRCs at M1 in the presence of an ACh ~EC20 by Ca2+ mobilization assay (Table 2). 
 
Table 2.  SAR for 3-position biaryl/heterobiaryl analogs based on VU0402606.  Ca2+ mobilization was 
used to obtain compound CRCs in the presence of an ACh ~EC20 with M1 cells. Data represent Mean 
values from at least three independent determinations.  Syntheses performed by P. Reid. 
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 Of these, only the parent N-methylpyrazole and its desmethyl congener exhibited 
robust M1 PAM activity.  Interestingly, the deletion of the methyl group conferred a 
subtle increase in potency but simultaneously reduced efficacy (VU0404010, EC50 = 2.2 
µM, 90% ACh max).  We concluded that the pyrazole would thus be held constant and 
hypothesized for our next iteration of synthesis that fluorination of the benzyl ring and/or 
indole core in a manner homologous to that of the VU0119498-derived and BQCA M1 
PAMs would confer a modest increase in potency.  In order to test this hypothesis, a 
library of fluorinated analogs was prepared according to general scheme of Figure 16.  
These compounds were then profiled in CRCs at M1 to determine potency (Table 3). 
 
Table 3.  SAR for fluorinated analogs based on VU0404010 lead.  Ca2+ mobilization was used to obtain 
compound CRCs in the presence of an ACh ~EC20 with M1 cells. Data represent Mean values from at least 
three independent determinations.  Syntheses performed by P. Reid. 
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 This effort proved fruitful as the 3-bromo,6-fluorobenzyl analog exhibited the 
highest potency of any compound in this series (VU0405652, EC50 = 1.4 µM, Table 3).  
4,6-difluorination of the indole core in combination with the des-methylpyrazole in the 3-
position of the benzyl ring provided a similarly potent analog (VU0405645, EC50 = 1.9 
µM, Table 3).  With such potencies, these two new leads had reached the general criteria 
for an M1 PAM probe compound and were therefore carried into further characterization 
with a concurrent halt in medicinal chemistry.  At 30 µM, both compounds exhibited 
large (~>45-100x) ACh CRC fold-shifts at rat M1 by Ca2+ mobilization assay (Fig. 19), 
which is comparable to the magnitude of potentiation induced by BQCA at human M1. 
 
 
Figure 19.  Structure and ACh CRC fold-shifts for M1 PAM leads VU0405652 and VU0405645.  Ca2+ 
mobilization was used to obtain CRCs for ACh in the absence and presence of 30 µM test compound using 
M1 cells (VU0405652 = 45x left-shift, VU0405645 = 98x left-shift).  Data represent Mean +/- SEM from at 
least three independent determinations. 
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 Although we had thus obtained potent and efficacious M1 PAMs of a novel HTS-
identified drug-like chemotype from this medicinal chemistry effort, subtype-selectivity 
remained a question for these final lead/probe compounds.  Throughout the optimization 
campaign, both of the parent HTS hits (VU0165202 and VU0108370) as well as various 
intermediate lead compounds from the project were evaluated in CRCs in the presence of 
an ACh ~EC20 at M3 and M5 by Ca2+ mobilization assays (Fig. 20).  This was performed 
due to the higher likelihood that any loss of subtype-selectivity would first manifest at 
one or both these two off-target mAChRs given the higher structural homology amongst 
M1/M3/M5 and based on the SAR from the other M1 PAM series.  None of these 
compounds exhibited any potentiation at either subtype (Fig. 20). 
 
 
Figure 20.  M3 and M5 subtype-selectivity CRCs for original M1 PAM HTS hits and select intermediate 
lead analogs.  Ca2+ mobilization was used to obtain CRCs for each compound in the presence of an ACh 
~EC20 using M3 (left panel) or M5 (right panel) cells.  Data represent Mean +/-SEM from at least three 
independent determinations. 
 
 However, to definitively assess full subtype-selectivity for the final probe 
compound VU0405652, CRC assays at M2-M5 were performed in the presence of an ACh 
~EC20 by Ca2+ mobilization assay.  These experiments revealed complete selectivity for 
M1 at up to 30 µM, further supporting the conclusion that this chemical series represents 
a third known chemotype of M1-selective PAMs in addition to the VU0119498- and 
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BQCA-derived series (Fig. 21).  Furthermore, this particular probe (VU0405652) 
possessed favorable physiochemical and drug-like properties in the form of relatively 
high aqueous solubility (cLogP = 3.9) and a general lack of obvious DMPK liabilities.  
Despite their high selectivity for M1 in functional PAM assays, it remains unknown if 
these novel compounds exhibit true binding specificity for M1 or if they indeed bind to 
one or more of the other mAChRs but exhibit neutral or negative modulatory effects.  
Further experiments to address this question as well as a number of in vitro and in vivo 
studies aimed at studying M1 neurobiology and therapeutic relevance have been planned 
and are presently underway. 
 
 
Figure 21.  mAChR subtype-selectivity for probe compound VU0405652.  Ca2+ mobilization was used to 
obtain CRCs in the presence of an ACh ~EC20 in M2-M5 cells (EC50 values all > 30 µM).  Data represent 
Mean +/-SEM from at least three independent determinations. 
 
 As a final effort to mine the VHTSC compound collection for additional SAR 
and/or indentify new related scaffolds around this series of novel M1 PAMs, a structure 
similarity search was performed using via a cheminformatic approach.  This virtual 
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screen produced a large number of compounds within the VU collection, which 
possessed varying degrees of similarity to the basic VU0108370 scaffold.  To assess M1 
PAM activity, these compounds were screened at 10 µM in singlepoint Ca2+ mobilization 
assays at M1 in the presence of an ACh ~EC20 (Fig. 22).  Remarkably, only direct 
congeners of the VU0108370 scaffold appeared as active hits, which further confirmed 
the shallow SAR observed among this series of M1 allosteric modulators. 
 
 
Figure 22.  Singlepoint (10 µM) screen of a large panel of compounds from the VU HTS collection 
identified from a VU0108370-based structure similarity virtual screen.  Ca2+ mobilization was used to 
obtain singlepoint (10 µM) % ACh max responses for each compound in the presence of an ACh ~EC20 
using M1 cells.  Data represent Mean +/-SEM from at least three independent determinations. 
 
 
 
M1 agonist VU0357017 and analogs 
 
 Although a number of useful M1 PAM small molecule tools had been identified 
from the  medicinal chemistry projects, no M1 agonists possessing optimal potency, 
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selectivity, and DMPK characteristics required for use as in vivo tools existed.  As 
discussed in the Introduction (Chapter I), a variety of compounds have been reported to 
activate the M1 receptor in the absence of ACh with high subtype-selectivity.  However, 
these compounds (such as AC-42, 77-LH-28-1, NDMC, and TBPB) all suffered from one 
or more flaws that precluded universal suitability as both in vitro and in vivo tools for 
studying M1 neurobiology and the therapeutic potential of M1 activation.  Such defects 
include, for example, functional antagonism of one or more of the other mAChRs, 
significant off-target ancillary pharmacological activities, and/or poor systemic PK 
profiles.  Therefore, it would be highly advantageous to discover novel drug-like M1 
agonist chemotype(s) that don’t suffer from these and related limitations.  Direct 
activation of M1 in the absence of ACh is likely to reveal deeper neurobiological insight 
than reliance on M1 PAMs alone, and M1 agonists may offer therapeutic advantages over 
PAMs in treatment of certain CNS disorders.  Furthermore, a growing body of evidence 
suggests that ligand-directed bias/signaling downstream of a given GPCR target may 
confer substantially different utilities/effects unique to each small molecule 
chemotype117.  In light of these considerations, identification of a novel class of M1 
agonists became a focus of our research and of the MLSCN/MLPCN probe discovery 
enterprise.  A comprehensive presentation and discussion of this project, which 
ultimately identified a number of novel allosteric M1 agonists, including VU0357017, lies 
beyond the scope of this Chapter142.  However, a brief overview highlighting this author’s 
contribution is shown in the remainder of this section. 
 Similar to many of the mAChR allosteric ligand discovery projects, a HTS was 
performed of the then 65,000-member MLSCN/MLPCN compound collection aimed at 
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discovering novel M1 agonists via functional cell-based fluorescent Ca2+ mobilization 
assay.  This screen provided approximately 2,000 putative agonist primary hits.  A subset 
of these compounds were tested in CRCs with M1-CHO cells, and in parallel, counter 
screened against M4/Gqi5 CHO cells using Ca2+ mobilization assays.  Two highly 
structurally-similar hits, resynthesized as VU0207811 and VU0177548, were found to be 
initially selective (>50-fold) for M1 vs. M4 with M1 EC50 values of 804 nM (69% ACh 
max) and 1.74 µM (52% ACh max), respectively, and both later displayed high 
selectivity for M1 versus all other mAChRs (Fig. 23).  These compounds provided an 
excellent starting point to initiate a chemical optimization effort aimed at increasing 
potency and developing properties suitable for studies of selective M1 activation in vivo. 
 
 
Figure 23.  Structure and subtype-selectivity profiles of novel M1 agonist HTS hits.  Ca2+ mobilization was 
used to obtain CRCs of each compound in M1-M5 cells.  Data represent Mean +/-SEM from at least three 
independent determinations.  Syntheses performed by P. Kennedy. 
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 Subsequently, medicinal chemistry began with synthesis of a 25-member matrix 
library, which simultaneously varied the western aryl, central linker, and eastern 
carbamate of the scaffold (data not shown).  From singlepoint screening of this library 
using Ca2+ mobilization with M1 cells (data not shown), it became clear that SAR was 
steepest at the western aryl region and progressively shallower throughout the remainder 
of the scaffold.  A variety of substituted phenyl moieties were well tolerated (Fig 24, top 
panel); however, a wide range of further modifications to the central linker and eastern 
carbamate resulted in complete loss of M1 activity (Fig. 24, bottom panel).   
 
 
Figure 24.  M1 agonist SAR revealed by initial matrix library and singleton syntheses.  Ca2+ mobilization 
was used to obtain CRCs of each compound with M1 cells.  Data represent Mean +/-SEM from at least 
three independent determinations.  Syntheses and experiments performed by E. Lebois. 
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 Of these early analogs, the naked phenyl-bearing VU0184670 and its 2-methyl 
congener VU0357017 exhibited the greatest balance of M1 potency and efficacy (Fig. 24, 
top panel).  Therefore, they were selected for further in vitro characterization in subtype-
selectivity (Fig. 25), M2-M5 functional antagonism (Fig. 26), and [3H]-NMS competition 
binding (Fig. 27) assays.  Similar to the parent HTS hits, neither VU0184670 nor 
VU0357017 exhibited any activation of M2-M5 at up to 30 µM (Fig. 25).  Furthermore, 
they possessed little to no functional antagonism of an ACh ~EC80 at these other 
mAChRs, in contrast to the M1 agonist TBPB control (Fig. 26).  Consistent with an 
allosteric mode of binding, both compounds failed to compete with the orthosteric 
radioligand [3H]-NMS for binding to M1-M5 membranes at up to 10 µM; however, 
moderate inhibition was observed at 30 µM (Fig. 27).  Whether or not this represents 
orthosteric competition or negative cooperativity via an allosteric site remains to be 
determined. 
 
 
Figure 25.  mAChR subtype-selectivity profiles of M1 agonist leads VU0184670 and VU0357017.  Ca2+ 
mobilization was used to obtain CRCs of each compound with M1-M5 cells.  Data represent Mean +/-SEM 
from at least three independent determinations. 
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Figure 26.  M2-M5 functional antagonism profiles of M1 agonist leads VU0184670 and VU0357017 as well 
as parent hits VU0177548 and VU0207811.  Ca2+ mobilization was used to obtain CRCs of each compound 
in the presence of an ACh ~EC80 with M2-M5 cells.  TBPB included as positive control.  Data represent 
Mean +/-SEM from at least three independent determinations.  Experiments performed in part by E. 
Lebois. 
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Figure 27.  [3H-NMS] competition binding CRCs with parent M1 agonist HTS hits VU0177548 and 
VU0207811 as well as lead compounds VU0184670 and VU0357017 (all test compound IC50 values = >30 
µM).  Atropine used as positive control. M1 atropine IC50 = 2.22 nM ± 0.60 nM; Ki of 1.27 nM ± 0.36 nM. 
M2 atropine IC50 = 4.32 nM ± 1.63 nM; Ki = 3.24 nM ± 1.16 nM.  M3 atropine IC50 = 4.16 nM ± 1.04 nM; 
Ki = 2.21 nM ± 0.53 nM.  M4 atropine IC50 = 2.38 nM ± 1.07 nM; Ki = 0.77 nM ± 0.34 nM.  M5 atropine 
IC50 = 3.39 nM ± 1.16 nM; Ki = 2.84 nM ± 0.84 nM.  Results represent Mean ± SEM from at least three 
independent experiments. 
 
 
 Additional evidence that this novel series of compounds activates M1 via an 
allosteric mechanism was obtained from Ca2+ mobilization assays at the orthosteric-site 
Y381A mutant M1 receptor, which exhibits a substantial loss in ACh potency versus the 
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WT M1 cell line via disruption of a crucial ACh-receptor interaction mediated by the 
native tyrosine residue.  The M1 allosteric agonist NDMC potently and fully activates this 
Y381A mutant M1 receptor, thereby providing a means for normalization of responses to 
other test compounds.  CRCs of both parent HTS hits as well as the two lead compounds 
in this cell line revealed retention of agonist potency and partial efficacy (Fig. 28), 
consistent with an allosteric receptor activation and in dramatic contrast to TBPB (data 
not shown). 
 
 
Figure 28.  CRCs of M1 agonist leads VU0184670 and VU0357017 as well as parent hits VU0177548 and 
VU0207811 in Y381A mutant M1 cells.  Ca2+ mobilization was used to obtain CRCs of each compound 
(and ACh itself as positive control).  EC50 values: VU017758 and VU0207811 = 1.2 µM and 0.66 µM, 
respectively; VU0184670 and VU0357017 = 0.30 µM and 0.38 µM, respectively.  Data represent Mean +/-
SEM from at least three independent determinations, normalized as % max response to a high 
concentration of NDMC.  
 
 
 Together, these data provided compelling evidence that this novel class of M1 
agonists activates the receptor via an allosteric site that is topographically distinct from 
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the orthosteric site and with a high degree of subtype-selectivity (>100x).  Further 
experiments, including Schild analysis of functional assays with orthosteric antagonist 
atropine that exhibited a non-competitive interaction (data not shown) and extensive M1 
receptor site-direct mutagenesis guided by computer GPCR homology models (data not 
shown), provided additional insight to the allosteric mechanism of action.  In particular, 
specific residues of extracellular loop 3 and the first turn of transmembrane-spanning 
helix 7 are believed to comprise the unique allosteric site at which these M1 agonists bind 
to the receptor (data not shown). 
 With these in vitro mAChR pharmacological and structural biochemical data in 
hand, we next evaluated the lead compounds VU0357017 and VU0184670 in 
ancillary/off-target pharmacology binding assays (at MDS Pharma/Ricerca) and in 
standard single-dose rat PK/PBL studies in order to assess their suitability as in vivo 
research tools (data not shown).  Gratifyingly, both compounds possessed remarkably 
clean ancillary pharmacology profiles at 10 µM across a large panel of 67 different 
GPCR, ion channel, enzyme, nuclear hormone receptor, and transporter off-targets (only 
significant activity for either compound was a modest ~65% inhibition of binding to the 
Sigma1 receptor).  Furthermore, they exhibited highly desirable in vivo rat PK, with high 
CNS penetration (brain/plasma ratios: both >>1.0).  Ultimately, these novel compounds 
served as the basis for a large number of ex-vivo brain slice electrophysiology and in vivo 
behavioral studies, which have provided crucial insight to the role of M1 activation in 
discrete brain regions and in various animal models of CNS function/disease.  Further 
chemical optimization of this series has uncovered comprehensive SAR for multiple sub-
 
 
234 
series, which possess even greater potency and efficacy as M1 allosteric agonists and are 
presently serving as potential drug discovery leads. 
 In order to pharmacologically investigate the role of M1 activation in 
hippocampal-depending learning and memory, a series of brain slice electrophysiology 
and in vivo behavioral experiments were performed using lead compound VU0184670142.  
M1-mediated regulation of NMDAR currents in CA1 hippocampal pyramidal neurons is 
believed to play an important role in certain aspects of learning and memory, and some of 
the pro-cognitive effects of traditional mAChR agonists seen in clinical trials have been 
attributed to this cholinergic mechanism.  We utilized whole-cell patch clamp techniques 
with rat brain slice preparations to determine the effect of VU0357017 on CA1 
hippocampal pyramidal NMDAR currents.  At 30 µM (bath application), VU0357017 
significantly increased the peak amplitude of NMDA-evoked inward currents to 137% of 
baseline after approximately 2 minutes (data not shown).  In a related rat behavioral study 
in vivo systemic dosing of VU0357017 fully reversed (at highest dose of 10 mg/kg, IP) 
scopolamine-induced disruption of contextual fear conditioning and in a dose-dependent 
manner (data not shown).  Under the specific test conditions used, contextual fear-
conditioning represents a traditional behavioral model of hippocampal-dependent 
learning and memory function, which is severely disrupted by mAChR antagonists such 
as scopolamine.  Therefore, these findings are consistent with the hypothesis that M1 
plays an essential role in ACh-mediated mechanisms of learning and memory in the 
hippocampus.  However, based on data from other pharmacological experiments and on 
studies using mAChR-KO mice, it is known that other subtypes in addition to M1 have 
important roles in cholinergic mechanisms of cognitive function (Chapter I). 
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M1 agonist TBPB and analogs 
 
 Prior to our discovery of the novel M1 allosteric agonist series represented by lead 
compound VU0357017, we reported on a structurally unrelated compound termed TBPB 
as a potent mAChR agonist possessing high M1-selectivity in functional cell-based assays 
(Fig. 29)143.  We performed extensive in vitro and in vivo characterization of TBPB and 
found via M1 mutagenesis and other molecular pharmacology studies that this ligand 
activates M1 in the absence of ACh with high subtype selectivity and via an allosteric 
mechanism.  We also found that TBPB potentiates NMDAR currents in rodent 
hippocampal pyramidal cells without altering excitatory or inhibitory synaptic 
transmission using ex-vivo electrophysiology techniques, and that TBPB-mediated M1 
activation drives non-amyloidogenic processing of APP and decreases amyloid-β in vitro.  
Furthermore, TBPB was efficacious in rodent behavioral models predictive of anti-
psychotic activity in vivo without inducing M2/M3-related side effects.   
  
 
Figure 29.  Structure and mAChR subtype-selectivity of M1 agonist TBPB.  Ca2+ mobilization was used to 
obtain CRCs of TBPB in M1-M5 cells.  Data represent Mean +/-SEM from at least three independent 
determinations.  Experiments performed by A. Brady. 
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 However, TBPB was an unoptimized screening hit with moderate antagonist 
activity at dopamine D2 receptor (D2) (IC50 = 2.6 µM).  Despite an [18F]-fallypride micro- 
positron emission tomography (PET) study that confirmed the in vivo efficacy in rodent 
models of psychosis observed with TBPB was the result of selective M1 activation and 
not due to D2, we hoped to diminish D2 activity through a lead optimization campaign 
using an iterative parallel synthesis approach144,145.  For our initial library, analogs were 
prepared by a reductive amination sequence employing a functionalized piperidone and 
4-(2-keto-1- benzoimidazolinyl)piperidine or the 5-chloro congener and polymer-
supported triacetoxyborohydride (Fig. 30).  
 
 
Figure 30.  First round of synthesis of TBPB analogs.  Reagents and conditions: (a)  K2CO3, ArCH2Br, 
DCM, 70-88%; (b) MP-B(OAc)3H, 4-(2-keto-1-benzoimidazolinyl)piperidine or 5-chloro-1-(4-
piperidinyl)-2-benzimidazolone, DCM, rt, 24 hr, 85-95%. 
 
 In the first round of library synthesis, efforts focused on commercially available 
piperidinones (wherein R1 is either an alkyl or carbamate moiety).  Subsequent rounds of 
library synthesis utilized the same scheme but with substituted benzylic R1 moieties 
generated by standard alkylation chemistry on the piperidone starting material.  These 
analogs were then tested in CRCs at both the M1 and dopamine D2 receptors in cell-based 
Ca2+ mobilization assays.  Out of an initial 24-member library with simple aliphatic and 
carbamate derivatives of TBPB, only an ethyl carbamate analog (compound 1b, Table 4) 
retained M1 agonist activity.   
 
 
237 
Table 4.  M1 and D2 potency/efficacy SAR for TBPB analogs synthesized according to Figure 30.  Ca2+ 
mobilization was used to obtain compound CRCs with M1 and D2 cells.  Data represent Mean +/-SEM of at 
least three independent determinations.  Experiments performed by A. Brady. 
 
 
 
 Compound 1b displayed substantially improved M1 potency (EC50 = 2.1 nM) with 
moderate efficacy (65% CCh max), but lost selectivity versus M2-M5, thereby 
degenerating into a pan-mAChR partial agonist (Fig. 31). 
 
 
Figure 31.  mAChR subtype-selectivity profile for TBPB analog 1b.  Ca2+ mobilization was used to obtain 
CRCs with M1-M5 cells.  Data represent Mean +/-SEM from at least three independent determinations.  
Experiments performed by A. Brady. 
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 The subsequent round of parallel synthesis focused on diverse distal benzylic 
substitutions at R1 with the 4-(2-keto-1-benzoimidazolinyl)piperidine TBPB headpiece 
bearing either hydrogen or a chlorine atom in the 5-position, the latter of which was 
introduced to block a site of oxidative metabolism we identified (data not shown).  This 
effort generated over 60 analogs; however, the SAR proved to be rather ‘flat’.  If the 
benzyl group possessed substituents in the 3- or 4-positions, all M1 agonism was lost 
(EC50 >20 µM).  As shown in Table 4, it was possible to synthesize other analogs with 
selective M1 partial agonism (M1 EC50 values of 120 nM to 1.8 µM, >50 µM vs. M2-M5), 
but the degree of efficacy varied widely (23-84%).  Incorporation of a 5-Cl atom into 
TBPB to block metabolism resulted in compound 1c, an analog that maintained the same 
efficacy as TBPB, but lost ~5-fold potency (Table 4).  Removal of the 2-Me group 
resulted in an analog comparable to TBPB, compound 1d (Table 4).  Attempts to replace 
the metabolically labile 2-methyl group with alternative chemical moieties (compounds 
1e-1l) generally led to a significant diminution in M1 efficacy (<50%), M1 potency, or 
both (Table 4).  However, the 2-nitrobenzyl analogue (compound 1i) proved more potent 
than TBPB (M1 EC50 = 120 nM), but efficacy fell to 42% CCh max response (Table 4).  
One exception to this was the 2-CF3 group, which provided an analog with an M1 EC50 of 
410 nM and 82% max efficacy (Table 4).     
 With respect to D2 inhibition, compound 1e maintained a mAChR profile 
comparable to TBPB, but D2 inhibition was greatly diminished (~30% @ 10 µM), 
indicating that this compound might prove to be a more useful biological tool to probe 
M1 than TBPB.  The moderately more potent than TBPB compound 1i, also displayed 
increased D2 inhibition (IC50 = 1.13 µM); however, a dual M1 agonist/D2 antagonist may 
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prove to be an acceptable profile for a novel schizophrenia treatment and therefore this 
SAR may provide a starting point for a dual-pharmacology optimization project. 
 We then decided to evaluate the effect of a small structural modification and 
targeted fluorine substituted 4-(2-keto-1-benzoimidazolinyl)piperidines, prepared by 
modification of the reported Merck route (Figure 32).  Commercial fluorine-substituted 
ortho-fluoro-nitroaromatic starting material (compounds 2) were heated under microwave 
irradiation with ethyl 4-amino-1-piperdinecarboxylate to deliver the SNAr products 
(compounds 3) in yields ranging from 70-90%.  A zinc-mediated nitro reduction afforded 
intermediates (compounds 4), which were then treated with triphosgene to provide the 
benzimidazolones (compounds 5).  Removal of the ethyl carbamate was accomplished 
under another microwave-assisted protocol to deliver the 4-, 5- and 6-fluoro-1-(piperdin-
4-yl)-1-H-benzo[d]imidazol-2(3H)-ones (compounds 6). 
 
 
 
Figure 32.  Synthesis of fluorine-substituted TBPB analogs.  Reagents and conditions: (a) Ethyl 4-
aminopiperidine, Na2CO3, KI, cyclohexanol, mw, 180 oC, 10 min, 70-90%; (b) Zn, 1N HCl, MeOH; (c) 
tripshosgene, Et3N, THF, rt, 2 h; (d) 10% NaOH, mw, 130 oC, 30 min, 50-60% from intermediate 3.  
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Figure 33. Synthesis of additional fluorinated TBPB analogs.  Reagents and conditions: (a) MP-B(OAc)3H, 
4-, 5- and 6-fluoro-1-(piperdin-4-yl)-1-H-benzo[d]imidazol-2(3H)-ones 17, 50-90%.  
 
 The final fluorine-substituted analogs were prepared by a reductive amination 
sequence employing either 2-methly benzyl piperidone (compounds 7) or 2-
trifluoromethly benzyl piperidone (compounds 8) and the 4-, 5- or 6-fluoro-1-(piperdin-
4-yl)-1-H-benzo[d]imidazol-2(3H)-ones (compounds 9) (Fig. 33).   As shown in Table 5, 
TBPB analog compounds 9 containing a fluorine atom were uniformly less active than 
the un-substituted parents, TBPB and compound 1e.  However, analogs such as 9b and 9c 
possessed sub-micromolar EC50s and were equally efficacious (850 nM, 85% CCh max 
and 760 nM, 84% CCh max, respectively); moreover, they carried no significant D2 
antagonism.  Based on these SAR data, we prepared additional 4-(2-keto-1-
benzoimidazolinyl)piperidines and TBPB analogues with alternative substitutions (Br, 
CN, CF3), as shown in Table 5. 
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Table 5.  SAR for fluorine-substituted TBPB analogs.  Ca2+ mobilization was used to obtain compound 
CRCs with M1 and D2 cells.  Data represent Mean +/-SEM of at least three independent determinations.  
Experiments performed by A. Brady. 
 
 
 
 Most fluoro-TBPB analogs were found to be either inactive or partial agonists 
with <20% maximum efficacy, or they were no longer selective for M1.  Ultimately, after 
numerous sets of analogs had been synthesized and evaluated, we found that this was a 
rare instance, from our experience, where the original screening hit, TBPB, could not be 
significantly improved upon using these types of structural modifications.  Further SAR 
was later explored by examining the effect of capping the TBPB scaffold’s distal basic 
piperidine nitrogen with amides, sulfonamides, and ureas (data not shown)144.  These 
efforts revealed similarly flat SAR; however, a number of such analogs retained moderate 
M1 potency, efficacy, and subtype-selectivity (data not shown). 
 In summary, we identified a novel series of allosteric partial agonists with high 
selectivity for M1 versus M2-M5 and with various degrees of D2 antagonism based on the 
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general TBPB scaffold.  SAR was essentially ‘flat’ within this series, with subtle changes 
resulting in pan-mAChR agonism, loss of M1 potency, significantly decreased efficacy, 
and/or ancillary D2 antagonism.  This was a rare example in which the screening lead 
proved very difficult to optimize, yet still possessed a profile that enabled both in vitro 
and in vivo studies to be conducted.  Moreover, this work further exemplifies the 
numerous challenges inherent to optimization of most allosteric GPCR ligands.  
 
M1 antagonist VU0255035 and analogs 
 
 In addition to the discovery and optimization of numerous new M1-targeted small 
molecule agonists and PAMs, we hoped to obtain novel M1-selective antagonists for use 
as research tools and to investigate the therapeutic potential of selective M1 blockade in 
movement-related and other CNS disorders.  Small molecule agonists and potentiators 
selective for a specific mAChR subtype have clear utility in neurobiology research and in 
therapeutic target validation contexts wherein activation of the receptor is required; for 
example, M1 activation in Alzheimer’s disease or schizophrenia.  Conversely, subtype-
selective mAChR antagonism provides a complementary but distinct utility in contexts 
that require diminution of receptor signaling, such as in the treatment of dystonia and in 
basic research on the role of M1 signaling under normal disease-free physiological 
conditions.  Furthermore, discovery of a truly selective M1 antagonist small molecule 
could provide a highly useful control in experiments with mAChR agonists or PAMs. 
 Therefore, our MLSCN/MLPCN center initiated an effort to identify a potent 
small molecule antagonist with high specificity for M1 versus M4 for use as a chemical 
 
 
243 
probe and lead for further optimization towards a novel therapeutic140,141.  Our functional 
HTS (performed as described previously in this Chapter for the MLSCN/MLPCN M1 
PAM project) identified a number of hits, and a limited optimization effort produced the 
M1 versus M4 selective antagonist VU0359517 (M1 IC50 = 440 nM, M4 IC50 >150 µM); 
however, this orthosteric mAChR antagonist displayed only 2- to 9-fold selectivity versus 
M2, M3 and M5 (data not shown).  This early effort also produced a series of weak (M1 
IC50 >3.5 µM) but selective  (M2-M5 IC50 >50 µM) antagonists based on a 3,6-
disubstituted-[1,2,4]-triazolo[4,3-b]pyridazine scaffold (data not shown)139. 
 While the vast majority of our HTS hits displayed no selectivity for M1 versus 
M4, compound 1, based on a N-(3-piperazin-1-yl)-3-oxopropyl)benzo[c][1,2,5] 
thiadiazole-4-sulfonamide scaffold, demonstrated a surprising >58-fold selectivity for rat 
M1 (IC50 = 2.55 µM) over rat M4 (IC50 >100 µM) with a similar IC50 (2.72 µM) for 
human M1 in Ca2+ mobilization assays examining the functional antagonism of an ACh 
~EC80.  Encouraged by this result, we explored the selectivity of compound 1 versus M2-
M5.  Gratifyingly, it was >58-fold selective for M1 versus M2- M5 (Fig. 34). 
    
 
Figure 34. M1-M5 CRCs for compound 1.  Ca2+ mobilization was used to obtain CRCs of test compound in 
M1-M5 cells in the presence of an ACh ~EC80.  M1 IC50 = 2.6 µM.  Data represent Mean +/- SEM from at 
least three independent determinations.  Experiments performed by D. Sheffler. 
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 While this level of selectivity was unprecedented for a small molecule M1 
antagonist, 1 did not meet the potency criteria for an MLSCN small molecule probe (IC50 
<500 nM).  Therefore, we launched a chemical lead optimization campaign to improve 
potency for M1 while maintaining high selectivity versus M2-M5.  Analogs of compound 
1 were synthesized in a library format according to the scheme presented in Figure 35.  
For the first round of library synthesis, our strategy was to explore alternative amides in 
place of the 2-pyridylpiperizine moiety.  Commercially available benzo[c]thiadiazole-4-
sulfonyl chloride (compound 2) was treated with β-alanine methyl ester to afford, after 
saponification, acid (compound 3).  Subsequent coupling with a diverse collection of 24 
primary and secondary amines under standard solution phase parallel synthesis conditions 
employing polymer-supported reagents and scavengers provided analogs 4.  All 
compounds were purified by mass-guided HPLC to analytical purity.   
 
 
 
Figure 35.  Synthesis of compound 1 analogs.  Reagents and conditions: (a) β-alanine methyl ester, DCM, 
DIEA, rt; (b) LiOH, THF/H2O/MeOH, rt; (c) R1R2NH, PS-DCC, HOBt, DCM, DIEA; (d) MP-CO32-.  
Syntheses performed by C. Lindsley. 
 
 
 
 
245 
 Evaluation of this library against M1-M5 cells by Ca2+ mobilization assay in the 
presence of an ACh ~EC80 demonstrated that SAR for this series was relatively flat, with 
regiosiomeric pyridylpiperazine amides 5 being the only active analogs of 4 (Table 6). 
The activity of the HTS lead compound 1 was confirmed by re-synthesis (M1 IC50 = 2.37 
µM, M2-M5 IC50 >10 µM).  With respect to SAR for this series, functionalized phenyl 
piperazine analogs, aliphatic piperazines, and other heterocyclic analogs were all devoid 
of M1 antagonist activity.  Relative to the 2-pyridyl analog (compound 1), the 3-pyridyl 
congener (compound 5a) possessed roughly equivalent activity at M1 (IC50 = 3.19 µM), 
while also maintaining selectivity versus M2-M5.  The 4-pyridyl variant (compound 5b) 
provided a ~17-fold increase in M1 activity (IC50 = 133 nM) relative to the HTS hit. 
 
Table 6.  M1-M5 SAR for active M1 antagonist analogs 5.  Ca2+ mobilization was used to obtain compound 
CRCs in M1-M5 cells in the presence of an ACh ~EC80.  Data represent Mean +/-SEM of at least three 
independent determinations.  Experiments performed by D. Sheffler. 
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 A high degree of subtype-selectivity (>75x for M1 versus M2-M5) was also 
maintained (M2-M5 IC50s >10 µM) for compound 5b as shown in Figure 36.  Compound 
concentrations were solubility limited, but little inhibition of an ACh ~EC80 at M2-M5 
was observed for compound 5b at up to 100 µM in some experiments.  Thus, this analog 
represented the most functionally subtype-selective small molecule M1 antagonist ever 
reported; however, its binding subtype-selectivity remained a question.  Due to this 
unprecedented mAChR subtype-selectivity in functional cell-based assays (Fig. 36), we 
hypothesized that this compound binds to an allosteric site on the M1 receptor. 
 
 
Figure 36.  M1-M5 CRCs for lead compound 5b.  Ca2+ mobilization was used to obtain CRCs of test 
compound in M1-M5 cells in the presence of an ACh ~EC80.  M1 IC50 = 133 +/- 28 nM.  Data represent 
Mean +/-SEM from at least three independent determinations.  Experiments performed by D. Sheffler. 
 
 To test this hypothesis, [3H]-NMS competition binding experiments were 
conducted under equilibrium conditions to obtain Ki values for compound 5b as well as 
atropine controls at M1-M5 cell membranes.  As shown in Table 7, compound 5b 
exhibited potent inhibition of orthosteric radioligand binding with an M1 Ki of 14.9 nM 
with 45- to 159-fold Ki selectivity versus M2-M5.  
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Table 7.  Summary of functional and binding mAChR subtype-selectivity for M1 antagonist (compound 
5b).  Ca2+ mobilization was used to obtain CRCs of test compound in M1-M5 cells in the presence of an 
ACh ~EC80.  [3H]-NMS competition binding was used to obtain CRCs of test compound and atropine 
positive control under equilibrium with M1-M5 cell membranes.  Atropine Ki values: M1 = 0.8 nM, M2 = 
2.6 nM, M3 = 1.1 nM, M4 = 0.6 nM, M5 = 1.6 nM.  Data represent Mean +/-SEM from at least three 
independent determinations.  Experiments performed by D. Sheffler. 
 
 
 
 
 These results were surprising and led us to further explore the mechanism of 
antagonism via Schild analysis of PI hydrolysis experiments.  In these experiments, 
compound 5b caused parallel concentration-dependent rightward shifts of an ACh CRC, 
which translated in a Schild analysis to a Kd of 16 nM (slope = 0.90+0.08, data not 
shown).  These data support the previous results from the [3H]-NMS binding experiments 
in suggesting that compound 5b is an orthosteric M1 antagonist.  Therefore, we rejected 
our original allosteric binding hypothesis pending further testing in the form of kinetic 
binding experiments. 
 Prior to conducting in vivo experiments, the selectivity of compound 5b was 
evaluated against larger panels of molecular targets.  In binding assays at both the UNC 
Psychoactive Drug Screen and against a large panel of GPCRs, ion channels, 
 
 
248 
transporters, nuclear hormone receptors, and kinases (MDS Pharma/Ricerca), compound 
5b was devoid of significant ancillary pharmacology (data not shown).  Next, we 
performed a rat single-dose (10 mg/kg) PK/PBL study that revealed a 
brainAUC/plasmaAUC ratio of 0.48 and other similarly acceptable PK parameters for use 
of this compound in vivo following systemic dosing (data not shown).   
 In a subsequent acute rodent behavioral study, our M1 antagonist (compound 5b) 
exhibited in vivo efficacy following systemic (I.P.) administration in a pilocarpine-
induced mouse seizure model by reducing M1-mediated seizure activity and increasing 
survival at doses that did not disrupt acquisition of contextual fear conditioning (data not 
shown).  These results suggested that M1 antagonism in a therapeutic context may not 
result in learning and memory related side effects, although further investigation is 
certainly required.  Based on these exciting data, we chose to further explore SAR around 
this chemical series by evaluating the six parameters shown in Figure 37.  However, 
SAR was again ‘flat’ with no active analogs arising from these modifications. 
 
 
Figure 37.  Additional SAR exploration around the M1 antagonist scaffold resulting in inactive analogs. 
 
 In summary, an MLSCN M1 antagonist chemical probe discovery project 
provided a selective M1 antagonist lead (compound 1) after a functional HTS campaign.  
One round of parallel synthesis afforded compound 5b, a highly functionally selective 
 
 
249 
(>75-fold vs M2-M5), potent (IC50 = 133 nM), and high-affinity (Ki = 14.9 nM) M1 
antagonist.  Moreover, this compound possessed no significant ancillary pharmacology 
and exhibited a pharmacokinetic profile acceptable for in vivo systemic dosing in 
behavioral and neurochemical studies.  Based on these and the preliminary in vivo 
efficacy data, compound 5b was declared an MLSCN/MLPCN small molecule in vitro/in 
vivo probe and assigned the identifier VU0255035140.  Further experiments utilizing this 
novel compound and aimed at investigating the therapeutic potential of selective M1 
antagonism as well as the role of M1 in basic neurobiology are currently underway. 
 
Summary 
 
 In summary, numerous novel small molecule ligands selectively-targeting the M1 
receptor and suitable for in vitro and in vivo use have been discovered, including three 
classes of PAMs, two classes of agonists, and a single class of antagonists.  Prior to this 
work, the mAChR field was largely devoid of truly M1-selective ligands that possessed 
the drug-like pharmacological characteristics necessary for use in rodent in vivo 
neurobehavioral and neurochemical studies.  Utilizing functional cell-based screening 
and hypothesis-driven medicinal chemistry techniques, highly-selective M1 tools have 
successfully been discovered, which have provided crucial insight to the role of M1 in 
basic neurobiology and within the context of therapeutic target validation.  Specifically, 
studies with these compounds have revealed and confirmed the role of M1 activation in 
mediating ACh-induced potentiation of NMDAR currents in CA1 hippocampal 
pyramidal neurons, in regulation of APP processing, and in a variety of anti-psychotic 
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and pro-cognitive behavioral effects.  Furthermore, the diversity of chemotypes across 
the different series of M1 PAMs (e.g. BQCA, VU0366369, and VU0405652) and M1 
agonists (e.g. VU0357017 and TBPB) provides a rich set of tools for studying ligand-
directed/biased signaling downstream of M1, which represents a growing area of research 
important to both basic and translational neurobiology. 
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Chapter VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 Muscarinic acetylcholine receptors are important to numerous physiological 
processes in both the CNS and periphery16,18.  In light of their distinct localizations and 
putative functional roles as suggested by genetic KO mice studies, multiple mAChR 
subtypes may represent attractive drug targets for treatment of a variety of CNS diseases 
and disorders44,111.  However, since the initial cloning of the genes encoding the 
individual rodent and human mAChR subtypes more than two decades ago, relatively 
little pharmacological progress has been made towards obtaining a deep understanding of 
the role(s) of each subtype in mammalian neurobiology.  This has been due largely to a 
failure of efforts aimed at discovering highly subtype-selective mAChR ligands.  Indeed, 
few drug-like muscarinic compounds exist that are suitable for use as research tools or as 
drug discovery leads.  Like other GPCR subfamilies, the orthosteric binding site is highly 
conserved across the mAChRs, which has contributed heavily to this longstanding 
paucity of highly subtype-selective ligands.  This is especially apparent in the case of M5, 
as no small molecules possessing even moderate selectivity for M5 have been reported in 
the international scientific or patent literature.  Similarly, until recently no ligands existed 
for studying the effects of selective M4 modulation.  A number of chemotypes have been 
discovered to possess high functional and/or binding selectivity for M1, yet many of these 
compounds suffer from sub-optimal pharmacological properties and off-target activities 
that limit their utility in basic and clinical research (Chapter I). 
 
 
252 
 Here we described a variety of medicinal chemistry and neuropharmacology 
research projects aimed at discovering, optimizing, and characterizing novel highly 
subtype-selective mAChR ligands for M1, M4, and M527,124,126,131,132,135,138-146.  Using 
functional HTS and cheminformatic techniques, screening hits were identified that, 
through subsequent chemical optimization, lead to discovery of novel series of M4 PAMs 
and M5 PAMs as well as multiple series of M1 PAMs, allosteric M1 partial agonists, and 
M1 antagonists, each possessing high subtype-selectivity (>30-100x) in functional cell-
based assays.  Lead compounds from the M4 PAM project and multiple M1-related 
projects were then used in a variety of electrophysiological and neurobehavioral 
experiments to investigate the precise role(s) of these subtypes in the CNS.  In the case of 
M5, the first and currently only series of highly subtype-selective ligands, M5 PAMs 
derived from an initial pan-M1, -M3, -M5 PAM screening hit, were obtained and 
characterized.  Abbreviated summaries for the M4 PAM and M5 PAM projects, associated 
potential further optimization efforts, as well as future in vitro and in vivo studies are 
presented below. 
 
M4 PAMs based on VU010010 
 
 The first series of small molecule mAChR PAMs possessing high potency and 
subtype-selectivity for rat M4 were obtained using a virtual cheminformatic database 
mining approach based on the structure of LY2033298, the first potent and selective 
human M4 PAM (Fig. 1)124,125,127.  This involved the initial discovery of VU010010, 
which possessed an approximately 400 nM rM4 potency and induced a robust 47x left-
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shift of an rM4 ACh CRC at 30 µM in Ca2+ mobilization assays (Fig. 1).  This compound, 
although useful in limited electrophysiological studies, suffered from poor 
physiochemical properties (logP ~ 4.5) and lacked CNS penetration in vivo following 
systemic dosing in a rat PK/PBL study.  Subsequent optimization efforts employing a 
DOS strategy revealed flat SAR around most regions of the VU010010 scaffold; 
however, multiple benzamide substitutions on the eastern side were well tolerated.  This 
initial optimization campaign identified VU0152099 and VU0152100 as analogs of 
VU010010 possessing similar rM4 PAM potency and efficacy but with improved 
solubility and ultimately acceptable in vivo rat PK profiles (Fig. 1).  After a series of in 
vitro characterization experiments, which revealed that these compounds potentiated both 
ACh binding affinity and efficiency of G-protein coupling through an allosteric 
mechanism, these lead M4 PAMs were used in rat behavioral studies to investigate the 
antipsychotic potential of selective M4 activation in vivo.  Both VU0152099 and 
VU0152100 exhibited robust and dose-dependent reversal of amphetamine-induced 
hyperlocomotion after I.P. injection with an absence of sedative effects, which provided 
the first reported behavioral evidence suggesting M4 activation (or PAM) may be 
efficacious in the treatment of psychosis. 
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Figure 1.  Optimization progression summary for M4 PAMs based on a substituted thienopyridine scaffold. 
 
 
 
254 
 A more comprehensive optimization campaign was then executed in order to 
further explore SAR and improve the metabolic stability of the VU010010-based M4 
PAM scaffold through an iterative analog library approach126.  This involved introduction 
of diverse western amino or ether substitutions at the 6-position of the thienopyridine 
core, although only ether-linked basic amine moieties were well tolerated.  Subsequent 
matrix-like derivatization of the eastern amide side chain led to the discovery of multiple 
lead compounds possessing high ACh CRC fold-shift (>40-60x at 30 µM) but relatively 
modest EC50 values (~2 µM) at rM4.  Importantly, these newer analogs, exemplified by 
VU0359508 (Fig. 1), maintained complete subtype-selectivity, possessed improved 
metabolic stability in vitro (>90% parent remaining after 90 min incubation with rat liver 
microsomes), and displayed superior vehicle solubility in in vivo formulation studies 
(>10 mg/mL across multiple non-toxic carriers).  However, these compounds exhibited 
poor/absent efficacy in reversal of amphetamine-induced hyperlocomotion following 
56.6 mg/kg (I.P.) dosing in rat behavioral studies, which may have been due to their 
relatively lower potency compared to VU0152099 and VU0152100.  Upon in vitro 
testing at the human M4 receptor, these analogs exhibited more than 10x greater potency 
(~100-200 nM range), contributing to evidence that they could serve as future drug leads.  
Additionally, alignment with the refined H3 antagonist pharmacophore model and 
subsequent competition binding experiments at H3 suggest that this latest generation M4 
PAM series may also be used as a starting point for discovery and optimization of dual 
M4 PAM/H3 antagonist compounds, which could potentially confer more comprehensive 
antipsychotic utility in addressing both positive and cognitive system clusters of 
schizophrenia. 
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 Although not discussed in Chapter III, preliminary in vitro data from experiments 
with a compound we discovered that is structurally related to the M4 PAM scaffold 
suggests that certain modifications to the thienopyridine core confer a switch in mode of 
pharmacology from PAM to NAM/antagonist for this series.  However, subtype-
selectivity, mode of binding, and tractability in further optimization has not yet been 
determined.  Discovery of a potent and selective M4 NAM from our series of M4 PAMs 
would provide a highly useful research tool that could be used to probe the effects of 
decreasing M4 signaling within numerous neurobiology and therapeutic discovery 
contexts.  Additional medicinal chemistry and in vitro characterization for such putative 
M4 NAMs is required. 
 Beyond these chemical optimization possibilities, a number of in vitro and in vivo 
pharmacological studies may be pursued with the highly-selective M4 PAMs described in 
Chapter III.  Each of the lead compounds from this series lacked any detectable PAM 
activity at M1, M2, M3, or M5 in Ca2+ mobilization assays; however, it is not known if this 
high selectivity is due to binding specificity for M4 or if these compounds in fact bind to 
one or more of the other mAChRs but exhibit neutral cooperativity (i.e. pharmacological 
silence) with ACh.  To address this question and to assess the potential for probe-
dependent PAM activity at other mAChRs, a series of in vitro experiments may be 
performed.  These could involve measurement of radioligand binding kinetics and/or 
functional activity of multiple orthosteric ligands in the absence and presence of a high 
concentration of M4 PAM test compound at each of the other mAChR subtypes.  If 
differences are seen in the presence of the test compound, such data would provide 
evidence that the compound does bind to other mAChR subtypes in addition to M4.  
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Similar assays could be performed using lead compounds from many of the mAChR 
projects described in Chapter V as well, as the question of binding versus functional 
selectivity remains unanswered for most mAChR allosteric chemotypes. 
 In electrophysiology experiments using rodent hippocampal slices, the early M4 
PAM lead VU010010 was found to increase CCh-mediated depression of synaptic 
transmission at excitatory but not inhibitory synapses.  Given the high expression of M4 
in the striatum and other components of the basal ganglia, additional electrophysiological 
investigation into the precise role(s) of M4 in these brain regions would advance the 
understanding of M4 basic neurobiology.  Furthermore, more comprehensive evaluation 
of the effects of selective M4 modulation within the therapeutic context of psychosis 
would shed additional light on the validity of this target.  Although reversal of 
amphetamine-induced hyperlocomotion is a highly useful acute model for predicting DA-
related positive symptom antipsychotic efficacy, additional behavioral studies including 
conditioned avoidance responding (CAR), reversal of PCP-induced disruption of PPI, and 
various models of cognition could be performed with our M4 PAMs.  For studies with the 
more recent lead compounds (e.g. VU0359508), which possess improved physiochemical 
properties and metabolic stability but only modest M4 potency, co-administration of a 
low dose of mAChR agonist may provide a solution to the lack of in vivo effect observed 
with these compounds.  This strategy was used in the case of the original hM4 PAM 
LY2033298, which lacked efficacy in a rodent CAR behavioral study when dosed alone 
but exhibited robust effects in the presence of a low dose of oxotremorine (that itself had 
no effect either)127.  Alternatively, the intermediate lead compounds VU0152099 or 
VU0152100 could be used.  Such experiments would provide valuable insight to the 
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question(s) about which mAChR(s) likely mediated the antipsychotic effects observed in 
clinical trials of the M1/M4-preferring agonist xanomeline. 
 
M5 PAMs based on VU0238429 
 
 Following discovery of VU0119498 as a small molecule mAChR PAM with 
similar in vitro potency, efficacy, and selectivity for M1, M3, and M5, SAR from a large 
matrix-analog library synthesis revealed that –OCF3 substitution at the 5-position of the 
isatin headpiece conferred preference for M5 activity.  This was exemplified by the early 
lead VU0238429, the first reported M5-preferring PAM, which possessed approximately 
1 µM potency, induced a 14x left-shift of an M5 ACh CRC at 30 µM, and exhibited >30x 
selectivity versus M1-M4 in functional Ca2+ mobilization assays.  Subsequent radioligand 
binding experiments indicated that VU0238429 modulates M5 by enhancement of ACh 
affinity through an allosteric mechanism.  This compound was then used as the lead 
structure for an exhaustive chemical optimization campaign aimed at further exploring 
SAR and obtaining analogs with superior drug-like pharmacological properties.  Guided 
by specific hypothesis-driven strategies, dozens of iterative parallel libraries were 
generated to systematically probe the effect of various structural modifications to the M5 
PAM scaffold on potency, efficacy, and subtype-selectivity.  These efforts led to the 
discovery of intermediate leads such as VU0365114, which possessed modestly lower 
potency (2.7 µM) but induced a pronounced >50x left-shift of the ACh CRC at 30 µM 
with even greater subtype-selectivity than VU0238429.  Other SAR revealed even more 
M5 subtype-selectivity could be engendered by introduction of biaryl/heterobiaryl ethers 
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to the southern region of the scaffold, as exemplified by VU0400265, which possessed a 
1.9 µM PAM EC50 at M5 and lacked any detectable activity at M1-M5 at up to 30 µM. 
 Comprehensive survey of SAR around the isatin headpiece confirmed the vital 
importance of the 5-OCF3 group for M5 PAM activity, as more than 40 different ether 
substitutions (including trifluoroethyl and trifluoropropyl) were inactive.  However, 
migration of this moiety to the 6-position was tolerated and actually improved efficacy, 
but simultaneously compromised subtype-selectivity.  Efforts to replace the 3-keto 
component of the isatin core successfully identified the gem-difluoro but not the 
spirocyclopropyl or tertiary alcohol isosteres as an optimal replacement, which conferred 
a moderate increase in potency, efficacy, and subtype-selectivity while removing the 
DMPK-related liabilities of the isatin structure.  In libraries containing ortho-fluoro, meta 
biaryl/heterobiaryl, or meta biaryl/heterobiaryl ether substitutions on the southern benzyl 
ring, SAR was flat and M5 PAM activity was essentially lost.  These and other SAR 
findings from this optimization campaign are summarized in Figure 2.  
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-OCF3 absolutely required
for M5 PAM activity
Migration of OCF3 to 6-position
improves efficacy/ACh fold-shift
but erodes subtype-selectivity
Gem di-fluoro isostere is well tolerated, improves 
potency, efficacy, and subtype-selectivity
Fluorination reduces
potency and efficacy
Not amenable to most substitutions
O
Replacement of -OMe with aryl/heteroaryl
moieties improves efficacy with variable
effects on subtype-selectivity
Aryl/heteroaryl ethers confer
high subtype-selectivity and
moderate potency/efficacy
 
 
Figure 2.  Abbreviated SAR summary for M5 PAM optimization based on early lead VU0238429. 
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 In general, the para position on the southern benzyl ring proved most amenable to 
derivatization, and therefore efforts to improve the physiochemical properties and reduce 
identified ancillary/off-target pharmacology liabilities focused on this region.  Analogs 
bearing linear heterobiaryl southern motifs containing one or more nitrogens in the 
proximal and/or distal aromatic ring(s), such as the p-phenyl substituted 3-picolyl 
compound VU0415478, were synthesized and found to possess improved aqueous 
solubility and also maintained M5 PAM activity with moderate potency and subtype-
selectivity, but with slightly diminished efficacy.  Similar analogs containing heterobiaryl 
ethers, such as the fluoro-pyridine analog VU0414747, were found to possess solubility, 
potency, and subtype-selectivity comparable to or greater than that of the  straight non-
ether heterobiaryl analogs, but with generally lower PAM efficacy.  
 However, despite their improved physiochemical properties, both of these later 
sub-series still suffered from numerous ancillary pharmacological activities revealed by a 
10 µM competition binding screen across a large panel of off-targets.  Ultimately, after 
hundreds of compounds were synthesized and evaluated, it proved difficult to obtain 
analogs with the ideal combination of each important parameter such as potency, 
efficacy, subtype-selectivity, physiochemical properties (i.e. logP), lack of ancillary 
pharmacology, and drug-like structural aspects favorable for DMPK.  The best analogs 
for each of these attributes were often from different libraries and chemical sub-series; 
however, a number of lead compounds containing relatively balanced pharmacological 
profiles, such as VU0402734, represent highly suitable M5 PAM research tools.  An 
overview of the optimization progression for this project, which highlights key early, 
intermediate, and advanced lead compounds, is presented in Figure 3.   
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Figure 3.  Overview of key lead compounds identified during M5 PAM optimization project. 
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 Prior to in vivo use, additional PK/PBL studies will be necessary to determine 
which compound(s) may be suitable for systemic dosing in rodent neurobehavioral and 
neurochemical investigations.  The careful use of experimental controls and thoughtful 
data interpretation will be required for future studies utilizing these novel compounds 
given the off-target activities exhibited by many of the lead analogs.  However, further 
optimization could be directed at this scaffold to address these activities, prior to 
initiation of neurobiology studies.  Such efforts could be focused on heterocyclic 
replacement of the southern benzyl ring with isosteres such as thiophene or m-
fluoropyridines.  Likewise, introduction of one or more heteroatom(s) to the western 
benzo ring of the isatin core has yet to be performed.  These modifications are likely to 
prove tolerable for M5 PAM activity and may reveal highly useful SAR. 
 Due to the discrete neuronal localization of M5, which is essentially limited to 
expression on mesolimbic and nigrostriatal DA projection neurons of the VTA and SNc, 
respectively, pharmacological investigation into the effects of selective M5 activation will 
likely focus on these midbrain DA pathways and on their neurobehavioral correlates34,37.  
As discussed in Chapter I, murine experiments measuring stimulation of forebrain DA 
efflux in the NAc following administration of a muscarinic agonist directly into the VTA 
or after electrical stimulation of hindbrain cholinergic neurons of the pons that project to 
the VTA (i.e. Ch.V-VI) found that genetic deletion of M5 abolished the increase in 
forebrain DA efflux that was observed in WT mice63.  Thus, under the hypothesis that 
post-synaptic M5 receptors in the VTA located on DA cell bodies and/or dendrites 
mediates ACh-induced neuronal excitation leading to increased DA neurotransmassion in 
the NAc, pharmacological M5 activation with a selective PAM would likely potentiate 
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DA efflux in the NAc under either of the conditions used in the two M5-KO mice 
experiments.  However, it is important to note that in vivo microdialysis studies have 
determined that extracellular/synaptic ACh levels in the VTA are near or below detection 
thresholds under resting conditions when no pharmacological or electrical stimulus of 
mesolimbic signaling is present, and often the measurement of changes in extracellular 
ACh in this region requires infusion of a low dose of an AChE inhibitor through the 
dialysis probe147,148.  It is therefore unlikely that administration of an M5 PAM by itself 
would increase forebrain DA levels, unless it is co-administered with a submaximal dose 
of muscarinic agonist or following electrical stimulation of hindbrain cholinergic neurons 
to increase ACh concentration in the VTA.  Analogous experiments focused on the 
parallel nigrostriatal DA pathway could be also be performed.  These would provide 
useful evidence for or against the putative functional role of M5 on midbrain DA neurons 
that has been hypothesized from results of M5-KO mice studies. 
 In animal models of drug reward, M5 PAM administration (be it directly to the 
VTA or SNc, or via systemic dosing with a suitable compound) would provide behavioral 
insight complementary to the neurochemical studies.  For instance, an M5 PAM would be 
hypothesized to exacerbate drug reward behavior in cocaine self-administration and CPP 
models as well as worsen withdrawal-induced anxiety behaviors.  Similarly, 
amphetamine-induced hyperlocomotion would presumably be increased by dosing of an 
M5 PAM; though, ideally a dose of amphetamine low enough to cause only a subtle 
elevation in locomotor activity would be used to provide a window for the M5 PAM 
effect.  Additional behavioral paradigms (e.g. CAR) traditionally used to predict 
antipsychotic efficacy could be used to further characterize an M5 PAM in vivo. 
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 Beyond these experiments focused primarily on the functions of neuronal M5, 
additional studies could be performed to assess the putative role of M5 in mediating ACh-
induced cerebrovasodilation.  M5-KO mice lack ACh-induced dilation of multiple 
cerebral blood vessels including capillary beds, arterioles, and larger arteries of the 
brain62.  Furthermore, absence of M5 but not M1 or M3 results in a constitutive 
constriction of the cerebrovasculature with a corresponding decrease in CBF66.  Thus, 
measurement of cerebral blood vessel diameter using cranial window techniques, in vivo 
magnetic resonance angiography, and/or ex-vivo tissue preparations following 
administration of an M5 PAM could provide pharmacological evidence to support the 
hypothesized vasodilatory role of M5 in the brain.  Control experiments examining the 
effect of an M5 PAM on ACh-induced vasodilation of peripheral blood vessels (where M3 
is highly-likely the mediating receptor subtype) could be used to indicate whether the M5 
PAM compound maintains subtype-selectivity in native tissues.  Hemodynamic measures 
of CBF following M5 PAM dosing could be obtained using laser doppler flowometry 
methods in vivo as well.    
 The question of whether or not the neuroanatomical and behavioral cognitive 
defects observed in M5-KO mice are due to absence of neuronal or cerebrovascular M5 
(or perhaps both) could be potentially addressed by use of an M5 PAM lacking BBB 
penetration and thereby acting primarily on non-neuronal M5 receptors of the brain’s 
blood vessels.  If the neuronal atrophy and cognitive defects arising from genetic M5 
deletion are due solely to decreased CBF arising from cerebrovasoconstriction, use of a 
non CNS-penetrant compound would be hypothesized to exert pro-cognitive effects, 
presumably by enhancement of CBF alone.  Conversely, if such effects were absent with 
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a non CNS-penetrant compound but were then found following dosing of a compound 
that provides high brain exposure, such results would provide evidence that lack of 
neuronal M5 in the M5-KO mice studies contributes to the cellular and behavioral defects 
in cognitive function.  However, each of these potential studies would require important 
controls, such as the use of muscarinic antagonists (e.g. atropine) to reverse or compete 
with any observed positive M5 PAM effects on cerebral hemodynamics or on pro-
cognitive behavioral efficacy, as well as the use of M5-KO mice.  Unfortunately, these 
latter studies aimed at exploring the possible role of M5 in learning and memory may be 
confounded by a lack of ‘window’ for which to observe such effects.  Put differently, 
enhancement of cognition beyond a normal physiological state in WT animals is 
generally more challenging to detect.  Conversely, neuroanatomical, electrophysiological, 
and behavioral measures of learning and memory are generally more sensitive to 
detection of impairments induced by experimental or pharmacological agents.  Therefore, 
discovery of subtype-selective and drug-like M5 NAMs or antagonists could potentially 
provide more useful and straightforward insight to this particular question. 
 As presented in Chapter IV, preliminary data suggests that incorporation of basic 
alkylamine moieties tethered by an ether at the 5-position of the isatin headpiece on the 
M5 PAM scaffold may engender M5 NAM activity.  SAR for this sub-series has revealed 
additional modifications that improve inhibitory potency of these putative M5 NAMs in 
functional assays.  However, the subtype-selectivity and mode of binding for these 
compounds has yet to be determined.  Indeed, the first series of M5 NAMs may arise 
from our novel series of M5 PAMs, which would provide a richer set of available 
pharmacological tools for use in obtaining a thorough understanding M5 neurobiology. 
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